<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/227614-calcium-receptor-modulating-compound-and-use-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:37:51 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 227614:CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7- membered ring; ring B is an optionally substituted 5- to 7- membered heterocyclic ring; X1 is CR1, CR1R2, N or NR13; X2 is N or NR3; Y is C, CR4 or N, Z is CR5, CR5R6, N or NR7; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and is a single bond or a double bond; R1, R2, R3, R4, R5, R6, R7 and R13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7- membered ring; Q is C, CR5 or N; R8, R9, R10, R11 and R12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X1, R3, R1, Y and X3 in formula (II) and (III) as before.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>DESCRIPTION<br>
CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF<br>
BACKGROUND OF THE INVENTION<br>
Field of the Invention<br>
The present invention relates to heterocyclic<br>
compounds having calcium-sensing receptor (CaSR,<br>
hereinafter simply referred to as Ca receptor) modulating<br>
(agonistic or antagonistic) activity, pharmaceutical<br>
compositions containing them and intermediate compounds<br>
useful for synthesizing them.<br>
Background Art<br>
Calcium ion (hereinafter simply referred to as Ca)<br>
plays an essential role to maintain and modulate functions<br>
of various cells such as endocrine and exocrine cells, etc.,<br>
in addition to nerve and muscle. For this reason, the<br>
blood Ca level is strictly maintained in a narrow range.<br>
Parathyroid hormone (PTH) plays a central role in<br>
maintaining this blood Ca level. Therefore, secretion of<br>
PTH from parathyroid gland responds sharply to change in<br>
the blood Ca level and is must be modulated according to<br>
this. In fact, when the blood Ca level is changed, the<br>
blood PTH level is rapidly changed in response to this.<br><br>
The possibility of a mechanism by which the extracellular<br>
Ca concentration is sensed by parathyroid gland cells and<br>
the information transmitted into cells has been pointed out<br>
early by Brown et al. In 1993, they succeeded in the<br>
cloning and characterization of a Ca-sensing receptor<br>
(CaSR; hereinafter, simply referred to as Ca receptor) from<br>
bovine parathyroid (Nature, 366, 575-580(1993)).<br>
The Ca receptor is composed of a large terminal<br>
extracellular region spanning 600 amino acids at the N-<br>
terminal, having seven transmembrane spanning domains like<br>
other G protein coupled receptors, and an intracellular<br>
region consisting of 200 or less amino acids at the caboxyl<br>
C-terminal.<br>
It is considered that, when the extracellular Ca<br>
concentration is increased, phospholipase (PL)-C is<br>
activated, leading to increase in the intracellular Ca<br>
concentration and inhibition of PTH secretion due to<br>
increase in inositol triphosphate (IP3) . Since when a high<br>
value of the extracellular Ca concentration is maintained,<br>
the intracellular Ca concentration is thereafter increased<br>
continuously, it is considered that influx of Ca from the<br>
outside of a cell is also promoted. PL-A2 and D are<br>
activated due to increase in extracellular Ca, but there is<br>
a possibility that these are via protein kinase (PK)-C and<br>
the like which are activated at the same time via Ca<br><br>
receptor. The Ca receptor also inhibits adenylyl cyclase<br>
via Gi protein or via arachidonic acid production due to<br>
activation of PL-A2 and decreases intracellular cyclic AMP<br>
(Bone, 20, 303-309 (1997)).<br>
Ca receptor mRNA is expressed in many tissues, and the<br>
expression amount is high, in parathyroid gland, thyroid<br>
gland C cell, medulla and cortex thick ascending limb (MTAL<br>
and CTAL) of kidney uriniferous tubule, intramedullary<br>
collecting tubule (IMCD) and encephalic subfornical organ<br>
(SFO) and hippocampus (Bone, 20, 303-309 (1997)). In<br>
addition, expression is recognized in many tissues such as<br>
encephalic hypothalamus, cerebellum and olfactory nucleus,<br>
regions other than TAL of renal uriniferous tubule, lung,<br>
stomach, pancreas, intestine and skin. Since the Ca<br>
receptor is present in various tissues, its physiological<br>
function has yet to be fully understood. However, it is<br>
expected that the Ca receptor modulating (agonistic or<br>
antagonistic) drug would provide for a novel treatment of<br>
various disease states which include the following:<br>
1. Drugs for Treating Bone Diseases<br>
Since the anabolic activity is manifested by<br>
intermittent administration of PTH, Ca receptor modulating<br>
drugs which are considered to be able to regulate secretion<br>
of PTH are promising as a drug for treating osteoporosis.<br>
In addition, Ca receptor modulating drugs which are<br><br>
selectable for thyroid gland C cell may be also effective<br>
for treating osteoporosis by stimulation of calcitonin<br>
secretion. Whether the same Ca receptor as that of<br>
parathyroid gland is present in osteoblast, osteoclast and<br>
bone cell or not is disputable. However, some Ca-sensing<br>
mechanism is assuredly present therein and, therefore,<br>
drugs which directly act on them can be expected as a drug<br>
for treating bone diseases.<br>
2.	Kidney-Acting Drugs<br>
Handling of water and mineral in kidney is not only<br>
based on the results of function as a target organ for<br>
hormones, such as PTH, vitamin D etc., but also the Ca<br>
receptor in kidney is presumed to function in a response to<br>
the Ca concentration and the magnesium ion concentration in<br>
the extracellular fluid (Kidney Int, 50, 2129-2139 (1996)).<br>
Further, it is also considered that Ca receptor modulating<br>
drugs may modulate the blood amount in kidney, the amount<br>
of glomerulus filtration, renin secretion and activation of<br>
vitamin D in addition to control of influx and efflux of<br>
water and mineral.<br>
3.	Central Nervous System and Endocrine-Acting Drugs<br>
Ca receptor is present in almost all areas in the<br>
central nervous system, and is remarkably expressed, in<br>
particular, in the hippocampus, cerebellum and subfornical<br>
organ (Brain Res, 744. 47-56 (1997)). Although the details<br><br>
of the function are still unclear, the term of Ca receptor<br>
expression after birth in the hippocampus is consistent<br>
with the term of acquisition of LTP (Long Tightening<br>
Phenomenon) (Develop Brain Res, 100, 13-21 (1997)) and,<br>
therefore, the relationship with memory and learning can be<br>
presumed. Therefore, Ca receptor modulating drugs which<br>
are high in brain-blood barrier permeability and selective<br>
for the central nerve system may be utilized for treating<br>
Alzheimer's disease. In addition, since dry mouth occurs<br>
in hypercalcemic patient, Ca receptor modulating drugs may<br>
control them. The presence of Ca receptor in mouse<br>
pituitary gland cells which secreteACTH has been reported<br>
(Mol Endocrinol, 10, 555-565 (1996)). It is also<br>
considered that Ca receptor modulating drugs can be applied<br>
to Sheehann's syndrome and hypopituitarism or<br>
hyperpituitarism.<br>
4. Digestive System-Acting Drugs<br>
It is considered that a Ca receptor is present in the<br>
Auerbach nerve plexus of the digestive tract and controls<br>
intestinal tract motion. Constipation is known in<br>
hypercalcemic patients and stimulation of digestive tract<br>
motion is known in hypocalcemic patients in clinical tests.<br>
The existence of a Ca receptor in the gastrin secreting<br>
cell (G cell) of the stomach has been reported (J. Clin<br>
Invest, 99, 2328-2333 (1997)), and intestinal tract<br><br>
absorption, constipation, diarrhea, defecation and<br>
secretion of acid in the stomach may be controlled by drugs<br>
which act on a Ca receptor in the digestive tract. Further,<br>
it has been found that a Ca receptor is present in human<br>
colon cancer cell strains and it controls c-myc expression<br>
and proliferation (Biochem Biophys Res Commum, 232, 80-83<br>
(1997)), this is better consistent with the fact that the<br>
Ca uptake and sideration of colon and rectum cancers<br>
exhibit the negative correlation and, therefore, Ca<br>
receptor regulating drugs can be expected also as a drug<br>
for preventing and treating such cancers.<br>
Various heterocyclic compounds have been disclosed in<br>
the prior art. For example, WO 01/53266 discloses a<br>
compound of the formula:<br><br>
where in R, R1 and R2 are independently H, hydroxyl, etc.<br>
This compound has a phosphoinositide 3-kinase inhibitory<br>
activity and is useful for treating coronary obstruction,<br>
etc. Indian J. Chem., Sect. B (1993), 32B(5), 586-9<br>
discloses the synthesis of a compound of the formula:<br><br><br>
wherein R is hydrogen, chlorine, methyl or methoxy.<br>
However, no utility is disclosed. U.S. Patent 4,746,656<br>
(JP 63-33380 A) discloses a compound of the formula:<br><br>
wherein R1 is aryl or heterocyclic group, R2 is aryl, etc.,<br>
R3 and R4 are independently H, alkyl, etc. This compound<br>
is a Ca channel blocker.<br>
EP 217142 discloses a compound of the formula:<br><br>
wherein R is hydrogen, alkyl, etc., R1 is hydrogen, nitro,<br>
cyano, etc., R2 is phenyl, cycloalkyl, etc., R3 is hydrogen,<br><br>
acyl etc., and R8is carboxyl, carbamoyl, etc. This<br>
compound is also a Ca channel blocker.<br>
However, a heterocyclic compound having Ca receptor<br>
modulating activity is not found in the prior art.<br>
OBJECTS OF THE INVENTION<br>
One object of the present invention is to provide<br>
compounds having Ca receptor modulating activity including<br>
novel compounds.<br>
Another object of the present invention is to provide<br>
pharmaceutical compositions containing the compounds of the<br>
present invention.<br>
These objects as well as other objects and advantages<br>
of the present invention will become apparent to those<br>
skilled in the art from the following description.<br>
SUMMARY OF THE INVENTION<br>
The present inventors have intensively investigated<br>
compounds having Ca receptor modulating activity. As a<br>
result, it has been found that compounds represented by<br>
formula (I) as shown hereinafter have Ca receptor<br>
modulating activity useful for medicine and, among them,<br>
compounds represented by the formulas (II), (III) and<br>
(IIIa) as shown hereinafter are novel compounds.<br>
According to the present invention, there is provided:<br><br>
1. A compound of the formula (II):<br><br>
wherein ring A is an optionally substituted 5- to 7-<br>
membered ring;<br>
Q is C, CR5 (wherein R5 is H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- is -CO-, -CS-, -SO- or -<br>
SO2-, and Z2 is an optionally substituted hydrocarbon group,<br>
an optionally substituted heterocyclic group, an optionally<br>
substituted hydroxyl group, or an optionally substituted<br>
amino group)), or N;<br>
X1 is CR1 (wherein R1 is H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- and Z2 are as defined<br>
above) ) , CR1R2 (wherein R1 is as defined above, and R2 is H,<br>
or an optionally substituted hydrocarbon group), N, or NR13<br><br>
(wherein R13 is H, an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted heterocyclic group, or a group of the formula:<br>
-Z1-Z2 (wherein -Z1- and Z2 are as defined above));<br>
R3 is H, an optionally substituted hydrocarbon group, an<br>
optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted<br>
heterocyclic group, or a group of the formula: -Z1-Z2<br>
(wherein -Z1- and Z2 are as defined above);<br>
Y is C, CR4 (wherein R4 is H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- and Z2 are as defined<br>
above)), or N;<br>
Ar is an optionally substituted cyclic group;<br>
R9 and R10 are the same or different and are H, an<br>
optionally substituted hydrocarbon group, an optionally<br>
substituted hydroxyl group, an optionally substituted amino<br>
group, an optionally substituted thiol group, cyano group,<br>
a halogen atom, an optionally substituted heterocyclic<br>
group, or a group of the formula: -Z1-Z2 (wherein -Z1- and<br>
Z2 are as defined above) ; and R11 and R12 are the same or<br><br>
different and are H, an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1'- is -CS-, -SO- or -SO2-,<br>
and Z2 is as defined above); or R9 and R10, or R11 and R12<br>
may be combined to form an oxo group, methylene group or a<br>
ring; or R10 and R11 may be combined to form a ring; and<br>
- - - is a single bond or a double bond;<br>
provided that<br>
(1)	when ring A is a 6-membered ring and Q is C or CR5, X1<br>
is C-Z1-Z2, C(-Z1-Z2)R2 or N-Z1-Z2, and both R9 and R10 are<br>
not H, or R9 and R10 are not combined to form an oxo group,<br>
or R10 and R11 are not combined to form a 5-membered ring,<br>
(2)	when ring A is a 6-membered ring and Q is N, X1 is C-<br>
Z1-Z2, C(-Z1-Z2)R2 or N-Z1-Z2, and R9 and R10 are not combined<br>
to form an oxo group,<br>
(3)	when ring A is a 5-membered ring and Q is C or CR5, X1<br>
is C-Z1-Z2, C(-Z1-Z2)R2 or N-Z1-Z2, and Z2 is an optionally<br>
substituted amino group, and<br>
(4)	when ring A is a 5-membered ring and Q is N, at least<br>
one of R9 and R10 is CHR15R16 (wherein at least one of R15 and<br>
R16 are the same or different and are H, an optionally<br>
substituted hydrocarbon group, an optionally substituted<br><br>
hydroxyl group, an optionally substituted amino group, an<br>
optionally substituted thiol group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula:-Z1-Z2 (wherein -Z1- and Z2 are as defined<br>
above)) and the other is other than an optionally<br>
substituted phenyl group; or a salt thereof;<br>
2. A compound of the formula (III):<br><br>
wherein R1 is H, an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted thiol group, an optionally<br>
substituted amino group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- is -CO-, -CS-, -SO- or -<br>
SO2-, and Z2 is an optionally substituted hydrocarbon group,<br>
an optionally substituted heterocyclic group, an optionally<br>
substituted hydroxyl group, or an optionally substituted<br>
amino group);<br>
R3 is H, an optionally substituted hydrocarbon group, an<br>
optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted<br>
heterocyclic group, or a group of the formula: -Z1-Z2<br><br>
(wherein -Z1- and Z2 are as defined above);<br>
Y is C, CR4 (wherein R4 is H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- and Z2 are as defined<br>
above)) or N;<br>
R8 is H, an optionally substituted hydrocarbon group, an<br>
optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted thiol<br>
group, cyano group, a halogen atom, an optionally<br>
substituted heterocyclic group, or a group of the formula:<br>
-Z1-Z2 (wherein -Z1- and Z2 are as defined above) ;<br>
Ar is an optionally substituted cyclic group;<br>
R9 and R10 are the same or different and are H, an<br>
optionally substituted hydrocarbon group, an optionally<br>
substituted hydroxyl group, an optionally substituted amino<br>
group, an optionally substituted thiol group, cyano group,<br>
a halogen atom, an optionally substituted heterocyclic<br>
group, or a group of the formula: -Z1-Z2 (wherein -Z1- and<br>
Z2 are as defined above) , or R9 and R10 may be combined to<br>
form an oxo group, methylene group or a ring;<br>
X3 is a bond, oxygen atom, an optionally oxidized sulfur<br>
atom, N, NR7' (wherein R7' is H, an optionally substituted<br><br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted heterocyclic group, or a group of the formula -<br>
Z1'-Z2 (wherein -Z1'- is -CS-, -SO- or -SO2-, and Z2 is as<br>
defined above)), or an optionally substituted bivalent C1-2<br>
hydrocarbon group; and<br>
  is a single bond or a double bond;<br>
provided that at least one of R9 and R10 is CHR15R16 (wherein<br>
R15 and R16 are the same or different and are H, an<br>
optionally substituted hydrocarbon group, an optionally<br>
substituted hydroxyl group, an optionally substituted amino<br>
group, an optionally substituted thiol group, a halogen<br>
atom, an optionally substituted heterocyclic group, or a<br>
group of the formula:-Z1-Z2 (wherein -Z1- and Z2 are as<br>
defined above)) and the other is other than an optionally<br>
substituted phenyl group; or a salt thereof;<br>
3.	The compound according to the above 1 or 2,<br>
wherein R1 is (1) an optionally substituted heterocyclic<br>
group, or (2) a group of the formula: -Z1-Z2 (wherein -Z1-<br>
is -CO-, -CS-, -SO- or -SO2-, and Z2 is an optionally<br>
substituted hydrocarbon group, an optionally substituted<br>
heterocyclic group, an optionally substituted hydroxyl<br>
group, or an optionally substituted amino group);<br>
4.	The compound according to the above 3, wherein Z1<br>
is -CO- and Z2 is an optionally substituted hydroxyl group<br><br>
or an optionally substituted amino group;<br>
5.	The compound according to the above 2, wherein R3<br>
is H, a C1-6 alkyl group or a C7-14 aralkyl group;<br>
6.	The compound according to the above 2, wherein R8<br>
is H, a C1-6 alkyl group, a C1-6 alkylthio group or a C1-6<br>
alkoxy group which may be substituted with hydroxyl group;<br>
7.	The compound according to the above 1 or 2,<br>
wherein R9 and R10 are the same or different and are a C1-6<br>
alkyl group or R9 and R10 are combined each other to form a<br>
ring;<br>
8.	The compound according to the above 2, wherein R1<br>
is a group of the formula: -Z1-Z2 (wherein -Z1- is -CO-, -<br>
CS-, -SO- or -SO2-, and Z2 is an optionally substituted<br>
hydrocarbon group, an optionally substituted heterocyclic<br>
group, an optionally substituted hydroxyl group, or an<br>
optionally substituted amino group) ; R3 is H; Ar is an<br>
optionally substituted aromatic ring group; X3 is CR11R12<br>
(wherein R11 and R12 are the same or different and are H, an<br>
optionally substituted hydrocarbon group, an optionally<br>
substituted hydroxyl group, an optionally substituted amino<br>
group, an optionally substituted thiol group, cyano group,<br>
a halogen atom, an optionally substituted heterocyclic<br>
group, or a group of the formula: -Z1-Z2 (wherein -Z1- and<br>
Z2 are as defined above) , or R11 and R12 may be combined to<br>
form an oxo group, methylene group or a ring) ; and R9 and<br><br>
R10 are the same or different and a C1-6 alkyl group, or R9<br>
and R10 may be combined to form a ring;<br>
9.	The compound according to the above 8, wherein R1<br>
is an optionally substituted carbamoyl group;<br>
10.	The compound according to the above 9, wherein R1<br>
is a group of the formula: -CONR20 (CR21R22R23) (wherein R20 is<br>
H or an optionally substituted hydrocarbon group, and R21,<br>
R22, and R23 are the same or different and are an optionally<br>
substituted hydrocarbon group or an optionally substituted<br>
heterocyclic group, or R20 and R21 may be combined to form a<br>
ring);<br>
11.	A compound of the formula (IIIa):<br><br>
wherein R1a is (1) an optionally substituted heterocyclic<br>
group, or (2) a group of the formula: -Z1a-Z2a (wherein -Z1a-<br>
is -CO-, -CS-, -SO- or -SO2-, and Z2a is (i) an optionally<br>
substituted heterocyclic group, (ii) -NR20a (CR21aR22aR23a)<br>
(wherein (a) R20a is H or an optionally substituted<br>
hydrocarbon group; and R21a is an optionally substituted<br>
heterocyclic group which may be fused with an optionally<br>
substituted benzene ring, or an optionally substituted<br>
phenyl group which may be fused with an optionally<br><br>
substituted aromatic heterocyclic ring and R22a and R23a are<br>
the same or different and are an optionally substituted<br>
hydrocarbon group or an optionally substituted heterocyclic<br>
group or R22a and R23a may be combined to form a ring, or (b)<br>
R20a is H or an optionally substituted hydrocarbon group;<br>
and R21a, R22a and R23a are the same or different and are an<br>
optionally substituted C1-8 aliphatic hydrocarbon group,<br>
provided that the sum total of the number of carbon atoms<br>
is 7 or more) , (iii) -NR20aR25a (wherein R20a is as defined<br>
above and R25a is an optionally substituted C6-10 aryl-C2-4<br>
alkyl, C6-10 aryloxy-C2-4 alkyl, C6-10 arylamino-C2-4 alkyl, C7-<br>
14 aralkylamino-C2-4 alkyl, heterocyclic ring-C2-4 alkyl or<br>
heterocyclic group), (iv) a substituted 5- to 7-membered<br>
cyclic amino group, or (v) -OR24a (wherein R24a is (a) an<br>
optionally substituted C7-14 aralkyl group, (b) an<br>
optionally substituted C3-7 alicyclic hydrocarbon group, (c)<br>
an optionally substituted C7-24 aliphatic hydrocarbon group,<br>
or (d) an optionally substituted heterocyclic group);<br>
R3 is H, an optionally substituted hydrocarbon group, an<br>
optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted<br>
heterocyclic group, or a group of the formula: -Z1-Z2<br>
(wherein -Z1- is -CO-, -CS-, -SO- or -SO2-, and Z2 is an<br>
optionally substituted hydrocarbon group, an optionally<br>
substituted heterocyclic group, an optionally substituted<br><br>
hydroxyl group, or an optionally substituted amino group);<br>
Y is C, CR4 (wherein R4 is H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1--Z2 (wherein -Z1- and Z2 are as defined<br>
above)) or N;<br>
R8 is H, an optionally substituted hydrocarbon group, an<br>
optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted thiol<br>
group, cyano group, a halogen atom, an optionally<br>
substituted heterocyclic group, or a group of the formula:<br>
-Z1-Z2 (wherein -Z1- and Z2 are as defined above);<br>
Ar is an optionally substituted cyclic group;<br>
R9 and R10 are the same or different and are H, an<br>
optionally substituted hydrocarbon group, an optionally<br>
substituted hydroxyl group, an optionally substituted amino<br>
group, an optionally substituted thiol group, cyano group,<br>
a halogen atom, an optionally substituted heterocyclic<br>
group, or a group of the formula: -Z1-Z2 (wherein -Z1- and<br>
Z2 are as defined above) , or R9 and R10 may be combined to<br>
form an oxo group, methylene group or a ring;<br>
X3 is a bond, oxygen atom, an optionally oxidized sulfur<br>
atom, N, NR7' (wherein R7' is H, an optionally substituted<br><br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted heterocyclic group, or a group of the formula -<br>
Z1--Z2 (wherein -Z1'- is -CS-, -SO- or -SO2-, and Z2 is as<br>
defined above)), or an optionally substituted bivalent C1-2<br>
hydrocarbon group; and<br>
  is a single bond or a double bond;<br>
provided that at least one of R9 and R10 is CHR15R16 (wherein<br>
R15 and R16 are the same or different and are H, an<br>
optionally substituted hydrocarbon group, an optionally<br>
substituted hydroxyl group, an optionally substituted amino<br>
group, an optionally substituted thiol group, a halogen<br>
atom, an optionally substituted heterocyclic group, or a<br>
group of the formula:-Z1-Z2 (wherein -Z1- and Z2 are as<br>
defined above)) and the other is other than an optionally<br>
substituted phenyl group; or a salt thereof;<br>
12.	The compound according to the above 11, wherein<br>
R1a is a group of the formula: -CONR20a (CR21bR22bR23b) (wherein<br>
R20a is as defined above and at least one of R21b, R22b, and<br>
R23b is an optionally substituted heterocyclic group which<br>
may be fused with an optionally substituted benzene ring,<br>
or an optionally substituted phenyl group which may be<br>
fused with an optionally substituted aromatic heterocyclic<br>
ring);<br>
13.	The compound according to the above 11, wherein<br><br>
R1a is (1) an optionally substituted 5- to 7-membered<br>
aromatic or non-aromatic heterocyclic group having 1-4<br>
hetero atoms selected from nitrogen atom, oxygen atom and<br>
sulfur atom, or (2) a group of the formula: -CO-Z2c<br>
(wherein Z2c is (i) an optionally substituted 5- to 7-<br>
membered aromatic or non-aromatic heterocyclic group having<br>
1-4 hetero atoms selected from nitrogen atom, oxygen atom<br>
and sulfur atom, (ii) -NR20c (CR21cR22cR23c) (wherein (a) R20c is<br>
H or an optionally substituted hydrocarbon group selected<br>
from C1-8 saturated aliphatic hydrocarbon group, C2-8<br>
unsaturated aliphatic hydrocarbon group, C3-7 saturated<br>
alicyclic hydrocarbon group, C3-7 unsaturated alicyclic<br>
hydrocarbon group, C9-10 partly saturated and fused bicyclic<br>
hydrocarbon group, C3-7 saturated or unsaturated alicyclic-<br>
C1-8 saturated or unsaturated aliphatic hydrocarbon group,<br>
C9-10 partly saturated and fused bicyclic hydrocarbon-Ci-4<br>
alkyl group, C9-10 partly saturated and fused bicyclic<br>
hydrocarbon-C2-4 alkenyl group, C6-10 aryl group and C7-14<br>
aralkyl group; and R21c is 1) an optionally substituted 5-<br>
to 7-membered aromatic or non-aromatic heterocyclic group<br>
having 1-4 hetero atoms selected from nitrogen atom, oxygen<br>
atom and sulfur atom, which may be fused with an optionally<br>
substituted benzene ring, or 2) an optionally substituted<br>
C6-10 aryl group which may be fused with an optionally<br>
substituted 5- to 7-membered aromatic heterocyclic ring<br><br>
having 1-4 hetero atoms selected from nitrogen atom, oxygen<br>
atom and sulfur atom; and R22c and R23c are the same or<br>
different and are an optionally substituted hydrocarbon<br>
group selected from C1-8 saturated aliphatic hydrocarbon<br>
group, C2-8 unsaturated aliphatic hydrocarbon group, C3-7<br>
saturated alicyclic hydrocarbon group, C3-7 unsaturated<br>
alicyclic hydrocarbon group, C9-10 partly saturated and<br>
fused bicyclic hydrocarbon group, C3-7 saturated or<br>
unsaturated alicyclic-Ci-g saturated or unsaturated<br>
aliphatic hydrocarbon group, C9-10 partly saturated and<br>
fused bicyclic hydrocarbon-C1-4 alkyl group, C9-10 partly<br>
saturated and fused bicyclic hydrocarbon-C2-4 alkenyl group,<br>
C6-10 aryl group and C7-14 aralkyl group or an optionally<br>
substituted 5- to 7-membered aromatic or non-aromatic<br>
heterocyclic group having 1-4 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom, or R22c and R23c<br>
may be combined to form a C3-7 carbon ring, or<br>
(b) R20c is H or an optionally substituted hydrocarbon group<br>
selected from C1-8 saturated aliphatic hydrocarbon group,<br>
C2-8 unsaturated aliphatic hydrocarbon group, C3-7 saturated<br>
alicyclic hydrocarbon group, C3-7 unsaturated alicyclic<br>
hydrocarbon group, C9-10 partly saturated and fused bicyclic<br>
hydrocarbon group, C3_7 saturated or unsaturated alicyclic-<br>
C1-8 saturated or unsaturated aliphatic hydrocarbon group,<br>
C9-10 partly saturated and fused bicyclic hydrocarbon-C1-4<br><br>
alkyl group, C9-10 partly saturated and fused bicyclic<br>
hydrocarbon-C2-4 alkenyl group, C6-10 aryl group and C7-14<br>
aralkyl group; and R21c, R22c and R23c are the same or<br>
different and are an optionally substituted C1-8 aliphatic<br>
hydrocarbon group, provided that the sum total of the<br>
number of carbon atoms is 7 or more),<br>
(iii) -NR20cR25c (wherein R20c is as defined above and R25c is<br>
an optionally substituted C6-10 aryl-C2-4 alkyl, C6-10<br>
aryloxy-C2-4 alkyl, C6-10 arylamino-C2-4 alkyl, C7-14<br>
aralkylamino-C2-4 alkyl, 5- to 7-membered heterocyclic ring<br>
(having 1-4 hetero atoms selected from nitrogen atom,<br>
oxygen atom and sulfur atom) -C2-4 alkyl or 5- to 7-membered<br>
heterocyclic group having 1-4 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom),<br>
(iv) a substituted 5- to 7-membered cyclic amino group, or<br>
(v) -OR24c (wherein R24c is (a) an optionally substituted C7-<br>
14 aralkyl group, (b) an optionally substituted C3-7<br>
alicyclic hydrocarbon group, (c) an optionally substituted<br>
C7-24 aliphatic hydrocarbon group, or (d) an optionally<br>
substituted 5- to 7-membered aromatic or non-aromatic<br>
heterocyclic group having 1-4 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom;<br>
wherein said substituents for R1a, Z2c, R20c, R21c, R22c, R23c,<br>
R24c and R25c are 1 to 3 substituents selected from the group<br>
consisting of<br><br>
1)	C1-6 alkyl,<br>
2)	C2-6 alkenyl,<br>
3)	C2-6 alkynyl,<br>
4)	C3-7 cycloalkyl,<br>
5)	C6-10 aryl which may be substituted with 1 to 3<br>
substituents selected from the group consisting of C1-6<br>
alkyl, amino, N-(C1-6 alkyl) amino, N, N-di-(C1-6 alkyl) amino,<br>
amidino, carbamoyl, N-(C1-6 alkyl) carbamoyl, N,N-di-(C1-6<br>
alkyl) carbamoyl, sulfamoyl, N- (C1-6 alkyl) sulfamoyl, N,N-<br>
di-(C1-6 alkyl) sulfamoyl, carboxyl, C2-7 alkoxycarbonyl,<br>
hydroxyl, C1-6 alkoxy, mercapto, C1-6 alkylthio, sulfo,<br>
cyano, azido, halogen, nitro, nitroso, phosphono, C1-6<br>
alkoxyphosphoryl, di- (C1-6 alkoxy) phosphoryl and C1-6 alkyl<br>
substituted with phosphono, C1-6 alkoxyphosphoryl and di-<br>
(C1-6 alkoxy)phosphoryl (hereinafter the group of 5) is<br>
referred to as group "C"),<br>
6)	aromatic heterocyclic group selected from (a) aromatic<br>
5- or 6-membered heterocyclic group having 1-4 hetero<br>
atoms selected from nitrogen atom, oxygen atom and sulfur<br>
atom, (b) fused bicyclic heterocyclic group formed by<br>
condensation of an aromatic 5- or 6-membered heterocyclic<br>
group having 1 to 3 hetero atoms selected from nitrogen<br>
atom, oxygen atom and sulfur atom with benzene ring or an<br>
aromatic 5- or 6-membered heterocyclic group having 1 to<br>
3 hetero atoms selected from nitrogen atom, oxygen atom<br><br>
and sulfur atom and (c) fused tricyclic heterocyclic<br>
group formed by condensation of [1] an aromatic 5- or 6-<br>
membered heterocyclic group having 1-3 hetero atoms<br>
selected from nitrogen atom, oxygen atom and sulfur atom,<br>
[2] benzene ring, and [3] an aromatic 5- or 6-membered<br>
heterocyclic group having 1-3 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom or benzene<br>
ring,<br>
7)	heterocyclic-oxy group formed by combining each of the<br>
above aromatic heterocyclic groups (a) , (b) and (c) with<br>
oxy group,<br>
8)	non-aromatic 4- or 7-membered heterocyclic group<br>
having 1 to 3 hetero atoms selected from nitrogen atom,<br>
oxygen atom and sulfur atom,<br>
9)	C7-14 aralkyl which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br>
10)	amino group,<br>
11)	N-mono-substituted amino selected from N-(C1-6<br>
alkyl) amino, N- (C2-6 alkenyl) amino, N-(C3-7<br>
cycloalkyl) amino group and N- (C6-10 aryl) amino which may<br>
be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
12)	amino substituted with two substituents selected from<br>
C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkenyl and C6-10 aryl<br>
which may be substituted with 1 to 3 substituents<br><br>
selected from the group "C",<br>
13)	amidino,<br>
14)	acyl selected from C2-8 alkanoyl, C3-8 alkenoyl, C3-7<br>
cycloalkyl-carbonyl, C3-7 cycloalkenyl-carbonyl, C6-10<br>
aryl-carbonyl which may be substituted with 1 to 3<br>
substituents selected from the group "C", and<br>
heterocyclic-carbonyl formed by binding of an aromatic or<br>
non-aromatic 5- or 6-membered heterocyclic group having<br>
1-3 hetero atoms selected from nitrogen atom, oxygen atom<br>
and sulfur atom with carbonyl,<br>
15)	carbamoyl,<br>
16)	mono-substituted carbamoyl group selected from N-(C1-6<br>
alkyl) carbamoyl, N- (C2-6 alkenyl) carbamoyl, N- (C3-7<br>
cycloalkyl) carbamoyl and N- (C6-10 aryl) carbamoyl which may<br>
be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
17)	carbamoyl substituted with two substituents selected<br>
from C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl and C6-10 aryl<br>
which may be substituted with 1 to 3 substituents<br>
selected from the group "C",<br>
18)	sulfamoyl,<br>
19)	N-mono-substituted sulfamoyl selected from N-(C1-6<br>
alkyl) sulfamoyl, N- (C2-6 alkenyl) sulfamoyl, N- (C3-7<br>
cycloalkyl) sulfamoyl and N-(C6-10 aryl) sulfamoyl which may<br>
be substituted with 1 to 3 substituents selected from the<br><br>
group "C",<br>
20)	sulfamoyl substituted with two substituents selected<br>
from C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl and C6-10<br>
aryl which may be substituted with 1 to 3 substituents<br>
selected from the group "C",<br>
21)	carboxyl,<br>
22)	C1-6 alkoxy-carbonyl,<br>
23)	hydroxy1,<br>
24)	C1-6 alkoxy,<br>
25)	C2-10 alkenyloxy,<br>
26)	C3-7 cycloalkyloxy,<br><br>
27)	C6-10 aryloxy which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br>
28)	C7-14 aralkyloxy which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br>
29)	mercapto,<br>
30)	C1-6 alkylthio,<br>
31)	C7-14 aralkylthio which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br><br>
32)	C6-10 arylthio which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br>
33)	C1-6 alkylsulfinyl,<br>
34)	C7-14 aralkylsulfinyl which may be substituted with 1<br>
to 3 substituents selected from the group "C",<br>
35)	C6-10 arylsulfinyl which may be substituted with 1 to<br><br>
3 substituents selected from the group "C",<br>
36) C1-6 alkylsulfonyl,<br>
38)	C7-14 aralkylsulfonyl which may be substituted with 1<br>
to 3 substituents selected from the group "C",<br>
39)	C6-10 arylsulfonyl which may be substituted with 1 to<br>
3 substituents selected from the group "C",<br>
40)	sulfo,<br>
41)	cyano,<br>
42)	azido,<br>
43)	halogen,<br>
44)	nitro,<br>
45)	nitroso,<br>
46)	phosphono,<br>
47)	C1-6 alkoxy-phosphoryl<br>
48)	di-C1-6 alkoxy-phosphoryl,<br>
49)	C1-6 alkyl substituted with phosphono, C1-6<br>
alkoxyphosphoryl or di-(C1-6 alkoxy) phosphoryl<br>
50)	C1-6 alkyl substituted with 1 to 4 halogen atoms<br>
51)	C1-6 alkoxy substituted with 1 to 4 halogen atoms and<br>
52)	C1-6 alkylenedioxy<br>
(hereinafter the group of above 1) to 52) is referred to<br>
as group "B");<br>
R3 is H, a C1-6 alkyl group or a C7-14 aralkyl group;<br>
Y is CH;<br>
R8 is H, a C1-6 alkyl group, a C1-6 alkylthio group or a C1-6<br><br>
alkoxy group which may be substituted with hydroxyl group;<br>
Ar is (1) a C6-10 aryl group, (2) a 5- to 7-membered<br>
aromatic or non-aromatic heterocyclic group having 1-4<br>
hetero atoms selected from nitrogen atom, oxygen atom and<br>
sulfur atom, or (3) a C3-7 saturated or unsaturated<br>
alicyclic hydrocarbon group, each of which may be<br>
substituted with 1 to 3 substituents selected from the<br>
group "B";<br>
one of R9 and R10 is a hydrogen atom or C1-6 alkyl group<br>
which may be substituted with 1 to 3 substituents selected<br>
from the group "B" and the other is (1) a hydrocarbon group<br>
selected from C1-8 saturated aliphatic hydrocarbon group,<br>
C2-8 unsaturated aliphatic hydrocarbon group, C3-7 saturated<br>
alicyclic hydrocarbon group, C3-7 unsaturated alicyclic<br>
hydrocarbon group, C9-10 partly saturated and fused bicyclic<br>
hydrocarbon group, C3-7 saturated or unsaturated alicyclic-<br>
C1-8 saturated or unsaturated aliphatic hydrocarbon group,<br>
C9-10 partly saturated and fused bicyclic hydrocarbon-C1-4<br>
alkyl group, C9-10 partly saturated and fused bicyclic<br>
hydrocarbon-C2-4 alkenyl group, C6-10 aryl group and C7-14<br>
aralkyl group, each of which may be substituted with 1 to 3<br>
substituents selected from the group "B" or (2) a 5- to 7-<br>
membered aromatic or non-aromatic heterocyclic group having<br>
1-4 hetero atoms selected from nitrogen atom, oxygen atom<br>
and sulfur atom, which may be substituted with 1 to 3<br><br>
substituents selected from the group "B", or<br>
R9 and R10 may be combined to form a C5-7 carbon ring; and<br>
X3 is CH2;<br>
14.	The compound according to the above 8, wherein R1<br>
is a group of the formula: -CONR20 (CR21R22R23) (wherein R20 is<br>
H, and R21, R22, and R23 are the same or different and are an<br>
optionally substituted hydrocarbon group or an optionally<br>
substituted heterocyclic group); R3 is H; Ar is an<br>
optionally substituted aromatic ring group; X3 is CH2; Y is<br>
CH; R8 is H or an optionally substituted hydrocarbon group,<br>
an optionally substituted alkoxy group, an optionally<br>
substituted sulfanyl group, an optionally substituted<br>
sulfinyl group, or an optionally substituted sulfonyl group,<br>
C1-6 alkoxy-carbonyl; and R9 and R10 are the same or<br>
different and are an optionally substituted hydrocarbon<br>
group;<br>
15.	The compound according to the above 14, wherein<br>
at least one of R21, R22, and R23 is an optionally<br>
substituted heterocyclic group or an optionally substituted<br>
phenyl group;<br>
16.	The compound according to the above 14, wherein<br>
R20 and R21 are combined to form an optionally substituted<br>
5- to 7-membered ring, and R22 and R23 are the same or<br>
different and are an optionally substituted hydrocarbon<br>
group, an optionally substituted heterocyclic group, or an<br><br>
optionally substituted phenyl group;<br>
17.	The compound according to the above 14, wherein<br>
R21 and R22 are the same or different and are a C1-8<br>
hydrocarbon group, and R23 is an optionally substituted 5-<br>
membered heterocyclic group which may be fused with an<br>
optionally substituted benzene ring, or an optionally<br>
substituted phenyl group;<br>
18.	The compound according to the above 16, wherein<br>
R20 and R21 are combined to form a 5- or 6-membered ring<br>
which may be fused with benzene ring and/or substituted<br>
with 1 to 3 substituents selected from the group consisting<br>
of (1) halogen, (2) hydrogen, (3) a phenoxy which may be<br>
substituted with 1 to 3 substituents selected from halogen,<br>
hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 acyl, cyano, amino,<br>
mono-C1-6 alkyl-amino, di-C1-6 alkyl-amino, C1-6 alkyl-<br>
sulfanyl, C1-6 alkyl-sulf inyl, C1-6 alkyl-sulf onyl, C1-6<br>
alkoxy-carbonyl, carbamoyl, N-C1-6 alkyl-carbamoyl and N,N-<br>
di-C1-6 alkyl-carbamoyl,<br>
(4) C1-6 alkoxy which may be substituted with 1 to 3<br>
substituents selected from halogen, hydroxyl, C1-6 alkyl,<br>
C1-6 alkoxy, C1-6 acyl, cyano, amino, mono-C1-6 alkyl-amino,<br>
di-C1-6 alkyl-amino, C1-6 alkyl-sulf anyl, C1-6 alkyl-sulf inyl,<br>
C1-6 alkyl-sulf onyl, C1-6 alkoxy-carbonyl, carbamoyl, N-C1-6<br>
alkyl-carbamoyl, N,N-di-C1-6 alkyl-carbamoyl and phenyl<br>
which may be substituted with 1 to 3 substituents selected<br><br>
from halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 acyl,<br>
cyano, halogeno C1-6 alkyl, amino, mono-C1-6 alkyl-amino, di-<br>
C1-6 alkyl-amino, C1-6 alkyl-sulfanyl, C1-6 alkyl-sulf inyl,<br>
C1-6 alkyl-sulf onyl, C1-6 alkoxy-carbonyl, carbamoyl, N-C1-6<br>
alkyl-carbamoyl and N,N-di-C1-6 alkyl-carbamoyl,<br>
and (5) a C1-8 hydrocarbon group which may be substituted<br>
with 1 to 3 substituents selected from halogen, hydroxyl,<br>
C1-6 alkyl, C1-6 alkoxy, C1-6 acyl, cyano, amino, mono-C1-6<br>
alkyl-amino, di-C1-6 alkyl-amino, C1-6 alkyl-sulfanyl, C1-6<br>
alkyl-sulf inyl, C1-6 alkyl-sulf onyl, C1-6 alkoxy-carbonyl,<br>
carbamoyl, N-C1-6 alkyl-carbamoyl, N,N-di-C1-6 alkyl-<br>
carbamoyl and phenyl which may be substituted with 1 to 3<br>
substituents selected from halogen, hydroxyl, C1-6 alkyl,<br>
C1-6 alkoxy, C1-6 acyl, cyano, halogeno C1-6 alkyl, amino,<br>
mono-C1-6 alkyl-amino, di-C1-6 alkyl-amino, C1-6 alkyl-<br>
sulfanyl, C1-6 alkyl-sulf inyl, C1-6 alkyl-sulf onyl, C1-6<br>
alkoxy-carbonyl, carbamoyl, N-C1-6 alkyl-carbamoyl and N,N-<br>
di-C1-6 alkyl-carbamoyl,<br>
and R22 and R23 are the same or different and C1-8<br>
hydrocarbon group which may be substituted with 1 to 3<br>
substituents selected from halogen, hydroxyl, C1-6 alkyl,<br>
C1-6 alkoxy, C1-6 acyl, cyano, amino, mono-C1-6 alkyl-amino,<br>
di-C1-6 alkyl-amino, C1-6 alkyl-sulfanyl, C1-6 alkyl-sulf inyl,<br>
C1-6 alkyl-sulf onyl, C1-6 alkoxy-carbonyl, carbamoyl, N-C1-6<br>
alkyl-carbamoyl, N,N-di-C1-6 alkyl-carbamoyl and phenyl<br><br>
which may be substituted with 1 to 3 substituents selected<br>
from halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 acyl,<br>
cyano, halogeno C1-6 alkyl, amino, mono-C1-6 alkyl-amino, di-<br>
C1-6 alkyl-amino, C1-6 alkyl-sulf anyl, C1-6 alkyl-sulf inyl,<br>
C1-6 alkyl-sulf onyl, C1-6 alkoxy-carbonyl, carbamoyl, N-C1-6<br>
alkyl-carbamoyl and N,N-di-C1-6 alkyl-carbamoyl;<br>
19. N-(1-ethyl-1-(4-methylphenyl)propyl)-7,7-<br>
dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-<br>
a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(1-ethyl-1-(4-methylphenyl)propyl)-5-(2-fluorophenyl)-<br>
7,7-dimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-<br>
carboxamide or a salt thereof,<br>
N-(1-ethyl-1-(4-methylphenyl)propyl)-2,7,7-trimethyl-5-<br>
phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-<br>
carboxamide or a salt thereof,<br>
N-(1-ethyl-1-(4-ethylphenyl)propyl)-2,7,7-trimethyl-5-<br>
phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-<br>
carboxamide or a salt thereof,<br>
N-(1-ethyl-1-(4-methylphenyl)propyl)-5-(2-fluorophenyl)-<br>
2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<br>
a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(1-ethyl-1-(4-ethylphenyl)propyl)-5-(2-fluorophenyl)-<br>
2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<br>
a]pyrimidine-3-carboxamide or a salt thereof,<br>
5-(2-chlorophenyl)-N-(1-ethyl-1-(4-methylphenyl)propyl)-<br><br>
2,7, 7-trimethyl-4,5,6,7-tetrahydropyrazolo [1,5-<br>
a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(1-(4-(dimethylamino)phenyl)-1-ethylpropyl)-5-(2-<br>
fluorophenyl)-2,7,7-trimethyl-4, 5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt<br>
thereof,<br>
N-(1,1-diethylbutyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide<br>
or a salt thereof,<br>
N-(1-ethyl-1-phenylpropyl)-5-(2-fluorophenyl)-2,7,7-<br>
trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-<br>
carboxamide or a salt thereof,<br>
3-(5-(1-ethyl-1-(4-methylphenyl)propyl)-1,3, 4-oxadiazol-2-<br>
yl)-2,7,7-trimethyl-5-phenyl-4 ,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof,<br>
3-(5-(1-ethyl-1-(4-methylphenyl)propyl)-1,3,4-thiadiazol-2-<br>
yl) -2, 7, 7-trimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof,<br>
3-((4-(benzyloxy)-2,2-diethyl-1-pyrrolidinyl)carbonyl)-7,7-<br>
dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-<br>
a]pyrimidine or a salt thereof,<br>
3-((2,2-diethyl-4-methoxy-1-pyrrolidinyl)carbonyl)-7,7-<br>
dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-<br>
a]pyrimidine or a salt thereof, or<br>
3-((2,2-diethyl-4-fluoro-1-pyrrolidinyl)carbonyl)-7,7-<br><br>
dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-<br>
a]pyrimidine or a salt thereof;<br>
20.	The compound according to the above 19, which is<br>
an optically active compound;<br>
21.	A prodrug of the compound according to the above<br>
1, 2 or 13;<br>
22.	A pharmaceutical composition which comprises the<br>
compound according to the above 1, 2 or 13 or a prodrug<br>
thereof;<br>
23.	A composition for modulating calcium receptor<br>
which comprises a compound of the formula (I):<br><br>
wherein ring A is an optionally substituted 5- to 7-<br>
membered ring;<br>
ring B is an optionally substituted 5- to 7-membered<br>
heterocyclic ring;<br>
X1 is CR1 (wherein R1 is H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- is -CO-, -CS-, -SO- or -<br>
SO2-, and Z2 is an optionally substituted hydrocarbon group,<br><br>
an optionally substituted heterocyclic group, an optionally<br>
substituted hydroxyl group, or an optionally substituted<br>
amino group) ) , CR1R2 (wherein R1 is as defined above, R2 is H<br>
or an optionally substituted hydrocarbon group), N or NR13<br>
(wherein R13 is H, an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, cyano group, a halogen<br>
atom, an optionally substituted heterocyclic group, or a<br>
group of the formula: -Z1-Z2 (wherein -Z1- and Z2 are as<br>
defined above));<br>
X2 is N or NR3 (wherein R3 is H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, cyano group, a<br>
halogen atom, an optionally substituted heterocyclic group,<br>
or a group of the formula: -Z1-Z2 (wherein -Z1- and Z2 are<br>
as defined above);<br>
Y is C, CR4 (wherein R4 is H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- and Z2 are as defined<br>
above)) or N;<br>
Z is CR5 (wherein R5 is H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br><br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- and Z2 are as defined<br>
above) ) , CR5R6 (wherein R5 and R6 are the same or different<br>
and are H, an optionally substituted hydrocarbon group, an<br>
optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted thiol<br>
group, cyano group, a halogen atom, an optionally<br>
substituted heterocyclic group, or a group of the formula:<br>
-Z1-Z2 (wherein -Z1- and Z2 are as defined above)) , N or NR7<br>
(wherein R7 is H, an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, cyano group, a halogen<br>
atom, an optionally substituted heterocyclic group, or a<br>
group of the formula: -Z1-Z2 (wherein -Z1- and Z2 are as<br>
defined above));<br>
Ar is an optionally substituted cyclic group;<br>
R is H, an optionally substituted hydrocarbon group, an<br>
optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted thiol<br>
group, an optionally substituted sulfonyl group or an<br>
optionally substituted sulfinyl group, or R and Z may be<br>
combined to form a ring B; and<br>
  is a single bond or a double bond;<br><br>
or a salt thereof or a prodrug thereof;<br>
24.	The composition according to the above 23, which<br>
is a calcium receptor antagonist;<br>
25.	The composition according to the above 23, which<br>
is an agent for preventing or treating diseases caused by<br>
abnormality of calcium concentration in a living body or a<br>
calcium receptor;<br>
26.	The composition according to the above 23, which<br>
is an agent for preventing or treating bone diseases;<br>
27.	The composition according to the above 23, which<br>
is an agent for preventing or treating osteoporosis or<br>
fracture;<br>
28.	A method for modulating a calcium receptor which<br>
comprises administering to a mammal an effective amount of<br>
a compound of the formula (I) or a salt thereof or a<br>
prodrug thereof according to the above 23;<br>
29.	A method for preventing or treating bone diseases,<br>
which comprises administering to a mammal an effective<br>
amount of a compound of the formula (I) or a salt thereof<br>
or a prodrug thereof according to the above 23;<br>
30.	Use of the compound of the formula (I) or a salt<br>
thereof or a prodrug thereof according to the above 23 for<br>
producing a calcium receptor modulator; and<br>
31.	Use of the compound of the formula (I) or a salt<br>
thereof or a prodrug thereof according to the above 23 for<br><br>
producing a composition for preventing or treating bone<br>
diseases.<br>
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS<br>
The above formula (I) includes a monocyclic<br>
heterocyclic compound containing ring A and a condensed<br>
heterocyclic compound containing rings A and B.<br>
In the above formulas, ring A of the formulas (I) and<br>
(II) is an optionally substituted 5- to 7-membered ring.<br>
Examples of the "5- to 7-membered ring" of "an<br>
optionally substituted 5- to 7-membered ring" includes an<br>
aromatic or non-aromatic 5- to 7-membered hydrocarbon ring<br>
or 5- to 7-membered heterocyclic ring which may contain 1<br>
to 3 heteroatoms selected from nitrogen, oxygen and sulfur<br>
atoms as the ring constituting atoms in addition to carbon<br>
atoms. Specific examples thereof include a hydrocarbon<br>
ring such as benzene, tropilidene, cyclopentane,<br>
cyclohexane, cycloheptane, 1-cyclopentene, 2-cyclopentene,<br>
3-cyclopentene, 1-cyclohexene, 2-cyclohexene, 3-cyclohexene,<br>
1-cycloheptene, 2-cycloheptene, 3-cycloheptene, 2,4-<br>
cycloheptadiene, etc.; a heterocyclic ring such as pyridine,<br>
pyrazine, pyrimidine, imidazole, furan, thiophene,<br>
dihydropyridine, diazepine, oxazepine, pyrrolidine,<br>
piperidine, hexamethylenimine, heptamethylenimine,<br>
tetrahydrofuran, piperazine, homopiperazine,<br><br>
tetrahydrooxazepine, morpholine, thiomorpholine, pyrrole,<br>
pyrazole, 1,2,3-triazole, oxazole, oxazolidine, thiazole,<br>
thiazolidine, isoxazole, imidazoline, triazole, thiadiazole,<br>
oxadiazole, oxathiadiazole, triazine, etc.; and the like.<br>
Examples of the substituent(s) of "an optionally<br>
substituted 5- to 7-membered ring group" include halogen,<br>
nitro, cyano, oxo, an optionally substituted hydrocarbon<br>
group, an optionally substituted heterocyclic group, an<br>
optionally substituted sulfinyl group, an optionally<br>
substituted sulfonyl group, an optionally substituted<br>
hydroxyl group, an optionally substituted thiol group, an<br>
optionally substituted amino group, an optionally<br>
substituted acyl group, an optionally esterified or<br>
amidated carboxyl group, an optionally substituted<br>
phosphoryl group, or the like.<br>
Examples of halogen include fluorine, chlorine,<br>
bromine, iodine, and the like, preferably, fluorine and<br>
chlorine.<br>
Examples of the hydrocarbon group in an optionally<br>
substituted hydrocarbon group as the substituent of the 5-<br>
to 7-membered ring group include an optionally substituted<br>
aliphatic hydrocarbon group, an optionally substituted<br>
alicyclic hydrocarbon group, an optionally substituted<br>
alicyclic-aliphatic hydrocarbon group, an optionally<br>
substituted aromatic hydrocarbon group, an optionally<br><br>
substituted aromatic-aliphatic hydrocarbon group (an<br>
aralkyl group), and the like.<br>
Examples of said aliphatic hydrocarbon group include a<br>
saturated aliphatic hydrocarbon group having 1-8 carbon<br>
atoms (e.g., alkyl group) such as methyl, ethyl, propyl,<br>
isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,<br>
isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, heptyl,<br>
octyl, etc.; and an unsaturated aliphatic hydrocarbon group<br>
having 2-8 carbon atoms (e.g., alkenyl group, alkynyl group,<br>
alkadienyl group, alkadiynyl group, etc.) such as vinyl,<br>
allyl, 1-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-<br>
butenyl, 3-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-<br>
pentenyl, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-<br>
hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2,4-<br>
hexadienyl, 1-heptenyl, 1-octenyl, ethynyl, 1-propynyl, 2-<br>
propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-<br>
pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-<br>
hexynyl, 4-hexynyl, 5-hexynyl, 2,4-hexadiynyl, 1-heptynyl,<br>
1-octynyl, etc.<br>
Examples of said alicyclic hydrocarbon group include a<br>
saturated alicyclic hydrocarbon group having 3-7 carbon<br>
atoms (e.g., cycloalkyl group, etc.) such as cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the<br>
like; an unsaturated alicyclic hydrocarbon group having 3-7<br>
carbon atoms (e.g., cycloalkenyl group, cycloalkadienyl<br><br>
group, etc.) such as 1-cyclopentenyl, 2-cyclopentenyl, 3-<br>
cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-<br>
cyclohexenyl, 1-cycloheptenyl, 2-cycloheptenyl, 3-<br>
cycloheptenyl, 2,4-cycloheptadienyl, etc.; a partly<br>
saturated and fused bicyclic hydrocarbon group [preferably,<br>
C6-10 partly saturated and fused bicyclic hydrocarbon group,<br>
etc. (including those where the benzene ring is combined to<br>
5- or 6-membered non-aromatic cyclic hydrocarbon group)]<br>
such as 1-indenyl, 2-indenyl, 1-indanyl, 2-indanyl,<br>
1,2,3,4-tetrahydro-1-naphthyl, 1,2,3,4-tetrahydro-2-<br>
naphthyl, 1,2-dihydro-1-naphthyl, 1,2-dihydro-2-naphthyl,<br>
1,4-dihydro-1-naphthyl, 1,4-dihydro-2-naphthyl, 3,4-<br>
dihydro-1-naphthyl, 3,4-dihydro-2-naphthyl, etc.; and the<br>
like. Said alicyclic hydrocarbon group may be cross-linked.<br>
Examples of said alicyclic-aliphatic hydrocarbon group<br>
include those where the above-mentioned alicyclic<br>
hydrocarbon group and the above-mentioned aliphatic<br>
hydrocarbon group are combined, for example, those having<br>
4-14 carbon atoms such as cyclopropylmethyl,<br>
cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl,<br>
cyclopentylmethyl,	2-cyclopentenylmethyl,	3-<br>
cyclopentenylmethyl, cyclopentylethyl, cyclohexylmethyl, 2-<br>
cyclohexenylmethyl, 3-cyclohexenylmethyl, cyclohexylethyl,<br>
cycloheptylmethyl, cycloheptylethyl, 2-(3,4-dihydro-2-<br>
naphtyl)ethyl, 2-(1,2,3,4-tetrahydro-2-naphtyl)ethyl, 2-<br><br>
(3,4-dihydro-2-naphtyl)ethenyl, etc. (e.g., C3-7 cycloalkyl-<br>
C1-4 alkyl group, C3-7 cycloalkenyl-C1-4 alkyl group, C3-7<br>
cycloalkyl-C2-4 alkenyl group, C3-7 cycloalkenyl-C2-4 alkenyl<br>
group, C9-10 partly saturated and fused bicyclic<br>
hydrocarbon-C1-4 alkyl group, C9-10 partly saturated and<br>
fused bicyclic hydrocarbon-C2-4 alkenyl groups, etc.).<br>
Examples of said aromatic hydrocarbon group include an<br>
aryl group having 6-10 carbon atoms (including that where a<br>
5- to 6-membered non-aromatic hydrocarbon ring is fused<br>
with phenyl group) such as phenyl, -naphthyl, -naphthyl,<br>
4-indenyl, 5-indenyl, 4-indanyl, 5-indanyl, 5,6,7,8-<br>
tetrahydro-1-naphthyl, 5, 6,7,8-tetrahydro-2-naphthyl, 5,6-<br>
dihydro-1-naphthyl, 5,6-dihydro-2-naphthyl, 5,6-dihydro-3-<br>
naphthyl, 5,6-dihydro-4-naphthyl, etc.; and the like.<br>
Examples of said aromatic-aliphatic hydrocarbon group<br>
include an aralkyl group having 7-14 carbon atoms (C6-10<br>
aryl-C1-4 alkyl group) such as phenyl-C1-4 alkyl group, e.g.,<br>
benzyl, phenethyl, 1-phenylethyl, 1-phenylpropyl, 2-<br>
phenylpropyl, 3-phenylpropyl, etc.; naphthyl-C1-4 alkyl<br>
group such as -naphthylmethyl, -naphthylethyl, -<br>
naphthylmethyl, -naphthylethyl, etc.; C6-10 aryl-C2-4<br>
alkenyl group such as phenyl-C2-4 alkenyl group, e.g.,<br>
styryl, cinnamyl, etc.; and the like.<br>
Examples of the heterocyclic group in an optionally<br>
substituted heterocyclic group as the substituent of the 5-<br><br>
to 7-membered ring include (i) a 5- to 7-membered<br>
heterocyclic group containing one sulfur atom, one nitrogen<br>
atom, or one oxygen atom, (ii) a 5- to 6-membered<br>
heterocyclic group containing 2-4 nitrogen atoms, (iii) a<br>
5- to 6-membered heterocyclic group containing 1-2 nitrogen<br>
atoms and one sulfur or oxygen atom, or the like; and (iv)<br>
these heterocyclic groups may be fused with a 5- to 6-<br>
membered ring containing 2 or less nitrogen atoms, benzene<br>
ring, or a 5-membered ring containing one sulfur atom. In<br>
addition, each of the heterocyclic groups exemplified in<br>
(i) to (iv) may be a saturated or unsaturated heterocyclic<br>
group and the unsaturated heterocyclic group may be either<br>
aromatic or non-aromatic.<br>
Examples of the heterocyclic group in an optionally<br>
substituted heterocyclic group as the substituent of the 5-<br>
to 7-membered ring include an aromatic monocyclic<br>
heterocyclic group, an aromatic fused heterocyclic group,<br>
and a non-aromatic heterocyclic group.<br>
Specific examples of the heterocyclic group in an<br>
optionally substituted heterocyclic group as the<br>
substituent of the 5- to 7-membered ring include (i) an<br>
aromatic monocyclic heterocyclic group (e.g., furyl,<br>
thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl,<br>
isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl,<br>
1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, furazanyl, 1,2,3-<br><br>
thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl,<br>
1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl,<br>
pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, etc.); (ii)<br>
an aromatic fused heterocyclic group (e.g., benzofuranyl,<br>
isobenzofuranyl, benzo[b]thienyl, indolyl, isoindolyl, 1H-<br>
indazolyl, benzimidazolyl, benzoxazolyl, 1,2-<br>
benzisothiazolyl, lH-benztriazolyl, quinolyl, isoquinolyl,<br>
cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl,<br>
naphthyridinyl, purinyl, pteridinyl, carbazolyl, a-<br>
carbolinyl, -carbolinyl, -carbolinyl, acridinyl,<br>
phenoxazinyl, phenothiazinyl, phenazinyl, phenoxatinyl,<br>
thianthrenyl, phenanthredinyl, phenanthrolinyl, indolizinyl,<br>
pyrrolo[l,2-b]pyridazinyl,	pyrazolo[1,5-a]pyridyl,<br>
imidazo[1,2-a]pyridyl, imidazo[1,5-a]pyridyl, imidazo[l,2-<br>
b]pyridazinyl, imidazo[1,2-a]pyridyl, imidazo[1,5-a]pyridyl,<br>
imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrimidinyl,<br>
l,2,4-triazolo[4,3-a]pyridyl,	l,2,4-triazolo[4,3-<br>
b]pyridazinyl, etc.); and (iii) a non-aromatic,<br>
heterocyclic group (e.g., oxiranyl, azetidinyl, oxetanyl,<br>
thietanyl, pyrrolidinyl, tetrahydrofuryl, thiolanyl,<br>
piperidyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl,<br>
piperazinyl, etc.).<br>
Examples of sulfinyl group in an optionally<br>
substituted sulfinyl group as the substituent of the 5- to<br>
7-membered ring include that where -SO- is combined with<br><br>
"the hydrocarbon group" or "the heterocyclic group" in "an<br>
optionally substituted hydrocarbon group" or "an optionally<br>
substituted heterocyclic group" of the substituent of the<br>
5- to 7-membered ring.<br>
Preferred examples include a C1-8 alkylsulf inyl group<br>
where sulfinyl group is combined with a C1-8 alkyl group<br>
such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl,<br>
sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-<br>
pentyl, hexyl, isohexyl, heptyl, octyl, etc.; a C6-10<br>
arylsulfinyl group where sulfinyl group is combined with a<br>
C6-10 aryl group such as phenyl, a-naphthyl, p-naphthyl, 4-<br>
indenyl, 5-indenyl, 4-indanyl, 5-indanyl, 5,6,7,8-<br>
tetrahydro-1-naphthyl, 5,6,7,8-tetrahydro-2-naphthyl, 5,6-<br>
dihydro-1-naphthyl, 5,6-dihydro-2-naphthyl, 5,6-dihydro-3-<br>
naphthyl, 5,6-dihydro-4-naphthyl, etc.; a group where<br>
sulfinyl group is combined with an aromatic monocyclic<br>
heterocyclic group (e.g., furyl, thienyl, pyrrolyl,<br>
oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl,<br>
pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-<br>
oxadiazolyl, furazanyl, 1,2,3-thiadiazolyl, 1,2,4-<br>
thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-<br>
triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl,<br>
pyrazinyl, triazinyl, etc.); and a group where sulfinyl<br>
group is combined with an aromatic fused heterocyclic group<br>
(e.g., benzofuranyl, isobenzofuranyl, benzo[b]thienyl,<br><br>
indolyl, isoindolyl, 1H-indazolyl, benzimidazolyl,<br>
benzoxazolyl, 1,2-benzisothiazolyl, 1H-benztriazolyl,<br>
quinolyl, isoquinolyl, cinnolinyl, quinazolinyl,<br>
quinoxalinyl, phthalazinyl, naphthyridinyl, purinyl,<br>
pteridinyl, carbazolyl, -carbolinyl, -carbolinyl, -<br>
carbolinyl, acridinyl, phenoxazinyl, phenothiazinyl,<br>
phenazinyl, phenoxatinyl, thianthrenyl, phenanthredinyl,<br>
phenanthrolinyl, indolizinyl, pyrrolo[1,2-b]pyridazinyl,<br>
pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[l,5-<br>
a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyridyl,<br>
imidazo[1,5-a]pyridyl,	imidazo[1,2-b]pyridazinyl,<br>
imidazo[1,2-a]pyrimidinyl, l,2,4-triazolo[4,3-a]pyridyl,<br>
1,2,4-triazolo[4,3-b]pyridazinyl, etc.).<br>
More preferred examples include a C1-8 alkylsulf inyl<br>
group where sulfinyl group is combined with a C1-8 alkyl<br>
group such as methyl, ethyl, propyl, isopropyl, butyl,<br>
isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl,<br>
neopentyl, tert-pentyl, hexyl, isohexyl, heptyl, octyl, etc.<br>
Examples of sulfonyl group in an optionally<br>
substituted sulfonyl group as the substituent of the 5- to<br>
7-membered ring include a group where -SO2- is combined<br>
with "the hydrocarbon group" or "the heterocyclic group" in<br>
"an optionally substituted hydrocarbon group" or "an<br>
optionally substituted heterocyclic group" of the<br>
substituent of the 5- to 7-membered ring.<br><br>
Preferred examples include a C1-8 alkylsulfonyl group<br>
where sulfonyl group is combined with a C1-8 alkyl group<br>
such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl,<br>
sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-<br>
pentyl, hexyl, isohexyl, heptyl, octyl, etc.; a C6-10<br>
arylsulfonyl group where sulfonyl group is combined with a<br>
C6-10 aryl group such as phenyl, a-naphthyl, (3-naphthyl, 4-<br>
indenyl, 5-indenyl, 4-indanyl, 5-indanyl, 5,6,7,8-<br>
tetrahydro-1-naphthyl, 5, 6,7,8-tetrahydro-2-naphthyl, 5,6-<br>
dihydro-1-naphthyl, 5,6-dihydro-2-naphthyl, 5,6-dihydro-3-<br>
naphthyl, 5,6-dihydro-4-naphthyl, etc.; a group where<br>
sulfonyl group is combined with an aromatic monocyclic<br>
heterocyclic group (e.g., furyl, thienyl, pyrrolyl,<br>
oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl,<br>
pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-<br>
oxadiazolyl, furazanyl, 1,2,3-thiadiazolyl, 1,2,4-<br>
thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-<br>
triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl,<br>
pyrazinyl, triazinyl, or the like); and a group where the<br>
sulfonyl group is combined with an aromatic, fused<br>
heterocyclic group (e.g., benzofuranyl, isobenzofuranyl,<br>
benzo[b]thienyl, indolyl, isoindolyl, 1H-indazolyl,<br>
benzimidazolyl, benzoxazolyl, 1,2-benzisothiazolyl, 1H-<br>
benztriazolyl, quinolyl, isoquinolyl, cinnolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl,<br><br>
purinyl, pteridinyl, carbazolyl, -carbolinyl, -carbolinyl,<br>
-carbolinyl, acridinyl, phenoxazinyl, phenothiazinyl,<br>
phenazinyl, phenoxatinyl, thianthrenyl, phenanthredinyl,<br>
phenanthrolinyl, indolizinyl, pyrrolo[1,2-b]pyridazinyl,<br>
pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[1,5-<br>
a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyridyl,<br>
imidazo[1,5-a]pyridyl,	imidazo[1,2-b]pyridazinyl,<br>
imidazo[1,2-a]pyrimidinyl, l,2,4-triazolo[4,3-a]pyridyl,<br>
1,2,4-triazolo[4,3-b]pyridazinyl, etc.).<br>
More preferred examples include a C1-8 alkylsulf onyl<br>
group where sulfonyl group is combined with a C1-8 alkyl<br>
group such as methyl, ethyl, propyl, isopropyl, butyl,<br>
isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl,<br>
neopentyl, tert-pentyl, hexyl, isohexyl, heptyl, octyl, etc.<br>
Examples of an optionally substituted hydroxyl group<br>
as the substituent of the 5- to 7-membered ring include<br>
hydroxyl group and that having an appropriate substituent,<br>
for example, "an optionally substituted hydrocarbon group"<br>
or "an optionally substituted heterocyclic group" of the<br>
above substituent of the 5- to 7-membered ring.<br>
Preferred examples include a C1-8 alkyloxy group whose<br>
substituent is a C1-8 alkyl group such as methyl, ethyl,<br>
propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl,<br>
pentyl, isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl,<br>
heptyl, octyl, etc.; a C6-10 aryloxy group whose substituent<br><br>
is a C6-10 aryl group such as phenyl, -naphthyl, -naphthyl,<br>
4-indenyl, 5-indenyl, 4-indanyl, 5-indanyl, 5,6,7,8-<br>
tetrahydro-1-naphthyl, 5, 6, 7 , 8-tetrahydro-2-naphthyl, 5,6-<br>
dihydro-1-naphthyl, 5, 6-dihydro-2-naphthyl, 5, 6-dihydro-3-<br>
naphthyl, 5,6-dihydro-4-naphthyl, etc.; a hydroxyl group<br>
substituted with an aromatic monocyclic heterocyclic group<br>
(e.g., furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl,<br>
thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-<br>
oxadiazolyl, 1, 2, 4-oxadiazolyl, 1, 3, 4-oxadiazolyl,<br>
furazanyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-<br>
thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl,<br>
pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl,<br>
etc.); a hydroxyl group substituted with an aromatic fused<br>
heterocyclic group (e.g., benzofuranyl, isobenzofuranyl,<br>
benzo[b]thienyl, indolyl, isoindolyl, 1H-indazolyl,<br>
benzimidazolyl, benzoxazolyl, 1,2-benzisothiazolyl, 1H-<br>
benztriazolyl, quinolyl, isoquinolyl, cinnolinyl,<br>
quinazolinyl, quinoxalinyl, phthalazinyl, naphthyridinyl,<br>
purinyl, pteridinyl, carbazolyl, -carbolinyl, -carbolinyl,<br>
-carbolinyl, acridinyl, phenoxazinyl, phenothiazinyl,<br>
phenazinyl, phenoxatinyl, thianthrenyl, phenanthredinyl,<br>
phenanthrolinyl, indolizinyl, pyrrolo[1,2-b]pyridazinyl,<br>
pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[1,5-<br>
a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyridyl,<br>
imidazo[1,5-a]pyridyl,	imidazo[1,2-b]pyridazinyl,<br><br>
imidazo[1,2-a]pyrimidinyl, l,2,4-triazolo[4,3-a]pyridyl,<br>
1,2,4-triazolo[4,3-b]pyridazinyl, etc.).<br>
More preferred examples include a C6-10 aryloxy group<br>
(in particular, phenyloxy) or a hydroxyl group substituted<br>
with an aromatic monocyclic heterocyclic group (in<br>
particular, pyridyl) or an aromatic fused heterocyclic<br>
group (in particular, quinolyl).<br>
"The hydrocarbon group" or "the heterocyclic group" as<br>
the substituent of the substituted hydroxyl group<br>
exemplified above may have the same substituent as that of<br>
"the hydrocarbon group" or "the heterocyclic group" in "an<br>
optionally substituted hydrocarbon group or an optionally<br>
substituted heterocyclic group" of the substituent of the<br>
5- to 7-membered ring.<br>
Examples of an optionally substituted thiol group as<br>
the substituent of the 5- to 7-membered ring include thiol<br>
group and that substituted with an appropriate group such<br>
as "an optionally substituted hydrocarbon group" or "an<br>
optionally substituted heterocyclic group" of the<br>
substituent of the 5- to 7-membered ring.<br>
Preferred examples include a C1-8 alkylthio group,<br>
whose substituent is a C1-8 alkyl group such as methyl,<br>
ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-<br>
butyl, pentyl, isopentyl, neopentyl, tert-pentyl, hexyl,<br>
isohexyl, heptyl, octyl, etc.; a C5-10 arylthio group, whose<br><br>
substituent is a C6-10 aryl group such as phenyl, a-naphthyl,<br>
P-naphthyl, 4-indenyl, 5-indenyl, 4-indanyl, 5-indanyl,<br>
5,6,7,8-tetrahydro-1-naphthyl, 5,6,7,8-tetrahydro-2-<br>
naphthyl, 5,6-dihydro-1-naphthyl, 5,6-dihydro-2-naphthyl,<br>
5,6-dihydro-3-naphthyl, 5,6-dihydro-4-naphthyl, etc.; a<br>
thiol group substituted with an aromatic monocyclic<br>
heterocyclic group (e.g., furyl, thienyl, pyrrolyl,<br>
oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl,<br>
pyrazolyl, 1,2,3-oxadiazolyl, 1,2, 4-oxadiazolyl, 1,3,4-<br>
oxadiazolyl, furazanyl, 1,2,3-thiadiazolyl, 1,2,4-<br>
thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-<br>
triazolyl, tetrazolyl, pyridyl, pyrimidinyl, pyridazinyl,<br>
pyrazinyl, triazinyl, etc.); and a thiol group substituted<br>
with an aromatic fused heterocyclic groups (e.g.,<br>
benzofuranyl, isobenzofuranyl, benzo[b]thienyl, indolyl,<br>
isoindolyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl,<br>
1,2-benzisothiazolyl, 1H-benzotriazolyl, quinolyl,<br>
isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl,<br>
phthalazinyl, naphthyridinyl, purinyl, pteridinyl,<br>
carbazolyl, -carbolinyl, -carbolinyl, -carbolinyl,<br>
acridinyl, phenoxazinyl, phenothiazinyl, phenazinyl,<br>
phenoxatinyl, thianthrenyl, phenanthredinyl,<br>
phenanthrolinyl, indolizinyl, pyrrolo[1,2-b]pyridazinyl,<br>
pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[l,5-<br>
a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyridyl,<br><br>
imidazo[1,5-a]pyridyl,	imidazo[1,2-b]pyridazinyl,<br>
imidazo[1,2-a]pyrimidinyl, l,2,4-triazolo[4,3-a]pyridyl,<br>
1,2,4-triazolo[4,3-b]pyridazinyl, etc.).<br>
"The hydrocarbon group" or "the heterocyclic group" as<br>
the substituent of the substituted thiol group exemplified<br>
above may have the same substituent as that of "the<br>
hydrocarbon group" or "the heterocyclic group" in "an<br>
optionally substituted hydrocarbon group" or "an optionally<br>
substituted heterocyclic group" of the substituent of the<br>
5- to 7-membered ring.<br>
More preferred examples include a C1-8 alkylthio group<br>
substituted with a C1-8 alkyl such as methyl, ethyl, propyl,<br>
isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl,<br>
isopentyl, neopentyl, tert-pentyl, hexyl, isohexyl, heptyl,<br>
octyl, or the like.<br>
Examples of an optionally substituted amino group as<br>
the substituent of the 5- to 7-membered ring include amino<br>
group, an N-mono-substituted amino group, and an N,N-di-<br>
substituted amino group. Examples of said substituted<br>
amino groups include that having one or two substituents of<br>
an optionally substituted hydrocarbon group (e.g., the same<br>
group as an optionally substituted hydrocarbon group of the<br>
substituent of the 5- to 7-membered ring, more specifically,<br>
a C1-8 alkyl group, a C3-7 cycloalkyl group, a C2-8 alkenyl<br>
group, a C2-8 alkynyl group, a C3-7 cycloalkenyl group, a C6-<br><br>
10 aryl group that may have a C1-4 alkyl group, etc.), an<br>
optionally substituted heterocyclic group (e.g., the same<br>
group as an optionally substituted heterocyclic group of<br>
the substituent of the 5- to 7-membered ring) , or the<br>
formula: -COR' (wherein R' represents hydrogen atom or an<br>
optionally substituted hydrocarbon group or an optionally<br>
substituted heterocyclic group. As for "the hydrocarbon<br>
group" or "the heterocyclic group" in "an optionally<br>
substituted hydrocarbon group" or "an optionally<br>
substituted heterocyclic group" of R' may have the same<br>
substituent as that of "the hydrocarbon group" or "the<br>
heterocyclic group" in "an optionally substituted<br>
hydrocarbon group" or "an optionally substituted<br>
heterocyclic group" of the substituent of the 5- to 7-<br>
membered ring), preferably a C1-10 acyl group (e.g., a C2-7<br>
alkanoyl, benzoyl, nicotinoyl, etc.). Specific examples<br>
thereof include methylamino, dimethylamino, ethylamino,<br>
diethylamino, dipropylamino, dibutylamino, diallylamino,<br>
cyclohexylamino, phenylamino, N-methyl-N-phenylamino,<br>
acetylamino, propionylamino, benzoylamino, nicotinoylamino,<br>
and the like.<br>
In addition, the two groups in said substituted amino<br>
groups may be combined to form a nitrogen-containing 5- to<br>
7-membered ring (e.g., piperidino, piperadino, morpholino,<br>
thiomorpholino, etc.).<br><br>
Examples of the optionally substituted acyl group as<br>
the substituent of the 5- to 7-membered ring include (i)<br>
formyl or (ii) a group where the carbonyl group is combined<br>
with a C1-10 alkyl group, a C2-10 alkenyl group, a C2-10<br>
alkynyl group, a C3-7 cycloalkyl group, a C5-7 cycloalkenyl<br>
group, or an aromatic group (e.g., phenyl group, pyridyl<br>
group, etc.) (e.g., acetyl, propionyl, butyryl, isobytyryl,<br>
valeryl, isovaleryl, pivaloyl, hexanoyl, heptanoyl,<br>
octanoyl, cyclobutanecarbonyl, cyclopentanecarbonyl,<br>
cyclohexanecarbonyl, cycloheptanecarbonyl, crotonyl, 2-<br>
cyclohexenecarbonyl, benzoyl, etc.) and the like.<br>
Examples of the optionally esterified carboxyl group<br>
as the substituent of the 5- to 7-membered ring include, in<br>
addition to carboxyl group, an alkyloxycarbonyl group, an<br>
alkenyloxycarbonyl, an alkynyloxycarbonyl, an<br>
aralkyloxycarbonyl group, an acyoxycarbonyl group, an<br>
aryloxycarbonyl group, and the like.<br>
Examples of the alkyl group in said alkyloxycarbonyl<br>
group include a C1-6 alkyl group (e.g., methyl, ethyl,<br>
propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl,<br>
etc.).<br>
Examples of the alkenyl group in said<br>
alkenyloxycarbonyl group include a C2-6 alkenyl group (e.g.,<br>
vinyl, allyl, isopropenyl, 1-propenyl, 1-butenyl, 2-butenyl,<br>
3-methylallyl, etc.).<br><br>
Examples of the alkynyl group in said<br>
alkynyloxycarbonyl group include a C2-6 alkynyl group (e.g.,<br>
ethynyl, 2-propynyl, etc.).<br>
The aralkyl group in said aralkyloxycarbonyl group<br>
means an aryl-alkyl group (e.g., C6-10 aryl-C1-6 alkyl, etc.).<br>
The aryl group in said aryl-alkyl group means a monocyclic<br>
or condensed polycyclic aromatic hydrocarbon group, and<br>
preferred examples include phenyl, naphthyl, anthryl,<br>
phenanthryl, acenaphthenyl, and the like. They may have a<br>
substituent such as a C1-10 alkyl group, a C2-10 alkenyl<br>
group, a C2-10 alkynyl group, a C3-8 cycloalkyl group, a C3-8<br>
cycloalkenyl group, a C4-8 cycloalkadienyl group, an aryl<br>
group (e.g., C6-14 aryl, etc.), an aromatic heterocyclic<br>
group (e.g., the same aromatic heterocyclic group as that<br>
of the substituent of the hydrocarbon group, the acyl group,<br>
the sulfonyl group, the sulfinyl group and the heterocyclic<br>
group of the above substituent of the 5- to 7-membered ring,<br>
etc.), a non-aromatic heterocyclic group (e.g., the same<br>
non-aromatic heterocyclic group as that of the substituent<br>
of the hydrocarbon group, the acyl group, the sulfonyl<br>
group, the sulfinyl group and the heterocyclic group of the<br>
above substituent of the 5- to 7-membered ring, etc.), an<br>
aralkyl group (e.g., a C6-14 aryl-C1-6 alkyl group, etc.),<br>
amino group, an N-mono-substituted amino group (e.g., the<br>
same N-mono-substituted amino group as that of the<br><br>
substituent of the hydrocarbon group, the acyl group, the<br>
sulfonyl group, the sulfinyl group and the heterocyclic<br>
group of the above substituent of the 5- to 7-membered ring,<br>
preferably a N-mono-C1-4 alkylamino group, etc.), a N,N-<br>
disubstituted amino group (e.g., the same N,N-disubstituted<br>
amino group as that of the substituent in the hydrocarbon<br>
group, the acyl group, the sulfonyl group, the sulfinyl<br>
group and the heterocyclic group of the above substituent<br>
of the 5- to 7-membered ring, preferably a N,N-di-C1-4<br>
alkylamino group, etc.), amidino group, an acyl group (e.g.,<br>
the same acyl group as that of the substituent of the<br>
hydrocarbon group, the acyl group, the sulfonyl group, the<br>
sulfinyl group and the heterocyclic group of the above<br>
substituent of the 5- to 7-membered ring, etc.), carbamoyl<br>
group, a N-mono-substituted carbamoyl group (e.g., a N-<br>
mono-C1-4 alkyl-carbamoyl group such as methylcarbamoyl,<br>
ethylcarbamoyl, etc.; phenylcarbamoyl; etc.), a N,N-<br>
disubstituted carbamoyl group (a N,N-di-C1-4 alkyl-carbamoyl<br>
group such as N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl,<br>
etc.; piperidinocarbamoyl; morpholinocarbamoyl; etc.),<br>
sulfamoyl group, a N-mono-substituted sulfamoyl group (e.g.,<br>
a N-mono-C1-4 alkylsulfamoyl group such as methylsulfamoyl,<br>
ethylsulfamoyl, etc.; phenylsulfamoyl; p-toluenesulfamoyl;<br>
etc.), a N,N-disubstituted sulfamoyl group (e.g., a N,N-<br>
disubstituted C1-4 alkylsulf amoyl group such as N,N-<br><br>
dimethylsulfamoyl, etc.; a N-C1-4 alkyl-N-phenylsulfamoyl<br>
group such as N-methyl-N-phenylsulfamoyl, etc.;<br>
piperidinosulfamoyl; morpholinosulfamoyl; etc.), carboxyl<br>
group, a C1-10 alkoxy-carbonyl group (e.g., methoxycarbonyl,<br>
ethoxycarbonyl, isopropoxycarbonyl, sec-butoxycarbonyl,<br>
isobutoxycarbonyl, tert-butoxycarbonyl, etc.), hydroxyl<br>
group, a C1-10 alkoxy group, a C2-10 alkenyloxy group, a C3-7<br>
cycloalkyloxy group, an aralkyloxy group (e.g., C6-14 aryl-<br>
C1-6 alkyloxy, etc.), an aryloxy group (e.g., C6-14 aryloxy,<br>
etc.), mercapto group, a C1-10 alkylthio group, an<br>
aralkylthio group (e.g., C6-14 aryl-C1-6 alkylthio, etc.), an<br>
arylthio group (e.g., C6-14 arythio, etc.), sulfo group,<br>
cyano group, azido group, nitro group, nitroso group, a<br>
halogen atom, or the like. As for an alkyl group in said<br>
aryl-alkyl group, a C1-6 alkyl group (e.g., methyl, ethyl,<br>
propyl, butyl, etc.) is preferred. Preferred examples of<br>
said aralkyl group, i.e., an aryl-alkyl group include<br>
benzyl, phenethyl, 3-phenylpropyl, (1-naphthyl)methyl, (2-<br>
naphthyl)methyl, and the like. Among them, benzyl,<br>
phenethyl, and the like are preferred.<br>
As the acyl group in said acyloxycarbonyl group, for<br>
example, there are formyl, a C2-4 alkanoyl group, a C3-4<br>
alkenoyl group, a C3-4 alkynoyl group, and the like.<br>
As the aryl group in said aryloxycarbonyl group, for<br>
example, there are phenyl, naphthyl, and the like.<br><br>
Examples of the amidated carboxyl group as the<br>
substituent of the hydrocarbon group, the acyl group, the<br>
sulfonyl group, the sulfinyl group and the heterocyclic<br>
group of the substituent of the 5- to 7-membered ring<br>
include the carboxyl group amidated with an optionally<br>
substituted amino group as the substituent of the<br>
hydrocarbon group, the acyl group, the sulfonyl group, and<br>
the heterocyclic group of the above substituent of the 5-<br>
to 7-membered ring, each of which may be substituted.<br>
Example of an optionally substituted phosphoryl group<br>
of the substituent of the 5- to 7-membered ring include<br>
phosphoryl group, a (C1-6 alkoxy) phosphoryl group such as<br>
ethoxyphosphoryl, a di-(C1-6 alkoxy)phosphoryl group such as<br>
diethoxyphosphoryl, etc.; a lower (C1-6) alkyl group<br>
substituted with an optionally esterified phosphono group<br>
such as a phosphono-C1-6 alkyl group, a C1-6<br>
alkoxyphosphoryl-C1-6 alkyl group, a di- (C1-6<br>
alkoxy) phosphoryl-C1-6 alkyl group such as<br>
diethoxyphosphorylmethyl, etc.; and the like.<br>
"The hydrocarbon group", "the heterocyclic group",<br>
"the sulfinyl group", or "the sulfonyl group" in "an<br>
optionally substituted hydrocarbon group", "an optionally<br>
substituted heterocyclic group", "an optionally substituted<br>
sulfinyl group", or "an optionally substituted sulfonyl<br>
group" of the substituent of the 5- to 7-membered ring may<br><br>
be further substituted with 1 to 3 substituents. Examples<br>
of said substituents include a lower (C1-6) alkyl group<br>
(e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl,<br>
sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl,<br>
etc.); a lower (C2-6) alkenyl group (e.g., vinyl, allyl, 1-<br>
propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-<br>
butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2-pentenyl, 3-<br>
pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1-hexenyl, 3-<br>
hexenyl, 4-hexenyl, 5-hexenyl, etc.); a lower (C2-6) alkynyl<br>
group (e.g., ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-<br>
butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-<br>
pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-<br>
hexynyl, etc.); a C3-7 cycloalkyl group (e.g., cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, etc.); a<br>
C6-10 aryl group (e.g., phenyl, -naphthyl, -naphthyl,<br>
etc.); an aromatic heterocyclic group [e.g., (i) an<br>
aromatic 5- or 6-membered heterocyclic group having 1-4<br>
heteroatoms selected from nitrogen atom, oxygen atom, and<br>
sulfur atom; (ii) a fused bicyclic heterocyclic group<br>
formed by condensation of an aromatic 5- or 6-membered<br>
heterocyclic group having 1 to 3 heteroatoms selected from<br>
nitrogen atom, oxygen atom, and sulfur atom with benzene<br>
ring or an aromatic 5- or 6-membered heterocyclic group<br>
having 1 to 3 heteroatoms selected from nitrogen atom,<br>
oxygen atom, and sulfur atom; (iii) a fused tricyclic<br><br>
heterocyclic group formed by condensation of [1] an<br>
aromatic, 5- or 6-membered heterocyclic group having 1-3<br>
heteroatoms selected from nitrogen atom, oxygen atom and<br>
sulfur atom, [2] benzene ring, and [3] an aromatic 5- or 6-<br>
membered heterocyclic group having 1-3 heteroatoms selected<br>
from nitrogen atom, oxygen atom and sulfur atom or benzene<br>
ring, such as furyl, thienyl, pyrrolyl, oxazolyl,<br>
isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl,<br>
1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl,<br>
furazanyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-<br>
thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl,<br>
pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl,<br>
benzofuranyl, isobenzofuranyl, benzo[b]thienyl, indolyl,<br>
isoindolyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl,<br>
1,2-benzisothiazolyl, 1H-benztriazolyl, quinolyl,<br>
isoquinolyl, cinnolinyl, quinazolinyl, quinoxalinyl,<br>
phthalazinyl, naphthyridinyl, purinyl, pteridinyl,<br>
carbazolyl, -carbolinyl, -carbolinyl, -carbolinyl,<br>
acridinyl, phenoxazinyl, phenothiazinyl, phenazinyl,<br>
phenoxatinyl, thianthrenyl, phenanthredinyl,<br>
phenanthrolinyl, indolizinyl, pyrrolo[1,2-b]pyridazinyl,<br>
pyrazolo[1,5-a]pyridyl, imidazo[1,2-a]pyridyl, imidazo[1,5-<br>
a]pyridyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyridyl,<br>
imidazo[1,5-a]pyridyl,	imidazo[1,2-b]pyridazinyl,<br>
imidazo[1,2-a]pyrimidinyl, l,2,4-triazolo[4,3-a]pyridyl,<br><br>
1, 2, 4-triazolo[4,3-b]pyridazinyl, etc.]; a heterocyclic-oxy<br>
group formed by combining each of the above heterocyclic<br>
groups (i), (ii) and (iii) with oxy group; a non-aromatic<br>
heterocyclic group (e.g., a non-aromatic, 4- or 7-membered<br>
heterocyclic group having 1 to 3 heteroatoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom, such as<br>
oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl,<br>
tetrahydrofuryl, thiolanyl, piperidinyl, tetrahydropyranyl,<br>
morpholinyl, thiomorpholinyl, piperazinyl, etc.); a C7-14<br>
aralkyl group (e.g., a C6-10 aryl-C1-4 alkyl group such as<br>
benzyl, phenethyl, 1-phenylethyl, 1-phenylpropyl, 2-<br>
phenylpropyl, 3-phenylpropyl, -naphthylmethyl, -<br>
naphthylethyl, -naphthylmethyl, -naphthylethyl, etc.);<br>
amino group; a N-mono-substituted amino group [e.g., a N-<br>
(C1-6 alkyl)amino group such as methylamino, ethylamino,<br>
allylamino, cyclohexylamino, phenylamino, a N- (C2-6<br>
alkenyl) amino group, a N-(C3-7 cycloalkyl) amino group, a N-<br>
(C6-10 aryl) amino group, etc.]; a N, N-disubstituted amino<br>
group [e.g., an amino group substituted with two<br>
substituents selected from a C1-6 alkyl group, a C2-6 alkenyl<br>
group, a C3-7 cycloalkenyl group, and a C6-10 aryl group,<br>
such as dimethylamino, diethylamino, dibutylamino,<br>
diallylamino, N-methyl-N-phenylamino, etc.]; amidino group;<br>
an acyl group (e.g., formyl, a C2-8 alkanoyl group such as<br>
acetyl, propionyl, butyryl, isobytyryl, valeryl, isovaleryl,<br><br>
pivaloyl, hexanoyl, heptanoyl, octanoyl,<br>
cyclopropanecarbonyl,	cyclobutanecarbonyl,<br>
cyclopentanecarbonyl, cyclohexanecarbonyl, crotonyl, 2-<br>
cyclohexenecarbonyl, benzoyl, nicotinoyl, etc.; a C3-8<br>
alkenoyl group; a C3-7 cycloalkyl-carbonyl group; a C3-7<br>
cycloalkenyl-carbonyl group; a C6-10 aryl-carbonyl group; a<br>
heterocyclic-carbonyl group formed by binding of an<br>
aromatic or non-aromatic 5- or 6-membered heterocyclic<br>
group having 1-3 heteroatoms selected from nitrogen atom,<br>
oxygen atom and sulfur atom with carbonyl group, etc.);<br>
carbamoyl group; a mono-substituted carbamoyl group [e.g.,<br>
a N-(C1-6 alkyl)carbamoyl group such as methylcarbamoyl,<br>
ethylcarbamoyl, cyclohexylcarbamoyl, phenylcarbamoyl,<br>
etc.]; a N-(C2-6 alkenyl) carbamoyl group; a N-(C3-7<br>
cycloalkyl) carbamoyl group; a N-(C6-10 aryl) carbamoyl group;<br>
etc.]; a N,N-disubstituted carbamoyl group [e.g., a<br>
carbamoyl group substituted with two substituents selected<br>
from a C1-6 alkyl group, a C2-6 alkenyl group, a C3-7<br>
cycloalkyl group, and a C6-10 aryl group, such as<br>
dimethylcarbamoyl, diethylcarbamoyl, dibutylcarbamoyl,<br>
diallylcarbamoyl, N-methyl-N-phenylcarbamoyl, etc.];<br>
sulfamoyl group, a N-mono-substituted sulfamoyl group [e.g.,<br>
a N-(C1-6 alkyl)sulfamoyl group such as methylsulfamoyl,<br>
ethylsulfamoyl, cyclohexylsulfamoyl, phenylsulfamoyl, etc.;<br>
a N-(C2-6 alkenyl) sulfamoyl group; a N-(C3-7<br><br>
cycloalkyl) sulfamoyl group; a N-(C6-10 aryl) sulfamoyl group;<br>
etc.], a N,N-disubstituted sulfamoyl group [e.g., sulfamoyl<br>
group substituted with two substituents selected from a C1-6<br>
alkyl group, a C2-6 alkenyl group, a C3-7 cycloalkyl group,<br>
and a C6-10 aryl group, such as dimethylsulf amoyl,<br>
diethylsulfamoyl, dibutylsulfamoyl, diallylsulfamoyl, N-<br>
methyl-N-phenylsulfamoyl, etc.]; carboxyl group; a lower<br>
(C1-6) alkoxy-carbonyl group (e.g., methoxycarbonyl,<br>
ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl,<br>
butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl,<br>
tert-butoxycarbonyl, pentyloxycarbonyl, hexyloxycarbonyl,<br>
etc.); hydroxyl group; a lower (C1-6) alkoxy group (e.g.,<br>
methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy,<br>
sec-butoxy, tert-butoxy, pentyloxy, hexyloxy, etc.); a<br>
lower (C2-10) alkenyloxy group (e.g., allyloxy, 2-butenyloxy,<br>
2-pentenyloxy, 3-hexenyloxy, etc.); a C3-7 cycloalkyloxy<br>
group (e.g., cyclopropyloxy, cyclobutyloxy, cyclopentyloxy,<br>
cyclohexyloxy, cycloheptyloxy, etc.); a C6-10 aryloxy group<br>
(e.g., phenoxy, naphthyloxy, etc.); a C7-14 aralkyloxy group<br>
(e.g., a C6-10 aryl-C1-4 alkyloxy group such as phenyl-C1-4<br>
alkyloxy, naphthyl-C1-4 alkyloxy, etc.); mercapto group; a<br>
lower (C1-6)alkylthio group (e.g., methylthio, ethylthio,<br>
propylthio, isopropylthio, butylthio, isobutylthio, sec-<br>
butylthio, tert-butylthio, pentylthio, isopentylthio,<br>
neopentylthio, hexylthio, etc.), a C7-14 aralkylthio group<br><br>
(e.g., a C6-10 aryl-C1-4 alkylthio group such as phenyl-C1-4<br>
alkylthio, naphthyl-C1-4 alkylthio, etc.); a C6-10 arylthio<br>
group (e.g., phenylthio, naphtylthio, etc.), a lower (C1-6)<br>
alkylsulfinyl group (e.g., methylsulfinyl, ethylsulfinyl,<br>
propylsulfinyl, isopropylsulfinyl, butylsulfinyl,<br>
isobutylsulfinyl, sec-butylsulfinyl, tert-butylsulfinyl,<br>
pentylsulfinyl, isopentylsulfinyl, neopentylsulfinyl,<br>
hexylsulfinyl, etc.); a C7-14 aralkylsulfinyl group (e.g., a<br>
C6-10 aryl-C1-4 alkylsulf inyl group such as phenyl-C1-4<br>
alkylsulf inyl, naphthyl-C1-4 alkylsulf inyl, etc.); a C6-10<br>
arylsulfinyl group (e.g., phenylsulfinyl, naphtylsulfinyl,<br>
etc.); a lower (C1-6) alkylsulf onyl group (e.g.,<br>
methylsulfonyl, ethylsulfonyl, propylsulfonyl,<br>
isopropylsulfonyl, butylsulfonyl, isobutylsulfonyl, sec-<br>
butylsulf onyl, tert-butylsulfonyl, pentylsulfonyl,<br>
isopentylsulfonyl, neopentylsulfonyl, hexylsulfonyl, etc.),<br>
a C7-14 aralkylsulf onyl group (e.g., a C6-10 aryl-C1-4<br>
alkylsulfonyl group such as phenyl-C1-4 alkylsulfonyl,<br>
naphthyl-C1-4 alkylsulf onyl, etc.), a C6-10 arylsulfonyl<br>
group (e.g., phenylsulfonyl, naphtylsulfonyl, etc.); sulfo<br>
group; cyano group; azido group; a halogen atom (e.g.,<br>
fluorine, chlorine, bromine, iodine, etc.); nitro group;<br>
nitroso group; an optionally esterified phosphono group<br>
[e.g., phosphono group, a (C1-6 alkoxy)phosphoryl group such<br>
as ethoxyphosphoryl, a di-(C1-6 alkoxy)phosphoryl group such<br><br>
as diethoxyphosphoryl, etc.]; a lower (C1-6) alkyl group<br>
substituted with an optionally esterified phosphono group<br>
(e.g., a phosphono-C1-6 alkyl group, a C1-6 alkoxyphosphoryl-<br>
C1-6 alkyl group, a di-(C1-6 alkoxy) phosphoryl-C1-6 alkyl<br>
group such as diethoxyphosphorylmethyl, etc.); a C1-6<br>
haloalkyl group (e.g., a C1-6 alkyl group substituted with 1<br>
to 4 halogen such as trifluoromethyl, etc.); a C1-6<br>
haloalkoxy group (e.g., a C1-6 alkoxy group substituted with<br>
1 to 4 halogen such as trif luoromethoxy, etc.); and the<br>
like.<br>
Among the above substituents, when hydroxyl group is<br>
located adjacent to a lower (C1-6) alkoxy group, they may<br>
form C1-6 alkylenedioxy groups such as methylenedioxy,<br>
ethylenedioxy, or the like.<br>
The above C6-10 aryl group, the C6-10 aryl group as a<br>
substituent of the aromatic heterocyclic group and the N-<br>
mono-substituted amino group, the C6-10 aryl group as a<br>
substituent of the N, N-di-substituted amino group, the C6-10<br>
aryl group as a substituent of the N-mono-substituted<br>
carbamoyl group, the C6-10 aryl group as a substituent of<br>
the N, N-di-substituted carbamoyl group, the C6-10 aryl as a<br>
substituent of the N-mono-substituted sulfamoyl group, the<br>
C6-10 aryl group as a substituent of the N, N-disubstituted<br>
sulfamoyl group, the C6-10 aryl group as a substituent of<br>
the C6-10 aryloxy group, the C6-10 aryl group of the C7-14<br><br>
aralkyloxy group, the C6-10 aryl group of the C7-14<br>
aralkylthio groups, the C6-10 aryl group of the C6-10<br>
arylthio groups, the C6-10 aryl group of the C7-14<br>
aralkylsulf inyl groups, the C6-10 aryl group of the C6-10<br>
arylsulfinyl group, the C6-10 aryl group of the C7-3.4<br>
aralkylsulfonyl groups, and the C6-10 aryl group in the C6-10<br>
arylsulfonyl group may be substituted further with 1 to 3<br>
substituents. Examples of said substituent include a lower<br>
(C1-6) alkyl group, amino group, a N-(C1-6 alkyl) amino group,<br>
a N,N-di-(C1-6 alkyl)amino group, amidino group, carbamoyl<br>
group, a N- (C1-6 alkyl) carbamoyl group, a N,N-di-(C1-6<br>
alkyl)carbamoyl group, sulfamoyl group, a N-(C1-6<br>
alkyl)sulfamoyl group, a N,N-di-(C1-6 alkyl)sulfamoyl group,<br>
carboxyl group, a lower (C2-7) alkoxycarbonyl group,<br>
hydroxyl group, a lower (C1-6) alkoxy group, mercapto group,<br>
a lower (C1-6) alkylthio group, sulfo group, cyano group,<br>
azido group, a halogen atom, nitro group, nitroso group, an<br>
optionally substituted phosphono group [e.g., phosphono<br>
group, a C1-6 alkoxyphosphoryl group, a di- (C1-6<br>
alkoxy) phosphoryl group, etc.], a lower (C1-6) alkyl group<br>
substituted with an optionally esterified phosphono group<br>
[e.g., a phosphono-C1-6 alkyl group, a C1-6 alkoxyphosphoryl-<br>
C1-6 alkyl group, a di- (C1-6 alkoxy) phosphoryl-C1-6 alkyl<br>
group such as diethoxyphosphorylmethyl, etc.], and the like<br>
Among the above substituent, when hydroxyl group is<br><br>
located adjacent to a lower (C1-6) alkoxyl group, they may<br>
form a C1-6 alkylenedioxy group such as methylenedioxy,<br>
ethylenedioxy, or the like.<br>
The number of the substituents of the 5- to 7-membered<br>
ring is 1 to 3, preferably 1 to 2 and the substituents may<br>
be the same or different and present at any possible<br>
positions of the ring.<br>
Q of the formula (II) is C, CR5, or N.<br>
R5 is H, an optionally substituted hydrocarbon group,<br>
an optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted thiol<br>
group, cyano group, a halogen atom, an optionally<br>
substituted heterocyclic group, or a group of the formula:<br>
-Z1-Z2 (wherein -Z1- is -CO-, -CS-, -SO- or -SO2-, and Z2 is<br>
an optionally substituted hydrocarbon group, an optionally<br>
substituted heterocyclic group, an optionally substituted<br>
hydroxyl group, or an optionally substituted amino group).<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group and an optionally<br>
substituted heterocyclic group of R5 or Z2 include the same<br>
groups as those exemplified with respect to the above<br>
substituents of the 5- to 7-membered ring of ring A.<br>
Examples of halogen and an optionally substituted<br>
thiol group of R5 include the same groups as those<br><br>
exemplified with respect to the above substituent of the 5-<br>
to 7-membered ring of ring A.<br>
X1 in the formulas (I) and (II) is CR1, CR1R2, N or NR13.<br>
R1 is H, an optionally substituted hydrocarbon group,<br>
an optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted thiol<br>
group, cyano group, a halogen atom, an optionally<br>
substituted heterocyclic group, or a group of the formula:<br>
-Z1-Z2 (wherein -Z1- and Z2 are as defined above) .<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted thiol group, halogen and an optionally<br>
substituted heterocyclic group of R1 include the same<br>
groups as those exemplified with respect to the<br>
substituents of the 5- to 7-membered ring of ring A.<br>
R2 is H, or an optionally substituted hydrocarbon<br>
group, and examples of an optionally substituted<br>
hydrocarbon group of R2 include the same group as that<br>
exemplified with respect to the substituent of the 5- to 7-<br>
membered ring of ring A.<br>
R13 is H, an optionally substituted hydrocarbon group,<br>
an optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted<br>
heterocyclic group, or a group of the formula: -Z1-Z2<br><br>
(wherein -Z1- and Z2 are as defined above) .<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group and an optionally<br>
substituted heterocyclic group of R13 include the same<br>
groups as those exemplified with respect to the<br>
substituents of the 5- to 7-membered ring of ring A.<br>
R1 of the formula (III) is H, an optionally<br>
substituted hydrocarbon group, an optionally substituted<br>
hydroxyl group, an optionally substituted thiol group, an<br>
optionally substituted amino group, cyano group, a halogen<br>
atom, an optionally substituted heterocyclic group, or a<br>
group of the formula: -Z1-Z2 (wherein -Z1- is -CO-, -CS-, -<br>
SO- or -SO2-, and Z2 is an optionally substituted<br>
hydrocarbon group, an optionally substituted heterocyclic<br>
group, an optionally substituted hydroxyl group, or an<br>
optionally substituted amino group).<br>
In R1 of the formula (III), preferred example of the<br>
group of the formula: -Z1-Z2 is a group of the formula: -<br>
CONR20(CR21R22R23) , wherein R20 is H or an optionally<br>
substituted hydrocarbon group, and R21, R22, and R23 are the<br>
same or different and are an optionally substituted<br>
hydrocarbon group, an optionally substituted heterocyclic<br>
group, or R20 and R21 may be combined to form a ring.<br>
Examples of an optionally substituted hydrocarbon<br><br>
group of R1, R20, R21, R22 and R23, an optionally substituted<br>
heterocyclic group of R1, R21, R22 and R23, and an optionally<br>
substituted hydroxyl group, an optionally substituted amino<br>
group, an optionally substituted thiol group and halogen of<br>
R1 include the same groups as those exemplified with<br>
respect to the substituents of the 5- to 7-membered ring of<br>
ring A of the formulas (I) and (II) .<br>
Preferably, at least one of R21, R22 and R23 is an<br>
optionally substituted heterocyclic group which may be<br>
fused with an optionally substituted benzene ring, or an<br>
optionally substituted phenyl group which may be fused with<br>
an optionally substituted aromatic heterocyclic ring.<br>
Examples of the "fused heterocyclic group" of the<br>
"optionally substituted heterocyclic group which may be<br>
fused with an optionally substituted benzene ring" and the<br>
"fused phenyl group" of the " optionally substituted phenyl<br>
group which may be fused with an optionally substituted<br>
aromatic heterocyclic ring" of R21, R22 and R23 include the<br>
same groups as those exemplified with respect to the<br>
aromatic fused heterocyclic group as the substituents of<br>
the 5- to 7-membered ring of ring A.<br>
Examples of these substituents include the same groups<br>
as those exemplified with respect to the substituents of<br>
the 5- to 7-membered ring of ring A of the formulas (I) and<br>
(II).<br><br>
The ring formed in combination with R20 and R21 is<br>
preferably an optionally substituted 5- to 7-membered ring,<br>
more preferably an optionally substituted 5- or 6-membered<br>
ring, and may be fused with an optionally substituted<br>
benzene ring. Such rings include the same rings as those<br>
exemplified with respect to the "5- to 7-membered ring" of<br>
"an optionally substituted 5- to 7-membered ring" in the<br>
ring A of the formulas (I) and (II).<br>
These rings may have 1 to 3 substituents selected from<br>
the group consisting of (1) halogen, (2) hydrogen, (3) a<br>
phenoxy which may be substituted with 1 to 3 substituents<br>
selected from halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6<br>
acyl (e.g., formyl, C2-6 alkanoyl, etc.), cyano, amino,<br>
mono-C1-6 alkyl-amino, di-C1-6 alkyl-amino, C1-6 alkyl-<br>
sulfanyl, C1-6 alkyl-sulf inyl, C1-6 alkyl-sulf onyl, C1-6<br>
alkoxy-carbonyl, carbamoyl, N-C1-6 alkyl-carbamoyl and N,N-<br>
di-C1-6 alkyl-carbamoyl,<br>
(4) C1-6 alkoxy which may be substituted with 1 to 3<br>
substituents selected from halogen, hydroxyl, C1-6 alkyl,<br>
C1-6 alkoxy, C1-6 acyl, cyano, amino, mono-C1-6 alkyl-amino,<br>
di-C1-6 alkyl-amino, C1-6 alkyl-sulf anyl, C1-6 alkyl-sulf inyl,<br>
C1-6 alkyl-sulf onyl, C1-6 alkoxy-carbonyl, carbamoyl, N-C1-6<br>
alkyl-carbamoyl, N,N-di-C1-6 alkyl-carbamoyl and phenyl<br>
which may be substituted with 1 to 3 substituents selected<br>
from halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 acyl,<br><br>
cyano, halogeno C1-6 alkyl (e.g., trifluoromethyl, etc.),<br>
amino, mono-C1-6 alkyl-amino, di-C1-6 alkyl-amino, C1-6 alkyl-<br>
sulfanyl, C1-6 alkyl-sulf inyl, C1-6 alkyl-sulf onyl, C1-6<br>
alkoxy-carbonyl, carbamoyl, N-C1-6 alkyl-carbamoyl and N,N-<br>
di-C1-6 alkyl-carbamoyl,<br>
and (5) a C1-8 hydrocarbon group (e.g., C1-8 alkyl, C3-7<br>
cycloalkyl, C2-8 alkenyl, C2-8 alkynyl, C3-7 cycloalkenyl,<br>
etc.) which may be substituted with 1 to 3 substituents<br>
selected from halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6<br>
acyl, cyano, amino, mono-C1-6 alkyl-amino, di-C1-6 alkyl-<br>
amino, C1-6 alkyl-sulf anyl, C1-6 alkyl-sulf inyl, C1-6 alkyl-<br>
sulfonyl, C1-6 alkoxy-carbonyl, carbamoyl, N-C1-6 alkyl-<br>
carbamoyl, N,N-di-C1-6 alkyl-carbamoyl and phenyl which may<br>
be substituted with 1 to 3 sunstitutents selected from<br>
halogen, hydroxyl, C1-6 alkyl, C1-6 alkoxy, C1-6 acyl, cyano,<br>
halogeno C1-6 alkyl (e.g., trifluoromethyl, etc.), amino,<br>
mono-C1-6 alkyl-amino, di-C1-6 alkyl-amino, C1-6 alkyl-<br>
sulfanyl, C1-6 alkyl-sulf inyl, C1-6 alkyl-sulf onyl, C1-6<br>
alkoxy-carbonyl, carbamoyl, N-C1-6 alkyl-carbamoyl and N,N-<br>
di-C1-6 alkyl-carbamoyl.<br>
Specific examples of these substituents include the<br>
same groups as those exemplified with respect to the<br>
substituents of the 5- to 7-membered ring of ring A of the<br>
formulas (I) and (II) .<br>
R1a of the formula (IIIa) is (1) an optionally<br><br>
substituted heterocyclic group or (2) a group of the<br>
formula: -Z1a-Z2a (wherein -Z1a- is -CO-, -CS-, -SO- or -SO2-,<br>
and Z2a is (i) an optionally substituted heterocyclic group,<br>
(ii) -NR20a(CR21aR22aR23a) (wherein (a) R20a is H or an<br>
optionally substituted hydrocarbon group; and R21a is an<br>
optionally substituted heterocyclic group which may be<br>
fused with an optionally substituted benzene ring, or an<br>
optionally substituted C6-10 aryl group which may be fused<br>
with an optionally substituted aromatic heterocyclic ring<br>
and R22a and R23a are the same or different and are an<br>
optionally substituted hydrocarbon group or an optionally<br>
substituted heterocyclic group or R22a and R23a may be<br>
combined to form a ring, or (b) R20a is H or an optionally<br>
substituted hydrocarbon group; and R21a, R22a and R23a are the<br>
same or different and are an optionally substituted C1-8<br>
aliphatic hydrocarbon group, provided that the sum total of<br>
the number of carbon atoms is 7 or more),<br>
(iii) -NR20aR25a (wherein R20a is as defined above and R25a is<br>
an optionally substituted C6-10 aryl-C2-4 alkyl, C6-10<br>
aryloxy-C2-4 alkyl, C6-10 arylamino-C2-4 alkyl, C7-14<br>
aralkylamino-C2-4 alkyl, heterocyclic ring-C2-4 alkyl or<br>
heterocyclic group), (iv) a substituted 5- to 7-membered<br>
cyclic amino group, or (v) -OR24a (wherein R24a is (a) an<br>
optionally substituted C7-14 aralkyl group, (b) an<br>
optionally substituted C3-7 alicyclic hydrocarbon group, (c)<br><br>
an optionally substituted C7-24 aliphatic hydrocarbon group,<br>
or (d) an optionally substituted heterocyclic group)).<br>
Examples of an optionally substituted hydrocarbon<br>
group of R20a, R22a and R23a and an optionally substituted<br>
heterocyclic group of Rla, Z2a, R21a, R22a and R23a include the<br>
same groups as those exemplified with respect to the<br>
substituents of the 5- to 7-membered ring of ring A of the<br>
formulas (I) and (II) .<br>
Examples of the "fused heterocyclic group" of the<br>
"optionally substituted heterocyclic group which may be<br>
fused with an optionally substituted benzene ring" and the<br>
"fused phenyl group" of "an optionally substituted phenyl<br>
group which may be fused with an optionally substituted<br>
aromatic heterocyclic ring" of R21a, R22a and R23a include the<br>
same groups as those exemplified with respect to the<br>
aromatic fused heterocyclic group as the substituents of<br>
the 5- to 7-membered ring of ring A.<br>
Examples of the ring formed in combination with R20a<br>
and R21a and the substituents thereof include the same rings<br>
and substituents as those exemplified with respect to the<br>
ring formed in combination with R20 and R21 and the<br>
substituents thereof.<br>
Examples of the "optionally substituted C1-8 aliphatic<br>
hydrocarbon group" of R20a include the same groups as those<br>
exemplified with respect to the aliphatic hydrocarbon group<br><br>
as the substituents of the 5- to 7-membered ring of ring A.<br>
Examples of the "optionally substituted C7-14 aralkyl<br>
group", the "optionally substituted C3-7 alicyclic<br>
hydrocarbon group" and the "optionally substituted<br>
heterocyclic group" of R24a include the same groups as those<br>
exemplified with respect to the substituents of the 5- to<br>
7-membered ring of ring A respectively.<br>
Examples of the "C7-24 aliphatic hydrocarbon group" of<br>
the "optionally substituted C7-24 aliphatic hydrocarbon<br>
group" in R24a include, for example, C7-24 alkyl, C7-24<br>
alkenyl, C7-24 alkynyl, C7-24 alkadienyl, C7-24 alkadiynyl such<br>
as heptyl, octyl, 1-heptenyl, 1-octenyl, 1-heptynyl, 1-<br>
octynyl, etc.<br>
Examples of the substituents of the "optionally<br>
substituted C7-24 aliphatic hydrocarbon group" in R24a<br>
include the same substituents as those exemplified with<br>
respect to the substituents of the hydrocarbon group as the<br>
substituents of 5- to 7-membered ring of ring A.<br>
In the formula (IIIa), Rla is preferably (1) an<br>
optionally substituted 5- to 7-membered aromatic or non-<br>
aromatic heterocyclic group having 1-4 hetero atoms<br>
selected from nitrogen atom, oxygen atom and sulfur atom,<br>
or (2) a group of the formula: -CO-Z2c (wherein Z2c is (i)<br>
an optionally substituted 5- to 7-membered aromatic or non-<br>
aromatic heterocyclic group having 1-4 hetero atoms<br><br>
selected from nitrogen atom, oxygen atom and sulfur atom,<br>
(ii) -NR20c(CR21cR22cR23c) (wherein (a) R20c is H or an<br>
optionally substituted hydrocarbon group selected from C1-8<br>
saturated aliphatic hydrocarbon group, C2-8 unsaturated<br>
aliphatic hydrocarbon group, C3-7 saturated alicyclic<br>
hydrocarbon group, C3-7 unsaturated alicyclic hydrocarbon<br>
group, C9-10 partly saturated and fused bicyclic hydrocarbon<br>
group, C3-7 saturated or unsaturated alicyclic-C1-8 saturated<br>
or unsaturated aliphatic hydrocarbon group, C9-10 partly<br>
saturated and fused bicyclic hydrocarbon-C1-4 alkyl group,<br>
C9-10 partly saturated and fused bicyclic hydrocarbon-C2-4<br>
alkenyl group, C6-10 aryl group and C7-14 aralkyl group; and<br>
R21c is 1) an optionally substituted 5- to 7-membered<br>
aromatic or non-aromatic heterocyclic group having 1-4<br>
hetero atoms selected from nitrogen atom, oxygen atom and<br>
sulfur atom, which may be fused with an optionally<br>
substituted benzene ring, or 2) an optionally substituted<br>
C6-10 aryl group (e.g., phenyl group, etc.) which may be<br>
fused with an optionally substituted 5- to 7-membered<br>
aromatic heterocyclic ring having 1-4 hetero atoms selected<br>
from nitrogen atom, oxygen atom and sulfur atom; and R22c<br>
and R23c are the same or different and are an optionally<br>
substituted hydrocarbon group selected from C1-8 saturated<br>
aliphatic hydrocarbon group, C2-8 unsaturated aliphatic<br>
hydrocarbon group, C3-7 saturated alicyclic hydrocarbon<br><br>
group, C3-7 unsaturated alicyclic hydrocarbon group, C9-10<br>
partly saturated and fused bicyclic hydrocarbon group, C3-7<br>
saturated or unsaturated alicyclic-C1-8 saturated or<br>
unsaturated aliphatic hydrocarbon group, C9-10 partly<br>
saturated and fused bicyclic hydrocarbon-C1-4 alkyl group,<br>
C9-10 partly saturated and fused bicyclic hydrocarbon-C2-4<br>
alkenyl group, C6-10 aryl group and C7-14 aralkyl group, or an<br>
optionally substituted 5- to 7-membered aromatic or non-<br>
aromatic heterocyclic group having 1-4 hetero atoms<br>
selected from nitrogen atom, oxygen atom and sulfur atom or<br>
R22c and R23c may be combined to form a C3-7 carbon ring, or<br>
(b) R20c is H or an optionally substituted hydrocarbon group<br>
selected from C1-8 saturated aliphatic hydrocarbon group,<br>
C2-8 unsaturated aliphatic hydrocarbon group, C3-7 saturated<br>
alicyclic hydrocarbon group, C3-7 unsaturated alicyclic<br>
hydrocarbon group, C9-10 partly saturated and fused bicyclic<br>
hydrocarbon group, C3-7 saturated or unsaturated alicyclic-<br>
C1-8 saturated or unsaturated aliphatic hydrocarbon group,<br>
C9-10 partly saturated and fused bicyclic hydrocarbon-C1-4<br>
alkyl group, C9-10 partly saturated and fused bicyclic<br>
hydrocarbon-C2-4 alkenyl group, C6-10 aryl group and C7-14<br>
aralkyl group; and R21c, R22c and R23c are the same or<br>
different and are an optionally substituted C1-8 aliphatic<br>
hydrocarbon group, provided that the sum total of the<br>
number of carbon atoms is 7 or more),<br><br>
(iii) -NR20cR25c (wherein R20c is as defined above and R25c is<br>
an optionally substituted C6-10 aryl-C2-4 alkyl, C6-10<br>
aryloxy-C2-4 alkyl, C6-10 arylamino-C2-4 alkyl, C7-14<br>
aralkylamino-C2-4 alkyl, 5- to 7-membered heterocyclic ring<br>
(having 1-4 hetero atoms selected from nitrogen atom,<br>
oxygen atom and sulfur atom)-C2-4 alkyl or 5- to 7-membered<br>
heterocyclic group having 1-4 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom),<br>
(iv) a substituted 5- to 7-membered cyclic amino group<br>
(e.g., piperidino, piperadino, morpholino, thiomorpholino,<br>
etc.), or<br>
(v) -OR24c (wherein R24c is (a) an optionally substituted C7-<br>
14 aralkyl group, (b) an optionally substituted C3-7<br>
alicyclic hydrocarbon group, (c) an optionally substituted<br>
C7-24 aliphatic hydrocarbon group, or (d) an optionally<br>
substituted 5- to 7-membered aromatic or non-aromatic<br>
heterocyclic group having 1-4 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom;<br>
wherein said substituents for R1a, Z2c, R20c, R21c, R22c, R23c,<br>
R24c and R25c are 1 to 3 substituents selected from the group<br>
consisting of<br>
1)	C1-6 alkyl,<br>
2)	C2-6 alkenyl,<br>
3)	C2-6 alkynyl,<br>
4)	C3-7 cycloalkyl,<br><br>
5)	C6-10 aryl which may be substituted with 1 to 3<br>
substituents selected from the group consisting of C1-6<br>
alkyl, amino, N-(C1-6 alkyl) amino, N,N-di-(C1-6 alkyl) amino,<br>
amidino, carbamoyl, N-(C1-6 alkyl) carbamoyl, N,N-di-(C1-6<br>
alkyl)carbamoyl, sulfamoyl, N-(C1-6 alkyl)sulfamoyl, N,N-<br>
di-(C1-6 alkyl) sulfamoyl, carboxyl, C2-7 alkoxycarbonyl,<br>
hydroxyl, C1-6 alkoxy, mercapto, C1-6 alkylthio, sulfo,<br>
cyano, azido, halogen, nitro, nitroso, phosphono, C1-6<br>
alkoxyphosphoryl, di-(C1-6 alkoxy) phosphoryl and C1-6 alkyl<br>
substituted with phosphono, C1-6 alkoxyphosphoryl and di-<br>
(C1-6 alkoxy)phosphoryl (hereinafter the group of 5) is<br>
referred to as group "C") ,<br>
6)	aromatic heterocyclic group selected from (a) aromatic<br>
5- or 6-membered heterocyclic group having 1-4 hetero<br>
atoms selected from nitrogen atom, oxygen atom and sulfur<br>
atom, (b) fused bicyclic heterocyclic group formed by<br>
condensation of an aromatic 5- or 6-membered heterocyclic<br>
group having 1 to 3 hetero atoms selected from nitrogen<br>
atom, oxygen atom and sulfur atom with benzene ring or an<br>
aromatic 5- or 6-membered heterocyclic group having 1 to<br>
3 hetero atoms selected from nitrogen atom, oxygen atom<br>
and sulfur atom and (c) fused tricyclic heterocyclic<br>
group formed by condensation of [1] an aromatic 5- or 6-<br>
membered heterocyclic group having 1-3 hetero atoms<br>
selected from nitrogen atom, oxygen atom and sulfur atom,<br><br>
[2] benzene ring, and [3] an aromatic 5- or 6-membered<br>
heterocyclic group having 1-3 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom or benzene<br>
ring,<br>
7)	heterocyclic-oxy group formed by combining each of the<br>
above aromatic heterocyclic groups (a) , (b) and (c) with<br>
oxy group,<br>
8)	non-aromatic 4- or 7-membered heterocyclic group<br>
having 1 to 3 hetero atoms selected from nitrogen atom,<br>
oxygen atom and sulfur atom,<br>
9)	C7-14 aralkyl which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br>
10)	amino group,<br>
11)	N-mono-substituted amino selected from N-(C1-6<br>
alkyl) amino, N-(C2-6 alkenyl) amino, N- (C3-7<br>
cycloalkyl) amino group and N- (C6-10 aryl) amino which may<br>
be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
12)	amino substituted with two substituents selected from<br>
C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkenyl and C6-10 aryl<br>
which may be substituted with 1 to 3 substituents<br>
selected from the group "C",<br>
13)	amidino,<br>
14)	acyl selected from C2-8 alkanoyl, C3-8 alkenoyl, C3-7<br>
cycloalkyl-carbonyl, C3-7 cycloalkenyl-carbonyl, C6-10<br><br>
aryl-carbonyl which may be substituted with 1 to 3<br>
substituents selected from the group "C", and<br>
heterocyclic-carbonyl formed by binding of an aromatic or<br>
non-aromatic 5- or 6-membered heterocyclic group having<br>
1-3 hetero atoms selected from nitrogen atom, oxygen atom<br>
and sulfur atom with carbonyl,<br>
15)	carbamoyl,<br>
16)	mono-substituted carbamoyl group selected from N-(C1-6<br>
alkyl) carbamoyl, N- (C2-6 alkenyl) carbamoyl, N-(C3-7<br>
cycloalkyl) carbamoyl and N-(C6-10 aryl) carbamoyl which may<br>
be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
17)	carbamoyl substituted with two substituents selected<br>
from C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl and C5-10 aryl<br>
which may be substituted with 1 to 3 substituents<br>
selected from the group "C",<br>
18)	sulfamoyl,<br>
19)	N-mono-substituted sulfamoyl selected from N-(C1-6<br>
alkyl) sulfamoyl, N- (C2-6 alkenyl) sulfamoyl, N-(C3-7<br>
cycloalkyl) sulfamoyl and N-(C6-10 aryl) sulfamoyl which may<br>
be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
20)	sulfamoyl substituted with two substituents selected<br>
from C1-6 alkyl, C2-6 alkenyl, C3-7 cycloalkyl and C6-10<br>
aryl which may be substituted with 1 to 3 substituents<br><br>
selected from the group "C",<br>
21)	carboxyl,<br>
22)	C1-6 alkoxy-carbonyl,<br>
23)	hydroxyl,<br>
24)	C1-6 alkoxy,<br>
25)	C2-10 alkenyloxy,<br>
26)	C3-7 cycloalkyloxy,<br><br>
27)	C6-10 aryloxy which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br>
28)	C7-14 aralkyloxy which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br>
29)	mercapto,<br>
30)	C1-6 alkylthio,<br>
31)	C7-14 aralkylthio which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br>
32)	C6-10 arylthio which may be substituted with 1 to 3<br>
substituents selected from the group "C",<br>
33)	C1-6 alkylsulfinyl,<br>
34)	C7-14 aralkylsulfinyl which may be substituted with 1<br>
to 3 substituents selected from the group "C",<br>
35)	C6-10 arylsulfinyl which may be substituted with 1 to<br>
3 substituents selected from the group "C",<br>
36)	C1-6 alkylsulfonyl,<br>
38) C7-14 aralkylsulf onyl which may be substituted with 1<br>
to 3 substituents selected from the group "C",<br><br>
39)	C6-10 arylsulfonyl which may be substituted with 1 to<br>
3 substituents selected from the group "C",<br>
40)	sulfo,<br>
41)	cyano,<br>
42)	azido,<br>
43)	halogen,<br>
44)	nitro,<br>
45)	nitroso,<br>
46)	phosphono,<br>
47)	C1-6 alkoxy-phosphoryl<br>
48)	di-C1-6 alkoxy-phosphoryl,<br>
49)	C1-6 alkyl substituted with phosphono, C1-6<br>
alkoxyphosphoryl or di-(C1-6 alkoxy) phosphoryl<br>
50)	C1-6 alkyl substituted with 1 to 4 halogen atoms<br>
51)	C1-6 alkoxy substituted with 1 to 4 halogen atoms and<br>
52)	C1-6 alkylenedioxy<br>
(hereinafter the group of above 1) to 52) is referred to<br>
as group "B").<br>
Specific examples of these substituents include the<br>
same groups as those exemplified with respect to the<br>
substituents of the 5- to 7-membered ring of ring A.<br>
As R1a of the formula (IIIa), more preferred is the<br>
group represented by the formula:<br>
CONR20c(CR21cR22cR23c) (wherein R20c, R21c, R22c and R23c are as<br>
defined above).<br><br>
Further more preferably, R1a is (1) a 5- to 7-membered<br>
aromatic heterocyclic group having 1-4 hetero atoms<br>
selected from nitrogen atom, oxygen atom and sulfur atom<br>
(e.g., 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, etc.) which<br>
is substituted with C1-4 alkyl-C7-14 aralkyl (e.g., 1-ethyl-<br>
1-(4-methylphenyl)propyl, etc.), or (2) a group represented<br>
by the formula: -CO-Z2c' (wherein Z2c' is<br>
(i) -NR20c' (CR21c'R22c'R23c') (wherein (a) R20c' is H or C1-6<br>
alkyl; R21c' is a C6-10 aryl group or a 5- to 7-membered<br>
aromatic heterocyclic group having 1-4 hetero atoms<br>
selected from nitrogen atom, oxygen atom and sulfur atom,<br>
each of which may be substituted with 1 to 3 substituents<br>
selected from the group consisting of halogen, C1-6 alkyl,<br>
C2-6 alkenyl, halogeno C1-6 alkyl, hydroxy-C1-6 alkyl, C1-6<br>
alkoxy, carboxyl, C1-6 alkoxy-carbonyl, C1-6 alkyl-<br>
carbonyloxy, C1-6 alkyl-carbonyloxy-C1-6 alkyl, carboxy-C1-6<br>
alkoxy, C1-6 alkoxy-carbonyl-C1-6 alkyl, C1-6 alkoxy-carbonyl-<br>
C1-6 alkoxy, C1-6 alkoxy-carbonyl-C1-6 alkoxy-C1-6 alkyl,<br>
carbonyl, C1-6 alkyl-carbonyl, amino, mono- or di- C1-6<br>
alkylamino, phenyl (said phenyl may be substituted with 1<br>
to 3 substituents selected from halogen, C1-6 alkyl and<br>
halogeno C1-6 alkyl) and a 5- to 7-membered aromatic<br>
heterocyclic group having 1-4 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom; R22c' and R23c'<br>
are the same or different and are C1-6 alkyl group, C5-7<br><br>
cycloalkyl group, phenyl group (said phenyl group may be<br>
substituted with 1 to 3 substituents selected from C1-6<br>
alkyl, halogeno C1-6 alkyl and C1-6 alkoxy) , C1-6 alkoxy-<br>
carbonyl-C1-6 alkyl group or C1-6 alkyl-carbonyl-C2-6 alkenyl<br>
group, or R22c' and R23c' may be combined each other to form a<br>
C3-7 carbon ring; or (b) R20c' and R21c' are combined each<br>
other to form a 5- to 7-membered ring and said ring may be<br>
substituted with C1-6 alkoxy or C7-14 aralkyl, and R22c' and<br>
R23c' are C1-6 alkyl group) ,<br>
(ii) -NR20C'R25C' (wherein R20c' is H or C1-6 alkyl group; R25c'<br>
is C6-10 aryl-C2-4 alkyl group, C6-10 aryloxy-C2-4 alkyl group,<br>
C6-10 arylamino-C2-4 alkyl group, C7-14 aralkylamino-C2-4 alkyl<br>
group, 5- to 7-membered heterocyclic ring-C2-4 alkyl group<br>
or 5- to 7-membered heterocyclic group, each of which may<br>
be substituted with 1 or 2 substituents selected from the<br>
group consisting of halogen, C1-6 alkyl, C6-10 aryl, C1-6<br>
alkoxy, amino, mono- or di- C1-6 alkylamino, 5- to 7-<br>
membered cyclic amino, hydroxy, oxo, C1-6 alkoxy-carbonyl<br>
and cyano), or<br>
(iii) a 5- to 7-membered cyclic amino group which is<br>
substituted with 1 to 3 substituents selected from the<br>
group consisting of halogen, C1-6 alkyl, C2-6 alkenyl, C1-6<br>
alkoxy-C1-6 alkyl, C5-7 cycloalkyl, C6-10 aryl (said aryl may<br>
have 1 or 2 substituents selected from halogen, C1-6 alkyl,<br>
halogeno C1-6 alkyl and C1-6 alkoxy) , C7-14 aralkyl (said<br><br>
aralkyl may have 1 or 2 substituents selected from halogen,<br>
C1-6 alkyl, halogeno C1-6 alkyl and C1-6 alkoxy) , hydroxy,<br>
hydroxy-C1-6 alkyl, C6-10 aryloxy (said aryloxy may have 1 or<br>
2 substituents selected from halogen, C1-6 alkyl, halogeno<br>
C1-6 alkyl and C1-6 alkoxy) , C7-14 aralkyloxy, C6-10 aryl-<br>
carbonyl, carboxyl, C1-6 alkoxy-carbonyl, carbamoyl, C6-10<br>
aryl-carbamoyl, amino, C6-10 aryl-carbonylamino, C1-6 alkyl-<br>
carbonylamino, C1-6 alkoxy-carbonylamino, C6-10 arylthio, C6-<br>
10 arylsulfonyl, cyano, oxo and 5- to 7-membered<br>
heterocyclic group.).<br>
R3 of the formulas (II), (III) and (IIIa) is H, an<br>
optionally substituted hydrocarbon group, an optionally<br>
substituted hydroxyl group, an optionally substituted amino<br>
group, an optionally substituted heterocyclic group, or a<br>
group of the formula: -Z1-Z2 (wherein -Z1- and Z2 are as<br>
defined above).<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group and an optionally<br>
substituted heterocyclic group of R3 include the same<br>
groups as those exemplified with respect to the<br>
substituents of the 5- to 7-membered ring of ring A.<br>
R3 is preferably H, a C1-6 alkyl group or a C7-14 aralkyl<br>
group, and more preferably R3 is H.<br>
Y in the formulas (I), (II), (III) and (IIIa) is C,<br><br>
CR4, or N.<br>
R4 is H, an optionally substituted hydrocarbon group,<br>
an optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted thiol<br>
group, cyano group, a halogen atom, an optionally<br>
substituted heterocyclic group, or a group of the formula:<br>
-Z1-Z2 (wherein -Z1- and Z2 are as defined above) .<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted heterocyclic group and halogen of R4 include<br>
the same groups as those exemplified with respect to the<br>
substituents of the 5- to 7-membered ring of ring A.<br>
Y is preferably CH.<br>
R8 of the formulas (III) and (IIIa) is H, an<br>
optionally substituted hydrocarbon group, an optionally<br>
substituted hydroxyl group, an optionally substituted amino<br>
group, an optionally substituted thiol group, cyano group,<br>
a halogen atom, an optionally substituted heterocyclic<br>
group, or a group of the formula: -Z1-Z2 (wherein -Z1- and<br>
Z2 are as defined above).<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted thiol group, halogen atom and an optionally<br><br>
substituted heterocyclic group of R include the same<br>
groups as those exemplified with respect to the<br>
substituents of the 5- to 7-membered ring of ring A.<br>
R8 is preferably H, a C1-6 alkyl group, a C1-6 alkylthio<br>
group or a C1-6 alkoxy group which may be substituted with<br>
hydroxyl group, and more preferably R8 is H or a C1-6 alkyl<br>
group.<br>
Ar in the formulas (I), (II), (III) and (IIIa) is an<br>
optionally substituted cyclic group.<br>
Examples of the optionally substituted cyclic group of<br>
Ar include an optionally substituted aromatic or non-<br>
aromatic hydrocarbon ring group or an optionally<br>
substituted aromatic or non-aromatic heterocyclic group,<br>
and the like.<br>
Examples of the aromatic hydrocarbon ring group and<br>
the heterocyclic group of Ar include the same aromatic<br>
hydrocarbon group and heterocyclic group as exemplified<br>
with respect to the above substituents of the 5- to 7-<br>
membered ring of ring A.<br>
Examples of the non-aromatic hydrocarbon ring group<br>
include a saturated alicyclic hydrocarbon group having 3-7<br>
carbon atoms (e.g., cycloalkyl group, etc.) such as<br>
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,<br>
cycloheptyl, and the like; an unsaturated alicyclic<br>
hydrocarbon group having 3-7 carbon atoms (e.g.,<br><br>
cycloalkenyl group, cycloalkadienyl group, etc.) such as 1-<br>
cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-<br>
cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1-<br>
cycloheptenyl, 2-cycloheptenyl, 3-cycloheptenyl, 2,4-<br>
cycloheptadienyl, etc.; a partly saturated and fused<br>
bicyclic hydrocarbon group [preferably, C9-10 partly<br>
saturated and fused bicyclic hydrocarbon group, etc.<br>
(including those where the benzene ring is combined to 5-<br>
or 6-membered non-aromatic cyclic hydrocarbon group)] such<br>
as 1-indenyl, 2-indenyl, 1-indanyl, 2-indanyl, 1,2,3,4-<br>
tetrahydro-1-naphthyl, 1, 2, 3, 4-tetrahydro-2-naphthyl, 1,2-<br>
dihydro-1-naphthyl, 1,2-dihydro-2-naphthyl, 1,4-dihydro-1-<br>
naphthyl, 1,4-dihydro-2-naphthyl, 3,4-dihydro-1-naphthyl,<br>
3,4-dihydro-2-naphthyl, etc.; and the like.<br>
Examples of the substituent of an optionally<br>
substituted aromatic ring group and an optionally<br>
substituted heterocyclic group of Ar include the same<br>
groups as those exemplified with respect to the above<br>
substituents of the 5- to 7-membered ring of ring A.<br>
Ar is preferably (1) a C6-10 aryl group, (2) a 5- to 7-<br>
membered aromatic or non-aromatic heterocyclic group having<br>
1-4 hetero atoms selected from nitrogen atom, oxygen atom<br>
and sulfur atom, or (3) a C3-7 saturated or unsaturated<br>
alicyclic hydrocarbon group, each of which may be<br>
substituted with 1 to 3 substituents selected from the<br><br>
group "B".<br>
More preferably, Ar is a C6-10 aryl group which may be<br>
substituted with 1 to 3 substituents selected from the<br>
group "B", a 5- to 7-membered aromatic heterocyclic group<br>
having 1-4 hetero atoms selected from nitrogen atom, oxygen<br>
atom and sulfur atom which may be substituted with 1 to 3<br>
substituents selected from the group "B", or a C3-7<br>
saturated or unsaturated alicyclic hydrocarbon group.<br>
Further more preferably, Ar is (1) a C6-10 aryl group<br>
(e.g., phenyl, naphthyl, etc.) which may be substituted<br>
with 1 or 2 substituents selected from the group consisting<br>
of halogen atom, C1-6 alkyl, C1-6 alkoxy, hydroxy, C7-14<br>
aralkyloxy and mono- or di-C1-4 alkylamino, (2) a 5- to 7-<br>
membered aromatic heterocyclic group having 1-4 hetero<br>
atoms selected from nitrogen atom, oxygen atom and sulfur<br>
atom (e.g., pyridyl, furyl, thiazolyl, thienyl, etc.) which<br>
may be substituted with C1-4 alkyl or (3) a C5-7 cycloalkyl<br>
group (e.g., cyclohexyl etc.), and most preferably, Ar is<br>
an optionally halogenated phenyl group.<br>
R9 and R10 of the formulas (II), (III) and (IIIa) are<br>
the same or different and are H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br><br>
the formula: -Z1-Z2 (wherein -Z1- and Z2 are as defined<br>
above), or R9 and R10 may be combined to form an oxo group,<br>
methylene group or a ring.<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted thiol group, a halogen atom and an optionally<br>
substituted heterocyclic group of R9 and R10 include the<br>
same groups as those exemplified with respect to the above<br>
substituents of the 5- to 7-membered ring of ring A.<br>
One of R9 and R10 is preferably a hydrogen atom or C1-6<br>
alkyl group which may be substituted with 1 to 3<br>
substituents selected from the group "B" and the other is<br>
(1) a hydrocarbon group selected from C1-8 saturated<br>
aliphatic hydrocarbon group, C2-8 unsaturated aliphatic<br>
hydrocarbon group, C3-7 saturated alicyclic hydrocarbon<br>
group, C3-7 unsaturated alicyclic hydrocarbon group, C9-10<br>
partly saturated and fused bicyclic hydrocarbon group, C3-7<br>
saturated or unsaturated alicyclic-C1-8 saturated or<br>
unsaturated aliphatic hydrocarbon group, C9-10 partly<br>
saturated and fused bicyclic hydrocarbon-C1-4 alkyl group,<br>
C9-10 partly saturated and fused bicyclic hydrocarbon-C2-4<br>
alkenyl group, C6-10 aryl group and C7-14 aralkyl group, each<br>
of which may be substituted with 1 to 3 substituents<br>
selected from the group "B" or (2) a 5- to 7-membered<br><br>
aromatic or non-aromatic heterocyclic group having 1-4<br>
hetero atoms selected from nitrogen atom, oxygen atom and<br>
sulfur atom, which may be substituted with 1 to 3<br>
substituents selected from the group "B", or<br>
R9 and R10 may be combined to form a C5-7 carbon ring.<br>
More preferably, one of R9 and R10 is preferably a<br>
hydrogen atom or C1-6 alkyl group and the other is an<br>
optionally halogenated C1-6 alkyl group, C6-10 aryl group, C7-<br>
10 aralkyl group or a 5- to 7-membered aromatic<br>
heterocyclic group, or R9 and R10 are a C5-7 carbon ring<br>
formed by combining together.<br>
Examples of R11 and R12 of the forumula (II) are the<br>
same or different and are H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1'-Z2 (wherein -Z1'- is -CS-, -SO- or -SO2-,<br>
and Z2 is as defined above).<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted thiol group, a halogen atom and an optionally<br>
substituted heterocyclic group of R11 and R12 include the<br>
same groups as those exemplified with respect to the above<br><br>
substituents of the 5- to 7-membered ring of ring A.<br>
R9 and R10, or R11 and R12 may be combined to form an<br>
oxo group, methylene group or a ring such as a C3-6<br>
saturated or unsaturated carbon ring (e.g., cyclopropyl,<br>
cyclobutyl, cyclopentyl, cyclohexyl, 1-cyclopentenyl, 2-<br>
cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-<br>
cyclohexenyl, 3-cyclohexenyl, etc.); or R10 and R11 may be<br>
combined to form a ring such as a C3-6 saturated or<br>
unsaturated carbon ring (e.g., cyclopropyl, cyclobutyl,<br>
cyclopentyl, cyclohexyl, 1-cyclopentenyl, 2-cyclopentenyl,<br>
3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-<br>
cyclohexenyl, etc.).<br>
  is a single bond or a double bond.<br>
Z in the formula (I) is CR5, CR5R6, N or NR7, and CR5<br>
is as defined above.<br>
R6 is H, an optionally substituted hydrocarbon group,<br>
an optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted thiol<br>
group, cyano group, a halogen atom, an optionally<br>
substituted heterocyclic group, or a group of the formula:<br>
-Z1-Z2 (wherein -Z1- and Z2 are as defined above)).<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted thiol group, and an optionally substituted<br><br>
heterocyclic group of R6 include the same groups as those<br>
exemplified with respect to the above substituents of the<br>
5- to 7-membered ring of ring A.<br>
R7 is H, an optionally substituted hydrocarbon group,<br>
an optionally substituted hydroxyl group, an optionally<br>
substituted amino group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- and Z2 are as defined<br>
above)).<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, a halogen atom and an<br>
optionally substituted heterocyclic group of R7 include the<br>
same groups as those exemplified with respect to the above<br>
substituents of the 5- to 7-membered ring of ring A.<br>
R5, R6 and R7 may be the same or different.<br>
R5 is H, an optionally substituted hydrocarbon group,<br>
an optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted thiol<br>
group, an optionally substituted sulfonyl group or an<br>
optionally substituted sulfinyl group.<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted thiol group, an optionally substituted sulfonyl<br><br>
group and an optionally substituted sulfinyl group of R<br>
include the same groups as those exemplified with respect<br>
to the above substituents of the 5- to 7-membered ring of<br>
ring A.<br>
R and Z may be combined to form a ring B<br>
Ring B in the formula (I) is an optionally substituted<br>
5- to 7-membered heterocyclic ring and examples thereof<br>
include the same group as that exemplified with respect to<br>
the 5- to 7-membered ring of ring A.<br>
X2 of the formula (I) is N or NR3 and R3 are as defined<br>
above.<br>
X3 of the formula (III) and (IIIa) is a bond, oxygen<br>
atom, an optionally oxidized sulfur atom, N, NR7', or an<br>
optionally substituted bivalent C1-2 hydrocarbon group.<br>
R7' is H, an optionally substituted hydrocarbon group,<br>
an optionally substituted hydroxyl group, an optionally<br>
substituted amino group, an optionally substituted<br>
heterocyclic group, or a group of the formula -Z1'-Z2<br>
(wherein -Z1'- is -CS-, -SO- or -SO2-, and Z2 is as defined<br>
above)).<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, and an optionally<br>
substituted heterocyclic group of R7' include the same<br>
groups as those exemplified with respect to the<br><br>
substituents of the 5- to 7-membered ring of ring A.<br>
Examples of an optionally substituted bivalent Ci_2<br>
hydrocarbon group include -CH2-, -(CH2)2-, -CH=CH- and the<br>
like which may be substituted with one or two substituents<br>
selected from those exemplified with respect to the<br>
substituents of the 5- to 7-membered ring of ring A.<br>
In the formula (IIIa), X3 is preferably CH2.<br>
Prefered compounds of the formula (I) include not only<br>
the compounds of the formula (IIIa) but also the other<br>
compounds wherein -Z1- is -CO- and Z2 is an optionally<br>
substituted hydroxyl group (e.g., hydroxy, C1-6 alkoxy,<br>
etc.) or amino group which is substituted with an<br>
optionally substituted phenyl group or an optionally<br>
substituted condensed phenyl group (e.g., phenylamino, 3,5-<br>
dimethoxyphenylamino, 3-biphenylylamino, 2,3-dihydro-1H-<br>
inden-5-yl-amino, quinolin-6-yl-amino, etc.).<br>
In the formula (II),<br>
(1)	when ring A is a 6-membered ring and Q is C or CR5, X1<br>
is C-Z1-Z2, C(-Z1-Z2)R2 or N-Z1Z2, and both R9 and R10 are<br>
not H, or R9 and R10 are not combined to form an oxo group,<br>
or R10 and R11 are not combined to form a 5-membered ring;<br>
(2)	when ring A is a 6-membered ring and Q is N, X1 is C-<br>
Z1-Z2, C(-Z1-Z2)R2 or N-Z1Z2, and R9 and R10 are not combined<br>
to form an oxo group;<br>
(3)	when ring A is a 5-membered ring and Q is C or CR5, X1<br><br>
is C-Z1Z2, C(-Z1-Z2)R2 or N-Z1-Z2, and Z2 is an optionally<br>
substituted amino group; and<br>
(4) when ring A is a 5-membered ring and Q is N, at least<br>
one of R9 and R10 is CHR15R16 (wherein R15 and R16 are the<br>
same or different and are H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, a halogen atom, an optionally<br>
substituted heterocyclic group, or a group of the formula:-<br>
Z1-Z2 (wherein -Z1- and Z2 are as defined above) .<br>
Examples of an optionally substituted hydrocarbon<br>
group, an optionally substituted hydroxyl group, an<br>
optionally substituted amino group, an optionally<br>
substituted thiol group, a halogen atom and an optionally<br>
substituted heterocyclic group include the same groups as<br>
those exemplified with respect to the above substituents of<br>
the 5- to 7-membered ring of ring A.<br>
In the formulas (II) and (III) , preferably, R1 is a<br>
group of the formula: -Z1-Z2; Z1 is -CO- and Z2 is an<br>
optionally substituted hydroxyl group or an optionally<br>
substituted amino group; Ar is an optionally substituted<br>
aromatic ring group; and both R9 and R10 are the same or<br>
different and are C1-6 alkyl groups or R9 and R10 are<br>
combined to form a ring such as a saturated or unsaturated<br>
C3-6 ring as described above.<br><br>
In the formula (III), preferably, R3 is H. More<br>
preferably, in the formula (III), R1 is a group of the<br>
formula: -Z1-Z2 (wherein -Z1- is -CO-, -CS-, -SO- or -SO2-,<br>
and Z2 is an optionally substituted hydrocarbon group, an<br>
optionally substituted heterocyclic group, an optionally<br>
substituted hydroxyl group, or an optionally substituted<br>
amino group) ; R3 is H; Ar is an optionally substituted<br>
aromatic ring group; X3 is CR11R12 (wherein R11 and R12 are<br>
the same or different and are H, an optionally substituted<br>
hydrocarbon group, an optionally substituted hydroxyl group,<br>
an optionally substituted amino group, an optionally<br>
substituted thiol group, cyano group, a halogen atom, an<br>
optionally substituted heterocyclic group, or a group of<br>
the formula: -Z1-Z2 (wherein -Z1- and Z2 are as defined<br>
above) , or R11 and R12 may be combined to form an oxo group,<br>
methylene group or a ring such as a saturated or<br>
unsaturated C3-6 ring as described above) ; and R9 and R10 are<br>
the same or different and are a C1-6 alkyl group, or R9 and<br>
R10 may be combined to form a ring such as a saturated or<br>
unsaturated C3-6 ring as described above.<br>
As for a salt of the compound of formula (I), (II),<br>
(III) or (IIIa) (hereinafter sometimes referred to as<br>
Compound (1), (II), (III) or (IIIa)), a pharmaceutically<br>
acceptable salt is preferred. Examples thereof include a<br>
salt with an inorganic base, a salt with an organic base, a<br><br>
salt with an inorganic acid, a salt with an organic acid, a<br>
salt with a basic or acidic amino acid, or the like.<br>
Preferred examples of a salt with an inorganic base include<br>
an alkali metal salt such as sodium salt, potassium salt,<br>
or the like; an alkaline earth metal salt such as calcium<br>
salt, magnesium salt, or the like; and aluminum salt;<br>
ammonium salt; or the like. Preferred examples of a salt<br>
with an organic base include a salt with trimethylamine,<br>
triethylamine, pyridine, picoline, ethanolamine,<br>
diethanolamine, triethanolamine, dicyclohexylamine, N,N'-<br>
dibenzylethylenediamine, or the like. Preferred examples<br>
of a salt with an inorganic acid include a salt with<br>
hydrochloric acid, hydrobromic acid, nitric acid, sulfuric<br>
acid, phosphoric acid, or the like. Preferred examples of a<br>
salt with an organic acid include a salt with formic acid,<br>
acetic acid, trifluoroacetic acid, fumaric acid, oxalic<br>
acid, tartaric acid, maleic acid, citric acid, succinic<br>
acid, malic acid, methanesulfonic acid, benzenesulfonic<br>
acid, p-toluenesulfonic acid, or the like. Preferred<br>
examples of a salt with a basic amino acid include a salt<br>
with arginine, lysine, ornithine or the like. Preferred<br>
examples of a salt with an acidic amino acid include a salt<br>
with aspartic acid, glutamic acid, or the like.<br>
Compound (I), (II), (III) or (IIIa) may be in the form<br>
of a prodrug thereof. The prodrug of Compound (I), (II),<br><br>
(III) or (IIIa) refers to a compound that is converted into<br>
Compound (I), (II), (III) or (IIIa) by a reaction with an<br>
enzyme, gastric acid, or the like under a physiological<br>
condition in the living body, namely, (i) a compound that<br>
is converted into Compound (I), (II), (III) or (IIIa) by an<br>
enzymatic oxidation, reduction, hydrolysis, or the like,<br>
and (ii) a compound that is converted into Compound (I),<br>
(II), (III) or (IIIa) by hydrolysis with gastric acid or<br>
the like. Examples of a prodrug of Compound (I), (II),<br>
(III) or (IIIa) to be used include a compound or its salt<br>
wherein hydroxyl group in Compound (I), (II), (III) or<br>
(IIIa) is acylated, alkylated, phosphorylated, or converted<br>
into borate (e.g., a compound or its salt wherein hydroxyl<br>
group in Compound (I), (II), (III) or (IIIa) is converted<br>
into acetyloxy, palmitoyloxy, propanoyloxy, pivaloyloxy,<br>
succinyloxy,	fumaryloxy,	alanyloxy,<br>
dimethylaminomethylcarbonyloxy, etc.), a compound or its<br>
salt wherein carboxyl group in Compound (I), (II), (III) or<br>
(IIIa) is esterified or amidated (e.g., a compound or its<br>
salt wherein carboxyl group in Compound (I), (II), (III) or<br>
(IIIa) is subjected to ethyl esterification, phenyl<br>
esterification, carboxyoxymethyl esterification,<br>
dimethylaminomethyl esterification, pivaloyloxymethyl<br>
esterification, ethoxycarbonyloxyethyl esterification,<br>
phthalidyl esterification, (5-methyl-2-oxo-l,3-dioxolan-4-<br><br>
yl)methyl esterification, cyclohexyloxycarbonyl<br>
esterification, or conversion into the methyl amide, etc.),<br>
or the like. These prodrugs can be produced according to a<br>
per se known method or its modified method.<br>
Further, a prodrug of Compound (I), (II), (III) or<br>
(IIIa) may be a compound or its salt that is converted into<br>
Compound (I), (II), (III) or (IIIa) under physiological<br>
conditions as described in "Development of Drugs", Volume 7,<br>
Molecular Design, Hirokawa Shoten, 1990; pages 163-198.<br>
Compound (I), (II), (III) or (IIIa) may be labeled<br>
with an isotope (for example, 2H, 3H, 14C, 35S, 125I, or the<br>
like) or the like.<br>
When the compound obtained by the present invention or<br>
a salt thereof has a double bond in its molecule and a<br>
steric configuration of Z or E exsits, each of the<br>
stereoisomers and a mixture thereof are included in the<br>
present invention.<br>
When a steric configuration exsits due to an<br>
asymmetric carbon in the molecule of the compound obtained<br>
by the present invention or a salt thereof, each of them<br>
and a mixture thereof are included in the present invention.<br>
Hereinafter, production of the compound of the present<br>
invention will be illustrated.<br>
A process for preparing Compound (II), Compound (III)<br>
and Compound (IIIa) of the present invention will be shown<br><br>
in the following schemes 1 to 13.<br>
A compound wherein Q is N, and Y is C or CR4 in<br>
Compound (II) can be prepared according to the schemes 1 to<br>
3.<br>
A compound wherein Q is C, and Y is C or CR4 in<br>
Compound (II) can be prepared according to the scheme 4.<br>
A compound wherein Q is N, and Y is N in Compound (II)<br>
can be prepared according to the scheme 5.<br>
A compound wherein Y is C or CR4 in Compound (III) and<br>
Compound (IIIa) can be prepared by the scheme 6.<br>
A compound wherein Y is N in Compound (III) and<br>
Compound (IIIa) can be prepared by the scheme 7.<br>
A compound wherein Q is C, and Y is N in Compound (II)<br>
can be prepared by the scheme 13.<br><br>
wherein A-1 is the same as A, and the other symbols are as<br>
defined above.<br>
In step A, Compound (II-1) is prepared by cyclization<br>
reaction of Compound (IV-1) and Compound (X) with an acid<br>
or a base. Examples of the acid used in this reaction<br><br>
include: inorganic acids such as hydrochloric acid,<br>
hydrobromic acid, sulfuric acid and phosphoric acid;<br>
organic acids such as acetic acid, trifluoroacetic acid,<br>
methanesulfonic acid, benzenesulfonic acid and p-<br>
toluenesulfonic acid; and Lewis acids such as zinc (II)<br>
chloride, tin (IV) chloride, aluminium chloride and the<br>
like.<br>
Examples of the base include alkali metal salts such<br>
as potassium hydroxide, sodium hydroxide, sodium<br>
bicarbonate and potassium carbonate; amines such as<br>
pyridine, triethylamine, N,N-dimethylaniline and 1,8-<br>
diazabicyclo[5.4.0]undec-7-ene; metal hydrides such as<br>
potassium hydride and sodium hydride; and alkali metal<br>
alkoxides such as sodium methoxide, sodium ethoxide and<br>
potassium t-butoxide.<br>
An amount of these acids or bases to be used is<br>
preferably about 0.1 to about 5 mole equivalent relative to<br>
Compound (IV-1).<br>
Examples of a solvent having no adverse effect on the<br>
reaction include aromatic hydrocarbons such as benzene,<br>
toluene and xylene; ethers such as tetrahydrofuran,<br>
dimethoxyethane, dioxane and diethyl ether; amides such as<br>
N,N-dimethylformamide; alcohol such as ethanol, propanol,<br>
tert-butanol and methoxyethanol; and sulfoxides such as<br>
dimethyl sulfoxide. These solvents may be used by mixing<br><br>
at an appropriate ratio.<br>
A reaction temperature is usually about -50C to about<br>
200C, preferably about -10C to about 150C.<br>
A reaction time is usually about 0.5 to about 60 hours.<br>
The thus obtained compound (II-l) can be isolated and<br>
purified by the known separating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br>
Compound (IV-1) used herein can be prepared, for<br>
example, according to the method described in Bilestein,<br>
vol.25, p.2033. In addition, Compound (X) can be prepared,<br>
for example, according to Organometallics, vol.11, p.954.<br>
In step B, Compound (II-2) is prepared by a reduction<br>
reaction for Compound (II-l).<br>
In the present reaction, a catalytic hydrogenation<br>
method using palladium carbon, palladium hydroxide or the<br>
like, or reduction using a reducing agent is performed. As<br>
the reducing agent, sodium borohydride, aluminium lithium<br>
hydride and lithium borohydride are used. In the present<br>
reaction, if needed, any solvents can be used as long as<br>
they do not inhibit the reaction. Inter alia, alcohols<br>
(e.g. C1-3 alcohol such as methanol, ethanol, propanol and<br>
the like) or ethers (diethyl ether, diisopropyl ether,<br>
ethylene glycol dimethyl ether, tetrahydrofuran, dioxane<br><br>
etc.) are preferable.<br>
A reaction time is usually about 0.5 to about 20 hours.<br>
The thus obtained Compound (II-2) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br><br>
wherein A-1 is the same as A, and the other symbols are as<br>
defined above.<br>
In step C, Compound (V) is prepared by a reaction for<br>
cyclizing Compound (IV-1) and Compound (XI). The present<br>
reaction is carried out in the presence of an acid in a<br>
solvent having no adverse effect on the reaction or without<br>
a solvent according to the conventional method.<br>
Examples of the acid include inorganic acids such as<br>
hydrochloric acid, hydrobromic acid, sulfuric acid and<br>
phosphoric acid; organic acids such as acetic acid,<br>
trifluoroacetic acid, methanesulfonic acid, benzenesulfonic<br>
acid and p-toluenesulfonic acid; Lewis acids such as zinc<br><br>
(II) chloride, tin (IV) chloride, aluminium chloride and<br>
the like.<br>
An amount of these acids is preferably about 0.1 to<br>
about 5 mole equivalent relative to Compound (IV-1).<br>
Examples of the solvent having no adverse effect on<br>
the reaction include aromatic hydrocarbons such as benzene,<br>
toluene and xylene; ethers such as tetrahydrofuran, dioxane<br>
and diethyl ether; halogenated hydrocarbons such as<br>
chloroform and dichloromethane; amides such as N,N-<br>
dimethylformamide; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used by mixing at an<br>
appropriate ratio.<br>
A reaction temperature is usually about -50C to 150C,<br>
preferably about -10C to about 120C.<br>
A reaction time is usually about 0.5 to about 20 hours.<br>
The thus obtained Compound ( V ) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br>
In step B, Compound (II-3) can be prepared according<br>
to step B in the scheme 1.<br><br><br>
wherein Y' is C or CR4, and L and L' is a leaving group,<br>
and L is more reactive than L' , and the other symbols are<br>
as defined above.<br>
In step D, Compound (VI-1) is prepared from Compound<br>
(IV-1). The present method is carried out in the presence<br>
of a base in a solvent having no adverse effect on the<br>
reaction according to the conventional method. Specific<br>
examples of leaving groups L and L' include halogen atom,<br>
sulfonyloxy group such as p-toluenesulfonyloxy group,<br>
methanesulfonyloxy group and trifluoromethanesulfonyloxy<br>
group, and acyloxy group such as acetyloxy group and<br>
benzoyloxy group.<br>
Example of the base include alkali metal salts such as<br>
potassium hydroxide, sodium hydroxide, sodium bicarbonate<br>
and potassium carbonate; amines such as pyridine,<br>
triethylamine, N,N-dimethylaniline and 1,8-<br>
diazabicyclo[5.4.0]undec-7-ene; metal hydrides such as<br>
potassium hydride and sodium hydride; and alkali metal<br>
alkoxides such as sodium methoxide, sodium ethoxide and<br><br>
potassium t-butoxide.<br>
An amount of these bases to be used is preferably<br>
about 1 to about 5 mole equivalent relative to Compound<br>
(IV) .<br>
Examples of the solvent having no adverse effect on<br>
the reaction include: aromatic hydrocarbon such as benzene,<br>
toluene and xylene; ethers such as tetrahydrofuran, dioxane<br>
and diethyl ether; amides such as N,N-dimethylformamide;<br>
and sulfoxides such as dimethyl sulfoxide. These solvents<br>
may be used by mixing at an appropriate ratio.<br>
A reaction temperature is usually about -50 to about<br>
150C, preferably about -10C to about 120C.<br>
A reaction time is usually about 0.5 about 20 hours.<br>
The thus obtained Compound (VI-1) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br>
In step E, Compound (II-4) is prepared by an<br>
intramolecular cyclization reaction of Compound (VI-1).<br>
The present method is carried out in the presence of an<br>
acid or a base in a solvent having no adverse effect on the<br>
reaction according to the conventional method. Specific<br>
example of a leaving group L' include halogen atom, p-<br>
toluenesulfonyloxy group, methanesulfonyloxy group and<br><br>
trifluoromethanesulfonyloxy group.<br>
Examples of the acid include inorganic acids such as<br>
hydrochloric acid, hydrobromic acid, sulfuric acid and<br>
phosphoric acid; organic acids such as acetic acid,<br>
trifluoroacetic acid, methanesulfonic acid, benzenesulfonic<br>
acid and p-toluenesulfonic acid; and Lewis acids such as<br>
zinc (II) chloride, tin (IV) chloride, aluminium chloride<br>
and the like. Examples of the base include: alkali metal<br>
salts such as potassium carbonate; amines such as pyridine,<br>
triethylamine, N,N-dimethylaniline and 1,8-<br>
diazabicyclo[5.4.0]undec-7-ene; metal hydrides such as<br>
potassium hydride and sodium hydride; and alkali metal<br>
alkoxides such as sodium methoxide, sodium ethoxide and t-<br>
butoxide.<br>
An amount of these acids or bases to be used is<br>
preferably about 1 to about 5 mole equivalent relative to<br>
Compound (IV-1).<br>
Examples of the solvent having no adverse effect on<br>
the reaction include aromatic hydrocarbons such as benzene,<br>
toluene and xylene; ethers such as tetrahydrofuran, dioxane<br>
and diethyl ether; haloganated hydrocarbons such as<br>
chloroform and dichloromethane; amides such as N,N-<br>
dimethylformamide; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used by mixing at an<br>
appropriate ratio.<br><br>
A reaction temperature is usually about -50C to about<br>
150C, preferably about -10C to about 120C.<br>
A reaction time is usually about 0.5 to about 20 hours.<br>
The thus obtained Compound (II-4) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br><br>
wherein A-2 is the same as A, and the other symbols are as<br>
defined above.<br>
In step F, Compound (VI-2) is prepared from Compound<br>
(IV-2) and Compound (XII). The present method is carried<br>
out in the presence of a base in a solvent having no<br>
adverse effect on the reaction according to the<br>
conventional method.<br>
Examples of the base include: alkali metal salts such<br>
as potassium carbonate, sodium carbonate and cesium<br>
carbonate; amines such as pyridine, triethylamine, N,N-<br>
dimethylaniline and 1,8-diazabicyclo[5.4.0]undec-7-ene;<br>
metal hydrides such as potassium hydride and sodium<br><br>
hydride; and alkali metal alkoxides such as sodium<br>
methoxide, sodium ethoxide and potassium t-butoxide.<br>
An amount of these bases to be used is preferably<br>
about 1 to about 5 mole equivalent relative to Compound<br>
(IV-2).<br>
Examples of the solvent having no adverse effect on<br>
the reaction include aromatic hydrocarbons such as benzene,<br>
toluene and xylene; ethers such as tetrahydrofuran; dioxane<br>
and diethyl ether; halogenated hydrocarbons such as<br>
chloroform and dichloromethane; amides such as N,N-<br>
dimethylformamide; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used by mixing at an<br>
appropriate ratio.<br>
A reaction temperature is usually about -50C to about<br>
200C, preferably about -10C to about 150C.<br>
A reaction time is usually about 0.5 to about 20 hours.<br>
The thus obtained Compound (VI-2) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br>
In step G, Compound (II-5) is prepared by a reaction<br>
for reducing Compound (VI-2).<br>
In the present reaction, a catalytic hydrogenation<br>
method using palladium carbon, palladium hydroxide or Raney<br><br>
nickel, or reduction using a reducing agent is carried out.<br>
As the reducing agent, sodium borohydride, aluminium<br>
lithium hydride and lithium borohydride are used. In the<br>
present reaction, if needed, any solvents can be used as<br>
long as they do not inhibit the reaction. Inter alia,<br>
alcohols (e.g. C1-3 alcohol such as methanol, ethanol,<br>
propanol and the like) or ethers (diethyl ether,<br>
diisopropyl ether, ethylene glycol dimethyl ether,<br>
tetrahydrofuran, dioxane etc.) are preferable.<br>
A reaction time is usually about 0.5 to 20 hours.<br>
The thus obtained Compound (II-5) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br><br><br>
hydrocarbon ring or an optionally substituent non-aromatic<br>
heterocyclic ring, Ar2 is an optionally substituted<br>
aromatic hydrocarbon ring or an optionally substituted<br>
aromatic heterocyclic ring, and A-3 is the same as A, and<br>
the other symbols are as defined above.<br>
In step H, an amino group of Compound (IV-3) is<br>
converted into a diazonium salt, and ylide is reacted<br>
thereon to prepare Compound (VIII-1). Diazotization in the<br>
present method is carried out in the presence of an acid in<br>
a solvent having no adverse effect on the reaction<br>
according to the conventional method. As the acid, for<br>
example, acetic acid and hydrochloric acid are used. As a<br>
diazotizing agent, sodium nitrite, alkyl nitrite or<br>
sulfated nitrosyl is used.<br>
As the solvent, water, dioxane, tetrahydrofuran and<br>
the like are used.<br>
A reaction temperature is usually about -50C to about<br>
150C, preferably about -10C to about 100C.<br>
A reaction time is usually about 0.5 to about 20 hours.<br>
The thus obtained diazonium salt of Compound (IV-3) is<br>
reacted with ylide produced from Compound (XIII-1) to<br>
prepare Compound (VIII-1). The present step is carried out<br>
in the presence of a base in a solvent having no adverse<br>
effect on the reaction. Examples of the base include:<br>
alkali metal salts such as potassium carbonate; amines such<br><br>
as pyridine, triethylamine, N,N-dimethylaniline and 1,8-<br>
diazabicyclo[5,4,0] undec-7-ene; metal hydrides such as<br>
potassium hydride and sodium hydride; and alkali metal<br>
alkoxides such as sodium methoxide, sodium ethoxide and<br>
potassium t-butoxide.<br>
An amount of these bases to be used is preferably<br>
about 1 to about 3 mole equivalent relative to Compound<br>
(XIII-1) .<br>
Examples of the solvent having no adverse effect on<br>
the reaction include aromatic hydrocarbons such as benzene,<br>
toluene and xylene; ethers such as tetrahyrdorufan, dioxane<br>
and diethyl ether; halogenated hydrocarbons such as<br>
chloroform and dichloromethane; amides such as N,N-<br>
dimethylformamide; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used by mixing at an<br>
appropriate ratio.<br>
Since the thus obtained Compound (VIII-1) is unstable<br>
depending on a kind of the compound, it is used in the next<br>
step without isolation and purification.<br>
In step I, a reduction reaction of Compound (VIII-1)<br>
is carried out to prepare Compound (IX-1). In the present<br>
reaction, a catalytic hydrogenation method using platinum<br>
oxide, Raney nickel, palladium carbon or palladium<br>
hydroxide, or reduction using a reducing agent is used. As<br>
the reducing agent, sodium borohydride, aluminium lithium<br><br>
hydride and lithium borohydride are used. In the present<br>
reaction, if needed, any solvents can be used as long as<br>
they do not inhibit the reaction. Inter alia, alcohols<br>
(e.g. C1-3 alcohol such as methanol, ethanol, propanol etc.)<br>
or ethers (diethyl ether, diisopropyl ether, ethylene<br>
glycol dimethyl ether, tetrahydrofuran, dioxane etc.) are<br>
preferable.<br>
A reaction time is usually about 0.5 to about 20 hours.<br>
The thus obtained Compound (IX-1) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br>
In step J, Compound (II-7) is prepared by a reductive<br>
amination reaction between Compound (IX-1) and ketone (XV).<br>
The present method is carried out in the presence of a<br>
reducing agent in a solvent having no adverse effect on the<br>
reaction. Examples of the reducing agent include sodium<br>
borohydride, sodium cyanoborohydride, sodium<br>
triacetoxyborohydride and lithium borohydride. Although<br>
alcohol solvents such as ethanol and methanol,<br>
dichloromethane, chloroform and carbon tetrachloride are<br>
used as a solvent, any solvents can be used as long as they<br>
do not inhibit the reaction.<br>
The thus obtained Compound (II-7) can be isolated and<br><br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br>
In step K, a bismuth regent is acted on Compound (IX-<br>
1) to prepare Compound (II-8). The present method is<br>
carried out in the presence of a metal catalyst in a<br>
solvent having no adverse effect on the reaction. As the<br>
metal catalyst, for example, copper catalysts such as<br>
copper (II) acetate and copper (II) pivalate are used.<br>
Although dichloromethane, chloroform and carbon<br>
tetrachloride are used as a solvent, any solvents can be<br>
used as long as they do not inhibit the reaction.<br>
A reaction temperature is usually about -80C to about<br>
150C, preferably about -80C to about 100C.<br>
A reaction time is usually about 0.5 to about 20 hours.<br>
The thus obtained Compound (II-8) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br><br><br>
wherein X4 is the same as X3, and the other symbols are as<br>
defined above.<br>
Step D and step E can be carried out according to step<br>
D and step E of the scheme 3, respectively, to prepare<br>
Compound (III-l).<br><br>
wherein Ar3 is an optionally substituted hydrocarbon ring,<br>
an optionally substituted non-aromatic heterocyclic ring,<br>
an aromatic hydrocarbon ring or an aromatic heterocyclic<br>
ring, X5 is the same as X3, and other respective symbols<br>
have the same meanings as described above.)<br><br>
Step H, step I, step J and step K can be carried out<br>
according to step H, step I, step J, and step K of the<br>
scheme 5, respectively, to prepare Compound (III-2) .<br>
In Compound (II), when X1 is C-COOR16, it can be<br>
converted as follows:<br><br>
wherein A-4 denote the same meaning as that of A, R16<br>
denotes an optionally substituted carbon atom, and the<br>
other symbols are as defined above.<br>
In step L, Compound (11-10) is prepared by a reaction<br>
for leaving a carboxyl-protecting group.<br>
All conventional methods used in a reaction for<br>
leaving a carboxyl-protecting group, for example,<br>
hydrolysis, reduction and elimination using a Lewis acid<br>
can be applied to the present reaction. It is preferable<br>
that hydrolysis is carried out in the presence of a base or<br>
an acid. Examples of the suitable base include inorganic<br>
bases such as alkali metal hydroxide (e.g. sodium hydroxide<br>
and potassium hydroxide), alkaline earth metal hydroxide<br>
(e.g. magnesium hydroxide and potassium hydroxide), alkali<br><br>
metal carbonate (e.g. sodium carbonate and potassium<br>
carbonate), alkaline earth metal carbonate (e.g. magnesium<br>
carbonate and calcium carbonate) , alkali metal bicarbonate<br>
(e.g. sodium bicarbonate and potassium bicarbonate), alkali<br>
metal acetate (e.g. sodium acetate and potassium acetate),<br>
alkaline earth metal phosphate (e.g. magnesium phosphate<br>
and calcium phosphate) and alkali metal hydrogen phosphate<br>
(e.g. disodium hydrogen phosphate and dipotassium hydrogen<br>
phosphate), and organic bases such as trialkylamine (e.g.<br>
trimethylamine and triethylamine), picoline, N-<br>
methylpyrrolidine,	N-methylmorpholine,	1,5-<br>
diazabicyclo[4.3.2]non-5-ene, 1,4-diazabicyclo[2.2.2]non-5-<br>
ene and 1,8-diazabicyclo[4.3.0]-7-undecene. Hydrolysis<br>
using a base is carried out in water or a hydrophilic<br>
organic solvent or a mixed solvent in many cases. Examples<br>
of the suitable acid include formic acid, hydrobromic acid<br>
and sulfuric acid.<br>
The present hydrolysis reaction is usually carried out<br>
in an organic solvent, water or a mixed solvent thereof. A<br>
reaction temperature is not particularly limited, but is<br>
appropriately selected depending on a kind of a carboxyl-<br>
protecting group and an elimination method. Elimination<br>
using a Lewis acid is carried out by reacting Compound (II-<br>
9) or a salt thereof with a Lewis acid, for example,<br>
trihalogenated boron (e.g. boron trichloride and boron<br><br>
trifluoride), tetrahalogenated titanium (e.g. titanium<br>
tetrachloride and titanium tetrabromide), and halogenated<br>
aluminium (e.g. aluminium chloride and aluminium bromide),<br>
or an organic acid (e.g. trichloroacetic acid and<br>
trifluoroacetic acid). This elimination reaction is<br>
preferably carried out in the presence of a cation<br>
scavenger (e.g. anisole and phenol) and is usually carried<br>
out in a solvent such as nitroalkane (e.g. nitromethane and<br>
nitroethane), alkylene halide (e.g., methylene chloride and<br>
ethylene chloride), diethyl ether, carbon disulfide, and a<br>
solvent having no adverse effect on the reaction. These<br>
solvents may be used as a mixture thereof.<br>
It is preferable that elimination by reduction is<br>
applied to elimination of a protecting group such as<br>
halogenated alkyl (e.g. 2-iodoethyl and 2,2,2-<br>
trichloroethyl) ester, and aralkyl (e.g. benzyl) ester.<br>
Examples of a reduction method using in the present<br>
elimination reaction include the conventional catalytic<br>
reduction in the presence of a combination of a metal (e.g.<br>
zinc and zinc amalgam) or a salt of a chromium compound<br>
(e.g. chromate chloride and chromate acetate) and an<br>
organic or inorganic acid (e.g. acetic acid, propionic acid<br>
and hydrochloric acid); or the conventional metal catalyst<br>
(e.g. palladium carbon and Raney nickel). A reaction<br>
temperature is not particularly limited, but a reaction is<br><br>
carried out under cooling, at room temperature of under<br>
warming.<br>
The thus obtained Compound (11-10) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br><br>
wherein R17 and R18 are optionally substituted alkyl group,<br>
allyl group or hydroxy group; or R17 and R18 may be combined<br>
each other to form a ring, Y" is the same as Y, and the<br>
other symbols are as defined above.<br>
In the present method, Compound (11-12) is prepared by<br>
reacting Compound (11-11) or a reactive derivative at a<br>
carboxyl group thereof and a salt thereof with the above<br>
Compound (XVI) or a reactive derivative at an amino group<br>
thereof or a salt thereof. Examples of the suitable<br>
reactive derivative at an amino group of Compound (XVI)<br>
include: Schiff base type imino produced by a reaction of<br>
Compound (XVI) with a carbonyl compound such as aldehyde,<br><br>
ketone and the like; silyl derivative produced by a<br>
reaction of Compound (XVI) and a silyl compound such as<br>
bis(trimethylsilyl)acetamide,	mono(trimethylsilyl)<br>
acetamide, bis(trimethylsilyl)urea and the like; derivative<br>
produced by a reaction of Compound (XVI) with phosphorus<br>
trichloride or phosgene.<br>
Specific examples of the suitable reactive derivative<br>
at a carboxyl group of Compound (II-11) include acid halide,<br>
acid anhydride, activated amide, activated ester and the<br>
like. Examples of the suitable reactive derivative<br>
include: acid chloride; acid azide; mixed acid anhydride<br>
with an acid such as substituted phosphoric acid such as<br>
dialkylphosphoric acid, phenylphosphoric acid,<br>
diphenylphosphoric acid, dibenzylphosphoric acid,<br>
halogenated phosphoric acid and the like,<br>
dialkylphosphorous acid, sulfurous acid, thiosulfuric acid,<br>
sulfuric acid, sulfonic acid such as methanesulfonic acid<br>
and the like, aliphatic carboxylic acid such as acetic acid,<br>
propionic acid, butyric acid, isobutyric acid, pivalic acid,<br>
pentanoic acid, isopentanoic acid, trichloroacetic acid and<br>
the like or aromatic carboxylic acid such as benzoic acid<br>
and the like; symmetric acid anhydride; activated amide<br>
with imidazole; 4-substituted imidazole, dimethylpyrazole,<br>
triazole or tetrazole; activated ester such as<br>
cyanomethylester, methoxymethyl ester, dimethyliminomethyl<br><br>
ester, vinyl ester, propargyl ester, p-nitrophenyl ester,<br>
trichlorophenyl ester, pentachlorophenyl ester, mesylphenyl<br>
ester, phenylazophenyl ester, phenyl thioester, p-<br>
nitrophenyl ester, p-cresyl thioester, carboxylmethyl<br>
thioester, pyranyl ester, pyridyl ester, piperidyl ester,<br>
8-quinolyl thioester and the like, or esters with N-hydroxy<br>
compound such as N,N-dimethylhydroxyamine, l-hydroxy-2-<br>
(1H)-pyridone, N-hydroxysuccineimide, N-hydroxyphthalimide,<br>
1-hydroxy-1H-benzotriazole and the like. These reactive<br>
derivatives can be arbitrarily selected depending on a kind<br>
of Compound (II-11) to be used. Examples of the suitable<br>
reactive derivative of Compound (II-12) include alkali<br>
metal salts such as sodium salt, potassium salt and the<br>
like, alkaline earth metal salts such as calcium salt,<br>
magnesium salt and the like, and basic salts such as<br>
organic base salts such as ammonium salt, trimethylamine<br>
salt, triethylamine salt, pyridine salt, picoline salt,<br>
dicyclohexylamine salt, N,N-dibenzylethylenediamine salt<br>
and the like. Although the reaction is usually carried out<br>
in the conventional solvent such as water, alcohols such as<br>
methanol, ethanol and the like, acetone, dioxane,<br>
acetonitrile, chloroform, methylene chloride, ethylene<br>
chloride, tetrahydrofuran, ethyl acetate, N,N-<br>
dimethylformamide and pyridine, the reaction may be carried<br>
out in any other organic solvents as long as they have no<br><br>
adverse effect on the reaction. These conventional<br>
solvents may be used as a mixture with water.<br>
When Compound (II-11) is used as the form of a free<br>
acid or a salt thereof in this reaction, it is desirable<br>
that the reaction is carried out in the presence of the<br>
normally used condensing agent such as so-called Vilsmeier<br>
regent and the like prepared by a reaction of N,N'-<br>
dicyclohexylcarbodiimide;	N-cyclohexyl-N'-<br>
morpholinoethylcarbodiimide;	N-cyclohexyl-N'-(4-<br>
diethylaminocyclohexyl)carbodiimide;	N,N'-<br>
diethylcarbodiimide, N,N'-diisopropylcarbodiimide, N-ethyl-<br>
N'-(3-dimethylaminopropyl)carbodiimide; N,N'-carbonylbis(2-<br>
methylimidazole); pentamethyleneketene-N-cyclohexylimine;<br>
diphenylketene-N-cyclohexylimine; ethoxyacetylene; 1-<br>
alkoxy-1-chloroethylene; trialkyl phosphite; polyethyl<br>
phosphate; polyisopropyl phosphate; phosphorus oxychloride;<br>
diphenylphosphorylazide; thionyl chloride; oxalyl chloride;<br>
lower alkyl haloformate such as ethyl chloroformate;<br>
isopropyl chloroformate and the like; triphenylphosphine;<br>
2-ethyl-7-hydroxybenzisooxazolium salt, 2-ethyl-5-(m-<br>
sulfopheny)isooxazoliumhydroxide internal salt; N-<br>
hydroxybenzotriazole; 1-(p-chlorobenzenesulfonyloxy)-6-<br>
chloro-1H-benzotriazole; N-N'-dimethylformamide with<br>
thionyl chloride, phosgene, trichloromethyl<br>
chloroformate, phosphorus oxychloride or the like.<br><br>
Alternatively, the reaction may be carried out in the<br>
presence of an inorganic base or an organic base such as<br>
alkali metal bicarbonate salt, tri(lower)alkylamine,<br>
pyridine,	N-(lower)alkylmorpholine,	N,N-<br>
di(lower)alkylbenzylamine and the like. A reaction<br>
temperature is not particularly limited, but the reaction<br>
is carried out under cooling or under warming.<br>
An amount of Compound (XVI) to be used is 1 to 10 mole<br>
equivalent, preferably 1 to 3 equivalent relative to<br>
Compound (II-11) .<br>
A reaction temperature is usually -30C to 100C.<br>
A reaction time is usually 0.5 to 20 hours.<br>
In addition, when a mixed acid anhydride is used,<br>
Compound (II-11) and chlorocarbonic ester (e.g. methyl<br>
chlorocarbonate, ethyl chlorocarbonate, isobutyl<br>
chlorocarbonate etc.) are reacted in the presence of a base<br>
(e.g. triethylamine, N-methylmorpholine, N,N-<br>
dimethylaniline, sodium bicarbonate, sodium carbonate,<br>
potassium carbonate etc.) and is further reacted with<br>
Compound (XVI).<br>
An amount of Compound (XVI) to be used is usually 1 to<br>
10 mole equivalent, preferably 1 to 3 mole equivalent<br>
relative to Compound (11-11).<br>
A reaction temperature is usually -30C to 100C.<br>
A reaction time is usually 0.5 to 20 hours.<br><br>
The thus obtained Compound (II-12) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br>
When X1 is C-COOR16 in Compound (III), the conversion<br>
can be carried out as follows:<br><br>
wherein the symbols are as defined above.<br>
Step L and step M can be carried out according to step<br>
L in the scheme 8 and step M in the scheme 9, respectively,<br>
to prepare Compound (III-4) and Compound (III-5).<br><br>
wherein R19 is an optionally substituted alkyl group, allyl<br>
group, hydroxy group, amino group or sulfanyl group, and<br>
the other symbols are as defined above.<br><br>
In the present method, Compound (11-13) is prepared by<br>
a reaction between Compound (V) and a nucleophilic regent.<br>
Examples of the nucleophilic regent include metal<br>
phenolate, metal alcoholate, Grignard regent, alkyl metal<br>
regent, aryl metal regent and thioalcoholate.<br>
An amount of the nucleophilic regent to be used is<br>
preferably about 1 to about 5 mole equivalent relative to<br>
Compound (V).<br>
Examples of a solvent having no adverse effect on the<br>
reaction include: ethers such as diethyl ether,<br>
tetrahydrofuran and dioxane; aromatic hydrocarbons such as<br>
benzene, toluene and xylene; amides such as N,N-<br>
dimethylformamide and 1-methylpyrrolidone; sulfoxides such<br>
as dimethyl sulfoxide. These solvents may be used by<br>
mixing at an appropriate ratio.<br>
A reaction temperature is usually about -50C to about<br>
150C, preferably about -10 to about 100C.<br>
A reaction time is usually about 0.5 to about 20 hours.<br>
The thus obtained Compound (II-13) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br><br><br>
wherein the symbols are as defined above.<br>
Step N can be carried out according to step N in the<br>
scheme 11 to prepare Compound (III-4).<br><br>
wherein A-6 is the same as A, and the other symbols are as<br>
defined above.<br>
In step H, an amino group of Compound (IV-5) is<br>
converted into a diazonium salt, and ylide is reacted<br>
thereon to prepare Compound (VIII-3). Diazotization in<br>
this method is carried out in the presence of an acid in a<br>
solvent having no adverse effect on the reaction according<br>
to the conventional method. As the acid, for example,<br>
acetic acid and hydrochloric acid are used. As the<br><br>
diazotizing agent, sodium nitrite, alkyl nitrite or<br>
sulfated nitrosyl is used.<br>
As the solvent, water, dioxane, tetrahydrofuran and<br>
the like are used.<br>
A reaction temperature is usually about -50C to about<br>
150C, preferably about -10C to about 100C.<br>
A reaction time is about 0.5 to about 20 hours.<br>
The thus obtained diazonium salt of Compound (IV-5) is<br>
reacted with ylide produced from Compound (XVII) to prepare<br>
Compound (VIII-3). The present step is carried out in the<br>
presence of a base in a solvent having no adverse effect on<br>
the reaction. Examples of the base include: alkali metal<br>
salts such as potassium carbonate; amines such as pyridine,<br>
triethylamine, N,N-dimethylaniline and 1,8-<br>
diazabicyclo[5.4.0]undec-7-ene; metal hydrides such as<br>
potassium hydride and sodium hydride; and alkali metal<br>
alkoxides such as sodium methoxide, sodium ethoxide and<br>
potassium t-butoxide.<br>
An amount of these bases to be used is preferably<br>
about 1 to about 3 mole equivalent relative to Compound<br>
(XVII).<br>
Examples of the solvent having no adverse effect on<br>
the reaction include aromatic hydrocarbons such as benzene,<br>
toluene and xylene; ethers such as tetrahydrofuran, dioxane<br>
and diethyl ether; halogenated hydrocarbons such as<br><br>
chloroform and dichloromethane; amides such as N,N-<br>
dimethylformamide; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used by mixing at an<br>
appropriate ratio.<br>
Since the thus obtained Compound (VIII-3) is unstable<br>
depending on a kind of the compound, it is used in the next<br>
step without isolation and purification.<br>
Step I, step J and step K can be carried out according<br>
to step I, step J and step K, respectively, to prepare<br>
Compound (11-14) and Compound (11-15).<br>
When R3 is a hydrogen atom in Compound (II) the<br>
following conversion is possible.<br><br>
wherein the symbols are as above.<br>
In step 0, Compound (II-4) is subjected to alkylation,<br>
acylation, carbamoylation, oxycarbonization or<br>
thiocarbamoylation to prepare Compound (II-6).<br>
The reaction is carried out according to the<br>
conventional method. In alkylation, alkyl halide is<br>
reacted, in acylation, acid halide or acid anhydride is<br>
reacted, in carbamoylation, isocyanate or carbonylimidazole<br><br>
is reacted and, thereafter, amine is reacted, in<br>
oxycarbonization, oxycarbonyl halide or oxycarboic acid<br>
anhydride is reacted and, in thiocarbamoylation,<br>
thioisocyanate is reacted, respectively, to prepare the<br>
compound. The present reaction is generally carried out in<br>
the presence of a base in a solvent having no adverse<br>
effect on the reaction. Examples of the base include<br>
alkali metal salts such as potassium hydroxide, sodium<br>
hydroxide, sodium bicarbonate and potassium carbonate;<br>
amines such as pyridine, triethyamine, N,N-dimethylaniline<br>
and 1,8-diazabicyclo[5,4,0]undec-7-ene; metal hydrides such<br>
as potassium hydride and sodium hydride; and alkali metal<br>
alkoxides such as sodium methoxide, sodium ethoxide and<br>
potassium t-butoxide.<br>
An amount of these bases to be used is preferably<br>
about 1 to about 5 mole equivalent relative to Compound<br>
(H-4) .<br>
Examples of the solvent having no adverse effect on<br>
the reaction include: aromatic hydrocarbons such as benzene,<br>
toluene and xylene; ethers such as tetrahydrofuran, dioxane<br>
and diethyl ether: halogenated hydrocarbons such as<br>
chloroform and dichloromethane; amides such as N,N-<br>
dimethylformamide; and sulfoxides such as dimethyl<br>
sulfoxide. These solvents may be used by mixing at an<br>
appropriate ratio.<br><br>
A reaction temperature is usually about -50C to about<br>
150C, preferably about -10C to about 120C<br>
A reaction time is usually about 0.5 to about 20 hours.<br>
The thus obtained Compound (II-6) can be isolated and<br>
purified by the known isolating and purifying methods, for<br>
example, concentration, concentration under the reduced<br>
pressure, extraction with solvent, crystallization,<br>
recrystallization, transfer dissolution and chromatography.<br>
When R3 is a hydrogen atom in Compound (III), the<br>
following conversion is possible.<br><br>
wherein the symbols are as above.<br>
Step 0 step J and step K can be carried out according<br>
to step 0 in the scheme 14, respectively, to prepare<br>
Compound (III).<br>
All the compounds used or obtained in the present<br>
invention include corresponding salts, even if specifically<br>
stated, and they can be exchanged to one another by a per<br>
se known method or modified methods thereof.<br>
When the compounds or salts thereof obtained by the<br><br>
present invention are asymmetric molecules, they can be<br>
separated into d-form isomer and 1-form isomer according to<br>
conventional optical resolution methods.<br>
The compound or its salt obtained by the present<br>
invention may be used in a next step as its reaction<br>
mixture without sufficient purification.<br>
Compound (I), (II), (III) or (IIIa) of the present<br>
invention has an excellent Ca receptor modulating activity<br>
and enhances the secretion of PTH, and therefore useful as<br>
drugs for treating bone diseases, kidney-acting drugs,<br>
central nervous system and endocrine-acting drugs,<br>
digestive system-acting drugs, and the like. Further, the<br>
toxicity is low. Therefore, Compound (I), (II), (III) or<br>
(IIIa) may be safely administered to mammalian animals (for<br>
example, human, rat, mouse, dog, rabbit, cat, cow, horse,<br>
pig, and the like).<br>
Thus, a pharmaceutical composition containing compound<br>
(I), (II), (III) or (IIIa) of the present invention is<br>
expected to be useful in the treatment and prevention of<br>
diseases, in which Ca receptor modulating activity is<br>
required, such as<br>
Ca receptor modulating drugs: primary or secondary hyper<br>
parathyroidism; hypoparathyroidism; hyperthyroidism;<br>
hypothyroidism; Graves' disease; Hashimoto's toxicosis;<br>
Paget's disease; hypercalcemia associated with malignant<br><br>
tumor; hypercalcemia; hypocalcemia; postmenopausal<br>
osteoporosis; senile osteoporosis; secondary osteoporosis;<br>
osteomalacia; renal osteodystrophy; fracture;<br>
osteoarthritis; rheumatoid arthritis; osteosarcoma;<br>
myeloma; hypertension; diabetes; myocardial infarction;<br>
Hachington's diseases; Parkinson's diseases; Alzheimer's<br>
disease; dementia; cerebral apoplexy; brain tumor; spinal<br>
injury; diabetic renal disease; renal insufficiency;<br>
gastric ulcer; duodenal ulcer; Basedow's disease;<br>
parathyroid gland tumor; thyride gland tumor;<br>
arteriosclerosis; and the like;<br>
Ca receptor antagonistic drugs: hyperthyroidism;<br>
hypocalcemia; postmenopausal osteoporosis; senile<br>
osteoporosis; secondary osteoporosis; osteomalacia; renal<br>
osteodystrophy; fracture; osteoarthritis; rheumatoid<br>
arthritis; osteosarcoma; myeloma; central nervous system<br>
diseases; and the like, in particular osteoporosis.<br>
The dosage of Compound (I), (II), (III) or (IIIa) can<br>
be selected in various ways depending on the administration<br>
route and the symptom of a patient to be treated. The<br>
dosage as Compound (I), (II), (III) or (IIIa) per an adult<br>
(a body weight of 50 kg) can be usually selected in a range<br>
of about 0.1 mg to about 500 mg, preferably about 1 mg to<br>
about 100 mg in the case of oral administration and in a<br>
range of about 0.01 mg to about 100 mg, further preferably<br><br>
about 0.1 mg to about 10 mg in the case of parenteral<br>
administration. The dosage can be administered with being<br>
divided in 1-3 times daily.<br>
Compound (I), (II), (III) or (IIIa) of the present<br>
invention can be formulated with a pharmaceutically<br>
acceptable carrier and can be orally or parenterally<br>
administered as solid formulations such as tablets,<br>
capsules, granules, powders, or the like; or liquid<br>
formulations such as syrups, injections, or the like. Also,<br>
there can be prepared formulations for transdermal<br>
administration such as patchings, cataplasms, ointments<br>
(including creams), plasters, tapes, lotions, liquids and<br>
solutions, suspensions, emulsions, sprays, and the like.<br>
As for a pharmaceutically acceptable carrier, a<br>
variety of organic or inorganic carrier substances, which<br>
have been conventionally employed as formulation materials,<br>
is used and compounded as a bulking agent, a lubricant, a<br>
binding agent, and a disintegrator in solid formulations; a<br>
vehicle, a solubilizing agent, a suspending agent, an<br>
isotonicity agent, a buffering agent, and an analgesic in<br>
liquid formulations. If necessary, formulation excipients<br>
such as a preservative, an antioxidant, a stabilizer, a<br>
coloring agent, a sweetening agent, and the like can be<br>
used.<br>
Preferred examples of the bulking agent include<br><br>
lactose, sucrose, D-mannitol, starch, crystalline cellulose,<br>
light anhydrous silicic acid, and the like. Preferred<br>
examples of the lubricant include magnesium stearate,<br>
potassium stearate, talc, colloidal silica, and the like.<br>
Preferred examples of the binding agent include crystalline<br>
cellulose, -starch, sucrose, D-mannitol, dextrin,<br>
hydroxypropyl cellulose, hydroxypropylmethyl cellulose,<br>
polyvinyl pyrrolidone, and the like. Preferred examples of<br>
the disintegrator include starch, carboxymethyl cellulose,<br>
calcium carboxymethyl cellulose, croscarmellose sodium,<br>
sodium carboxymethyl starch, low-substituted hydroxypropyl<br>
cellulose, and the like. Preferred examples of the vehicle<br>
include water for injection, alcohol, propylene glycol,<br>
macrogol, sesame oil, corn oil, and the like.<br>
If necessary, for the purpose of taste masking,<br>
enteric coating, or prolonged action, oral formulations can<br>
be prepared by coating by a per se known method. Examples<br>
of this coating agent include hydroxypropylmethyl cellulose,<br>
ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl<br>
cellulose, polyoxyethylene glycol, Tween 80, Pluronic F68<br>
[polyoxyethylene (160) polyoxypropylene (30) glycol],<br>
cellulose acetate phthalate, hydroxypropylmethyl cellulose<br>
phthalate, hydroxymethyl cellulose acetate phthalate,<br>
Eudragit (manufactured by Rohm Company, methacrylic acid-<br>
acrylic acid copolymer), and the like.<br><br>
Preferred examples of the solubilizing agent include<br>
polyethylene glycol, propylene glycol, benzyl benzoate,<br>
ethanol, trisamiomethane, cholesterol, triethanolamine,<br>
sodium carbonate, sodium citrate, and the like. Preferred<br>
examples of the suspending agent include surface active<br>
agents such as stearyltriethanolamine, sodium lauryl<br>
sulfate, laurylaminopropionic acid, lecithin, benzalkonium<br>
chloride, benzethonium chloride, glycerin monostearate, and<br>
the like; hydrophilic, high molecular substances such as<br>
polyvinyl alcohol, polyvinyl pyrrolidone, sodium<br>
carboxymethyl cellulose, methyl cellulose, hydroxymethyl<br>
cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose,<br>
and the like; and so on. Preferred examples of the<br>
isotonicity agent include sodium chloride, glycerin, D-<br>
mannitol, and the like. Preferred examples of the<br>
buffering agent include buffer solutions of a phosphate, an<br>
acetate, a carbonate, a citrate, or the like. Preferable<br>
examples of the analgesic include benzyl alcohol and the<br>
like. Preferred examples of the preservative include<br>
paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol,<br>
phenethyl alcohol, dehydroacetic acid, sorbic acid, and the<br>
like. Preferred examples of the antioxidant include<br>
sulfites, ascorbic acid, and the like.<br>
The following examples, preparations and experiments<br>
describe the manner and process of making and using the<br><br>
present invention and are illustrative rather than limiting.<br>
It is to be understood that there may be other embodiments<br>
which fall within the spirit and scope of the present<br>
invention as defined by the claims appended hereto.<br>
Abbreviations employed herein are defined below.<br>
DCM = dichloromethane<br>
DCE = dichloroethane<br>
DMAP = dimethylaminopyridine<br>
DMF = dimethylformamide<br>
WSC = 1-(3-Dimethylaminopropyl)-3-ethyl-carbodiimide<br>
hydrochloride<br>
M+H = monoisotopic mass plus one proton<br>
Me = methyl<br>
Et = ethyl<br>
Ph = phenyl<br>
h = hours<br>
min = minutes<br>
HPLC = high performance liquid chromatography<br>
HOBt = hydroxybenzotriazole<br>
LC/MS = liquid chromatography/mass spectrometry<br>
MS = mass spectrometry<br>
Rt = retention time<br>
TEA = triethylamine<br>
TFA = trifluoroacetic acid<br>
IPE = diisopropylether<br><br>
TLC = thin layer chromatography<br>
THF = tetrahydrofuran<br>
TMSCN = trimethylsilyl cyanide<br>
HATU = 0-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyl-<br>
uronium hexafulorophosphate<br>
DIPEA = diisopropylethylamine<br>
Example 1<br>
Ethyl 5-phenyl- 7-(trifluoromethyl)-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxylate<br><br>
Step A: A mixture of 4,4,4-trifluoro-1-phenyl-1,3-<br>
butanedione 1 (6.97 g, 32.24 mmol) and ethyl 3-<br>
aminopyrazole-4-carboxylate 2 (5.0 g, 32.22 mmol) in AcOH<br>
3 (100 mL) was refluxed for 4 h. The mixture was cooled to<br>
room temperature and concentrated and precipitated crystals<br>
were collected by filtration to give 8.63 g (79%) of the<br>
title compound as yellow crystals. 1H NMR (CDC13, 200 MHz):<br><br>
1.47 (3H, t, J=7.0 Hz), 4.47 (2H, q, J=7.0 Hz), 7.54-7.61<br>
(3H, m), 7.80 (1H, s), 8.23-8.28 (2H, m), 8.68 (1H, s).<br>
Step B: To a solution of 3 (3.51 g, 10.3 mmol) in MeOH<br>
was added NaBH4 (1.4 g, 3.7 mmol) at room temperature. The<br>
whole was stirred at the same temperature for 5 h, quenched<br>
with saturated citric acid solution, concentrated in vacuo,<br>
and extracted with AcOEt. The extract was successively<br>
washed with aq. NaHCO3, water and brine, dried over MgSO4<br>
and then concentrated to give 1.73 g (49%) of compound 4 as<br>
colorless oil. 1H HMR (CDC13, 200 MHz): 1.32 (3H, t, J=6.8<br>
Hz), 2.28-2.46 (1H, m) , 2.50-2.61 (1H, m) , 4.25 (2H, q,<br>
J=6.8 Hz), 4.58 (1H, dd, J=11.4, 3.4 Hz), 4.85 (1H, ddd,<br>
J=3.4, 3.0, 2.6 Hz), 6.15 (1H, s)7.34-7.48 (5H, m) , 7.74<br>
(1H, s) .<br>
Compounds of Examples 2-14, shown in the Table 1, were<br>
prepared in a manner similar to that described in Example 1.<br><br><br><br><br><br><br><br>
Example 15<br>
Ethyl	7,7-dimethyl-5-(2-pyridyl)-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxylate<br><br><br>
Step A: To a stirred solution of compound 1 (7.0 g,<br>
4 4.3 mmol) in THF (100 mL) was added n-BuLi (1.6 M hexane<br>
solution, 28 mL, 44.8 mmol) at -78 C. After the mixture<br>
was stirred for 30 min, compound 2(6.34 g, 44.3 mmol) was<br>
added thereto. The resulting mixture was stirred at -78--<br>
50C for 2h, quenched with saturated citric acid solution<br>
and extracted with AcOEt. The extract was successively<br>
washed with water and brine, dried over MgSO4 and then<br>
concentrated in vacuo. The residue was chromatographed on<br>
silica gel with AcOEt/hexane (1:9) as an eluent to give<br>
3.16 g (44% yield) of compound 3 as colorless liquid.<br>
Step B: To a solution of compound 3 and compound 4 in<br>
methoxyethanol (60 mL) was added TFA (4.47 g, 39.2 mmol)<br>
with ice-water cooling. The mixture was refluxed for 12 h,<br>
diluted with AcOEt, and the mixture was washed with<br>
saturated NaHCO3 solution, water and brine, dried over<br><br>
MgSO4, and then concentrated in vacuo. The residue was<br>
chromatographed on silica gel with AcOEt/hexane (1:4) as an<br>
eluent to give 2.03 g (36% yield) of compound 5 as<br>
colorless prisms.<br>
Step C: A mixture of 5 (1.98 g, 6.96 mmol) and 10 %<br>
Pd-C (1.0 g) in EtOH (100 mL) was stirred for 2h under the<br>
H2 atmosphere (balloon pressure). After the insoluble<br>
materials were filtered off, the residue was concentrated<br>
in vacuo to give the residue. Crystallization from<br>
hexane/IPE gave the title compound 6 (1.00g, 48%) as<br>
colorless solid. 1H NMR (CDC13, 200 MHz): 1.34 (3H, t,<br>
J=7.0 Hz), 4.26 (2H, q, J=7.0 Hz), 4.80 (1H, dd, J=11.4,<br>
2.6 Hz), 6.39 (1H, s) , 7.24-7.31 (1H, m) , 7.51 (1H, d,<br>
J=7.6 Hz), 7.76 (1H, td, J=7.6, 1.8 Hz), 8.60-8.63 (1H, m).<br>
Compounds of Examples 16-29, 439-447 and 924-938 shown<br>
in the Table 2, were prepared in a manner similar to that<br>
described in Example 15.<br><br><br><br><br><br><br><br><br><br><br><br><br><br>
A mixture or 1, 1.5 N KOH solution (14 mL) and EtOH<br>
(20 mL) was stirred at 60 C for 12h, acidified with<br>
saturated citric acid solution, and the precipitated solid<br>
was collected by filtration, which was washed with water<br>
and IPE to give 1.59 g (76% yield) of the title compound as<br>
colorless prisms, mp 184.8-185.0 C, 1H NMR (CDC13, 300<br>
MHz): 2.31-2.44 (1H, m), 2.50-2.59 (1H, m), 4.59 (1H, dd,<br>
J=11.4, 3.0 Hz), 4.79 (1H, m), 6.10 (1H, s), 7.20-7.26 (5H,<br>
m) , 7.78 (lH,s) .<br>
Compounds of Examples 22-39, 448-458 and 939-953 shown<br>
in the Table 3, were prepared in a manner similar to that<br>
described in Example 21.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Example 4 0<br>
N-Cyclooctyl-5-phenyl-7-(trifluoromethyl)-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide<br><br><br>
Cyclooctylamine (24 mg, 0. 19 mmol) was added to a<br>
suspension of compound 1 (0.05 g, 0. 16 mmol), WSC (37 mg,<br>
0. 19 mmol), HOBt (29 mg, 0.19 mmol) and DMAP (23 mg, 0. 19<br>
mmol) in DMF (1.5 mL). The reaction mixture was stirred at<br>
room temperature for 14 h, diluted with DCM (0.5mL) and<br>
saturated NaHCO3 solution (0.5 mL) , and then separated<br>
using PHASE-SEP filtration syringe. The organic layer was<br>
concentrated and loaded onto preparative HPLC (Gilson 215<br>
system). The purest fractions were combined to give 64.6 mg<br>
(96% yield) of the title compound as a white solid. Reverse<br>
Phase LC/MS: CAPCELLPAKCC18UG120, S-3  m, 2.0 x 50 mm, UV<br>
detection at 220, 8 min. gradient 10-100% Solvent B/A<br>
(Solvent A: CH3CN with 0.1% TFA, Solvent B: H2O with 0.1%<br>
TFA), 0.5 mL/min. Rt=1.90 min, (96% pure). MS (M+H: 421).<br>
Example 41<br>
N-(1-ethyl-1-(4-(trifluoromethyl)phenyl)propyl)-7,7-<br>
dimethyl-5-phenyl-4, 5, 6, 7-tetrahydropyrazolo[1,5-<br>
a]pyrimidine-3-carboxamide<br><br><br>
To a solution of 3 (0.5g, 1.84mmol) and HATU (0.84g,<br>
2.21mmol) in DMF (3mL) was added DIPEA (0.67mL, 3.68mmol)<br>
at room temperature. After 30 min, compound 2 (0.59g,<br>
2.21mmol) was added thereto. The resulting mixture was<br>
stirred at 80 C for 18 h, concentrated in vacuo, and the<br>
residue was chromatographed on silica gel with AcOEt/hexane<br>
(1/1) as an eluent to give 0.28 g (31% yield) of compound 4<br>
as colorless prisms, mp 193-194 C.<br>
Compounds of Examples 42 - 434, 459-867 and 954-1008<br>
shown in the table 4, were prepared in a manner similar to<br>
that described in Example 40 or 41.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Example 1009<br>
Ethyl	7,7-dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxylate<br>
Racemic compound obtained in Example 16 (80 g)<br>
was subjected to preparative high performance liquid<br>
chromatography (HPLC) to afford optically pure materials<br>
(38 g, 99.8% ee (shorter retention time) and 39 g, 99.4% ee<br>
(longer retention time)). [column: CHIRALCEL OD 50 mmol x<br>
500 mm (manufactured by Daicel Kagaku Kogyo Kabushiki<br>
Kaisha), temperature: 30C, mobile phase: hexane/Ethanol =<br>
95/5, flow rate: 60 ml/minute, detection wavelength: 254 ran,<br>
and 1 shot: about 800 mg].<br>
Compounds of Examples 1010 - 1017 shown in the<br>
Table 8~11, were prepared in a manner similar to that<br>
described in Example 1009.<br><br><br><br>
The determination of the optical purity was carried out<br>
by HPLC using a chiral column (column: CHIRALCEL OD 4.6 mm<br>
x 250 mm (manufactured by Daicel Kagaku Kogyo Kabushiki<br>
Kaisha), temperature: about 30C, mobile phase:<br>
hexane/ethanol = 96/4, flow rate: 0.5 ml/minute, and<br>
detection wavelength: 254 nm).<br><br><br><br>
The determination of the optical purity was carried out<br>
by HPLC using a chiral column (column: CHIRALPAK AD 4.6 mm<br>
x 250 mm (manufactured by Daicel Kagaku Kogyo Kabushiki<br>
Kaisha), temperature: about 30C, mobile phase: hexane/IPA<br>
= 95/5, flow rate: 0.5 ml/minute, and detection wavelength:<br>
254 nm).<br><br>
The determination of the optical purity	was carried out<br>
by HPLC using a chiral column (column: CHIRALPAK AD 4.6 mm<br>
x 250 mm (manufactured by Daicel Kagaku	Kogyo Kabushiki<br>
Kaisha), temperature: about 30C,	mobile phase:<br>
hexane/ethanol = 995/5, flow rate: 0.5	ml/minute, and<br>
detection wavelength: 220 nm).<br>
Table 11<br><br><br>
The determination of the optical purity was carried out<br>
by HPLC using a chiral column (column: CHIRALCEL OD 4.6 mm<br>
x 250 mm (manufactured by Daicel Kagaku Kogyo Kabushiki<br>
Kaisha), temperature: about 30C, mobile phase:<br>
hexane/ethanol = 95/5, flow rate: 0.5 ml/minute, and<br>
detection wavelength: 258 nm).<br>
Example 1018<br>
(-)-7,7-Dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid<br><br>
A mixture of 1(0.73 g) obtained in Example 1009, KOH<br>
(0.41 g) , H2O(20 ml) and EtOH (20 mL) was stirred at 90 C<br>
for 12h, acidified with 1N HCl, and extracted with AcOEt.<br><br><br>
Compounds of Examples 1019-1027 shown in the Table 12,<br>
were prepared in a manner similar to that described in<br>
Example 1018.<br><br><br><br><br><br>
(S)-N-(1-(4-Chlorophenyl)-1-ethylpropyl)-7,7-dimethyl-<br>
5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-<br>
carboxamide hydrochloride<br><br>
Step A: To a solution of 1 (0.4g, 1.47mmol) and HATU<br>
(0.67g, 1.77mmol) in DMF (5mL) was added DIPEA (0.57g,<br>
4.41mmol) at room temperature. After 1 h, compound 2 (0.41g,<br>
1.77mmol) was added thereto. The resulting mixture was<br>
stirred at 80 C for 12 h, and concentrated in vacuo. The<br>
residue was diluted with AcOEt, washed with sat.NaHCO3aq<br>
and brine, dried over MgSO4, and concentrated in vacuo. The<br>
residue was chromatographed on silica gel with AcOEt/hexane<br><br>
(1/1) to give 0.41 g (62% yield) of compound 4 as colorless<br>
prisms, mp 105-106 C. []D20c = -17.68 in CHC13, C = 0.30.<br>
Step B: To a stirred solution of compound 3 (90 mg, 0.2<br>
mmol) in Et2O (3 mL) was added 4M HCl-AcOEt (0.1 mL, 0.4<br>
mmol) at room temperature. The precipitate was collected by<br>
filtration to give 60mg (62% yield) of compound 4 as prisms.<br>
mp 130-132 C. []D20c = 24.3 in CHC13 C = 0.48.<br>
Compounds of Examples 102 9 - 1122 shown in the Table<br>
13, were prepared in a manner similar to that described in<br>
Example 1028.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Example 435<br>
N-(1-adamantyl)-7-ethyl-5-phenyl-7-(trifluoromethyl)-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide<br><br><br>
Step A: To a stirred solution of compound 1 (2.00 g,<br>
6.00 mmol) in DCM (50 mL) was added triethylaluminium (2.0<br>
M hexane solution, 18 mL, 36 mmol) at room temperature.<br>
After the mixture was stirred for 2 h, it was quenched with<br>
water, and extracted with AcOEt. The extract was<br>
successively washed with water and brine, dried over MgSO4<br>
and then concentrated in vacuo to give compound 2 (2.20 g,<br>
100% yield) as yellow syrup. MS (ESI,m/z) 366 (M + H)+ .<br>
Step B: A mixture of compound 2 (2.20 g, 6.00 mmol),<br>
LiOH (0.51 g, 12.15 mmol), EtOH (50 mL) and H2O (30 mL) was<br><br>
stirred at 70 C for 12 h, concentrated in vacuo, diluted<br>
with aq.citric acid solution and extracted with AcOEt. The<br>
extract was successively washed with water, saturated<br>
NaHCO3 solution and brine, dried over MgSO4 and then<br>
concentrated to give compound 3 (2.00 g, 100%) as colorless<br>
crystals. MS (ESI,m/z) 352 (M + H)+ .<br>
Step C: 1-Adamantylamine (0.72 g, 4.7 6 mmol) was added<br>
to a suspension of compound 3 (1.60 g, 4.74 mmol), WSC<br>
(0.91 g, 4.74 mmol), HOBt (0.64 g, 4.74 mmol) and DMAP<br>
(0.58 g, 4.75 mmol) in DMF (20 mL) . The reaction mixture<br>
was stirred at 70 C for 13 h and then concentrated in<br>
vacuo. The residue was chromatographed on silica gel with<br>
AcOEt/hexane (1/6) as an eluent to give compound 4 (0.71 g,<br>
32 %) as colorless crystals. MS(ESI,m/z) 472 (M+H)+.<br>
Step D: To a solution of 4 (0.58 g, 1.23 mmol) in EtOH<br>
was added NaBH4 (0.2 g, 5.29 mmol) at room temperature. The<br>
whole was stirred at 60 C for 3 h, concentrated in vacuo,<br>
diluted with water and extracted with AcOEt. The extract<br>
was successively washed with aq. NaHCO3, water and brine,<br>
dried over MgSO4 and then concentrated to give 0.43 g (74%)<br>
of compound 5 as colorless crystals. MS(ESI,m/z) 474 (M+H)+.<br>
Compounds of Examples 436, shown in the Table 5, were<br>
prepared in a manner similar to that described in Example<br>
435.<br><br><br>
Example 4 37<br>
2-cyclohexyl-4-methyl-N-(1-methyl-1-phenylethyl) -<br>
1,2,3,4-tetrahydropyrazolo[5,1-c][1,2,4]triazine-8-<br>
carboxamide<br><br><br>
Step A: To a 250 mL round bottom flask equipped with<br>
magnetic stir bar and 2 addition funnels was added 1.0 g<br>
(6.44 mmol) of compound 1 by 3.5 ml of cone, hydrochloric<br>
acid and 7.0 ml of water. The solution was cooled to 0 C<br>
and a solution containing 0.50 g (7.25 mmol) of sodium<br>
nitrite in 2 ml of water dropwise. After complete addition,<br>
the reaction was allowed to stir for 30 min. at 0 C,<br>
followed by the addition of 65 ml of dichloromethane and 35<br>
ml of a saturated sodium bicarbonate solution while<br>
maintaining the reaction temperature below 10 C. A<br>
solution containing 2.05 g (6.44 mmol) of 1-<br>
triphenylphosphoroanylidene-2-propanone in 30 ml of<br>
dichloromethane was then added dropwise. After complete<br><br>
addition, the reaction was allowed to stir for 5 min.,<br>
diluted with 50 ml of dichloromethane and washed with water.<br>
The organic phase was separate and the solvent removed<br>
under reduced pressure to afford 3.50 g (100%) of crude<br>
compound 2 which is taken on without further purification.<br>
MS Calcd.: 206; Found 207 (M+H).<br>
Step B: To a solution containing the crude product<br>
from above in 30 ml of ethanol and 30 ml of THF under a<br>
nitrogen atmosphere was added 1.20 g (3.72 mmol) of sodium<br>
borohydride. The reaction was allowed to stir at room<br>
temperature for 30 min. The reaction was diluted with ethyl<br>
acetate and washed with water. The organic phase was dried<br>
over MgSO4. Filtration, removal of solvent and purification<br>
of the residue via Biotage chromatography eluting with 70%<br>
AcOEt/hexanes gave 0.7 9 g (58.9%) of compound 3 as a pale<br>
yellow solid. MS Calcd.: 208; Found 209 (M+H)<br>
Step C: A solution containing 0.54 g (2.59 mmol) of<br>
compound 3 and 0.18 g of LiOH (7.52 mmol) in 15 ml of<br>
ethanol and 10 ml of water was heated to 70 C. After 1.5h,<br>
HPLC of reaction mixture indicated no starting material<br>
remaining. The ethanol was removed under reduced pressure<br>
and the residue acidified with 1N hydrochloric acid and<br>
extracted with ethyl acetate. The organic phase was dried<br>
over magnesium sulfate. Filtration and removal of solvent<br>
gave 0.48 g (92.2%) of compound 4. MS Calcd.: 180; Found<br><br>
181 (M+H).<br>
Step D: To a solution containing 2.80 g (15.54 mmol)<br>
of compound 4 in 150 ml of DMF under a nitrogen atmosphere<br>
was added 6.50 g (17.10 mmol) of HATU, 2.31 g (17.10 mmol)<br>
of cumyl amine and 2.98 ml (17.10 mmol) of<br>
diisopropylethylamine. The reaction was heated to 50 C<br>
overnight, diluted with ethyl acetate and washed with water.<br>
The organic phase was dried over magnesium sulfate.<br>
Filtration, removal of solvent and purification of the<br>
residue via Biotage chromatography eluting with 60% AcOEt/<br>
hexanes gave 3.0 9 g (66.9%) of compound 5. MS Calcd.: 297;<br>
Found 298 (M+H).<br>
Step E: To a Parr flask was added 1.11 g (3.90 mmol)<br>
of compound 5 and 75 ml of EtOH. The flask was purged with<br>
nitrogen and 0.30 g of platinum oxide added. The flask was<br>
evacuated and pressurized to 20 psig hydrogen (3x) then<br>
pressurized to 50 psig hydrogen and shaken for 1h. After<br>
completion as determined by HPLC, the reaction was filtered<br>
through GF/F filter paper and the filtrate concentrated<br>
under reduced pressure to afford 1.1 g (100%) of compound 6.<br>
MS Calcd.: 299; Found 300 (M+H)<br>
Step F: To a solution containing 0.43 g (1.44 mmol) of<br>
compound 6 in 4 0 ml of DCE under a nitrogen atmosphere was<br>
added 0.30 ml (2.89 mmol) of cyclohexanone followed by 0.90<br>
g (4.25 mmol) of sodium triacetoxy borohydride. The<br><br>
reaction was allowed to stir at room temperature overnight.<br>
The reaction was diluted with dichloromethane and washed<br>
with saturated sodium bicarbonate solution. The organic<br>
phase was dried over MgSO4. Filtration, removal of solvent<br>
and purification of the residue via Biotage chromatography<br>
eluting with 75% AcOEt/hexanes gave 0.35 g (63.7%) of<br>
compound 7. MS Calcd.: 381; Found 382 (M+H)<br>
Example 438<br>
4-Methyl-N-(1-methyl-1-phenylethyl)-2-phenyl-l,2,3,4-<br>
tetrahydropyrazolo[5,1-c][1,2,4]triazine-8-carboxamide<br><br>
To a solution containing 0.20 g (0.71 mmol) of<br>
compound 1 in 25 ml of DCM under a nitrogen atmosphere at -<br>
78 C was added 0.36 g (0.64 mmol) of triphenylbismuth<br>
diacetate followed by 0.02 g (0.075 mmole) of copper (II)<br>
dipivalate. The reaction was allowed to warm to 0 C over<br>
1.5 h. The reaction was diluted with dichloromethane and<br>
washed with saturate sodium bicarbonate. The organic phase<br>
was dried over magnesium sulfate. Filtration, removal of<br>
solvent and purification of the residue via Biotage<br><br>
chromatography eluting with 70% AcOEt/ hexanes gave 0.025 g<br>
(9.4%) of compound 2. MS Calcd.: 375; Found 376 (M+H)<br>
Example 1123<br>
1-(7,7-Dimethyl-5-phenyl-4, 5, 6, 7-<br>
tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)-2-methyl-2-(4-<br>
methylphenyl)-1-propanone<br><br>
Step A<br>
4-Benzyl-7,7-dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid (2) :<br>
To a 100 mL round bottom flask equipped with a magnetic<br><br>
stir bar was added 1.80 g (6.01 mmol) of 7,7-dimethyl-5-<br>
phenyl-4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrimidine-3-<br>
carboxylic acid ethyl ester, 30 mL of DMF and 0.786 mL<br>
(6.61 mmol) of benzyl bromide, followed by 0.265 g (6.6<br>
mmol) of sodium hydride (60% dispersion in mineral oil)<br>
which was added in several portions. After 2 h, the<br>
reaction was quenched with water and the product was<br>
extracted with AcOEt. The combined organic layers were<br>
washed with brine, dried over sodium sulfate, filtered and<br>
concentrated to give the crude N-benzylated ester as a<br>
golden colored oil. The crude ester was dissolved in 15 mL<br>
of ethanol and 2.5 mL of 6 N potassium hydroxide was added.<br>
The solution was then heated to 70 C for 18 h at which<br>
time no starting material could be detected by HPLC<br>
analysis. The crude reaction mixture was concentrated in<br>
vacuo and diluted with water. The aqueous solution was<br>
acidified with 6 N HC1 and the resulting cream-colored<br>
precipitate was collected by filtration. The crude acid<br>
thus isolated was dissolved in AcOEt, dried over sodium<br>
sulfate, filtered and concentrated to a cream colored<br>
powder. The resulting acid was washed with several<br>
portions of hexanes and dried in vacuo to give 1.95 g (90%)<br>
of the title compound as an off white powder. 1H NMR<br>
(DMSO-d6)  1.10 (s, 3H) , 1.40 (s, 3H) , 1.98-2.16 (m, 2H) ,<br>
3.71 (d, J = 15.4 Hz, 1H), 4.36 (dd, J = 4.5, 11.5 Hz, 1H),<br><br>
5.81 (d, J = 15.6 Hz), 6.97 (dd, J = 1.4, 7.2 Hz, 2H) ,<br>
7.26-7.45 (m, 7H), 7.67 (s, 1H), 11.81 (s, 1H). MS Calcd.:<br>
361; Found: 344 (M-OH).<br>
Step B<br>
4-Benzyl-7,7-dimethyl-5-phenyl-4,5,6, 7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxylic acid<br>
methoxy-methyl-amide (3) : To a 5 mL NMP solution<br>
containing 0.72 g (1.99 mmol) of 2 was added 0.91 g (2.39<br>
mmol) of O-7-azabenzotriazolo-1-yl) -N,N,N' ,N'-<br>
tetramethyluroniumhexafluorophosphate (HATU) and 0.416 mL<br>
(2.39 mmol) of diisopropylethylamine. After stirring for<br>
30 min, 0.233 g (2.39 mmol) of O,N-dimethyl-hydroxylamine<br>
hydrochloride was added and the reaction heated to 50 C.<br>
After 1 h, the reaction mixture was poured into water and<br>
extracted with AcOEt. The combined organic layers were<br>
washed with brine, dried over sodium sulfate, filtered and<br>
concentrated in vacuo to give a crude oil. Purification of<br>
this oil by flash chromatography eluting with a 60 to 50%<br>
hexanes/AcOEt gradient gave 0.65 g (81%) of the title<br><br><br>
(M+H).<br>
Step C<br>
l-(4-Benzyl-7,7-dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)-2-(4-<br>
methylphenyl) ethanone (4) : To 0.65 g (1.61 mmol) of 3<br>
dissolved in 20 mL of THF was added 6.4 mL (3.2 mmol) of a<br>
0.5 M solution of 4-methylbenzylmagnesium chloride in THF<br>
via syringe over 10 min. After stirring at room<br>
temperature for 1 h, the reaction was quenched by addition<br>
of approximately 2 mL of saturated aqueous ammonium<br>
chloride. The reaction was then diluted with AcOEt and<br>
dried over sodium sulfate. Filtering the solution through<br>
a short plug of silica gel and concentrating in vacuo<br>
provided the crude product as an oil. Purification of this<br>
oil by flash chromatography eluting with 75% hexanes/ AcOEt<br>
gave 0.64 g (89%) of the title compound as a white foam.<br>
MS Calcd.: 449; Found: 450 (M+H).<br>
Step D<br>
1-(4-Benzyl-7,7-dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)-2-(4-<br>
methylphenyl)-1-propanone (5) : To 0.64 g (1.42 mmol) of 4<br>
dissolved in 10 mL of THF was added 0.177 mL (2.85 mmol) of<br>
iodomethane followed by 0.11 g (2.8 mmol) of sodium hydride<br>
(60% dispersion in mineral oil). After stirring at room<br>
temperature for 2 h, the reaction was quenched by addition<br><br>
of approximately 2 mL of saturated aqueous ammonium<br>
chloride. The reaction was then diluted with AcOEt and<br>
dried over sodium sulfate. Filtering the solution through<br>
a short plug of silica gel and concentrating in vacuo<br>
provided the crude product. Purification by flash<br>
chromatography eluting with 90% hexanes/ethyl acetate gave<br>
0.42 g (64%) of the title compound as a cream colored<br>
powder. MS Calcd.: 463; Found: 464 (M+H).<br>
Step E<br>
1-(4-Benzyl-7,7-dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidin-3-yl)-2-methyl-2-(4-<br>
methylphenyl)-1-propanone (6) : To 0.110 mL (0.785 mmol) of<br>
diisopropyl amine dissolved in 5 mL of THF at -78 C was<br>
added 0.314 mL (0.785 mmol) of a 2.5 M solution of n-<br>
butyllithium in hexanes. After stirring for 30 min, 0.28 g<br>
(0.604 mmol) of 5 was added as a solution in 1 mL of THF.<br>
The reaction was stirred at room temperature for 1 h before<br>
0.04 9 mL (0.79 mmol) of iodomethane was added as a solution<br>
in 1 mL of THF. After 1h the reaction was quenched by<br>
addition of approximately 0.5 mL of saturated aqueous<br>
ammonium chloride, diluted with AcOEt and dried over sodium<br>
sulfate. Filtering the solution through a short plug of<br>
silica gel and concentrating in vacuo provided the crude<br>
product. Purification by flash chromatography eluting with<br>
90% hexanes/ AcOEt gave 0.067 g (23%) of the title<br><br>
compound as an off white solid. MS Calcd.: 477; Found: 478<br>
(M+H).<br>
Step F<br>
1-(7,7-Dimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-<br>
a]pyrimidin-3-yl)-2-methyl-2-(4-methylphenyl)-1-propanone<br>
(7) : To 0.060 g (0.126 mmol) of 6 dissolved in 4 mL of 1:1<br>
THF:ethanol was added 0.080 g of 10% palladium on carbon.<br>
The reaction vessel was capped with a rubber septum and<br>
charged with hydrogen via a balloon. After 1 h, the<br>
catalyst was removed via filtration and the filtrate<br>
concentrated to a cream colored solid. Purification by<br>
flash chromatography eluting with 90% hexanes/ethyl acetate<br>
gave 0.041 g (84%) of the title compound as a white solid.<br>
1H NMR (CDC13)  1.49 (s, 3H) , 1.54 (s, 9H), 2.04-2.11 (m,<br>
2H), 2.32 (s, 3H), 4.63 (dd, J = 4.1, 10.7 Hz, 1H), 6.66 (s,<br>
1H), 7.12-7.26 (m, 5H), 7.31-7.44 (m, 5H). MS Calcd.: 387;<br>
Found: 388 (M+H).<br>
Compounds of Examples 1124-1131 shown in the Table 14,<br>
were prepared in a manner similar to that described in<br>
Example 1123.<br>
Table 14<br><br><br><br><br>
Example 1132<br>
7,7-Dimethyl-3-((1-methyl-1-(4-<br>
methylphenyl)ethyl)sulfonyl)-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine<br><br><br>
Step A<br>
p-Tolylmethanesulfonylacetonitrile (2): To a 10 mL ethanol<br>
solution containing 4.1 g (30 mmol) of p-tolylmethanethiol<br>
at 0 C was added 4.1 mL (30 mmol) of triethylamine and 4.4<br>
g (30 mmol) of sodium iodide. After allowing the reaction<br>
to stir at room temperature for approximately 30 min, the<br>
reaction cooled to 0 C and 1.9 mL (30 mmol) of<br>
chloroacetonitrile was added dropwise as a solution in 10<br>
mL of ethanol. The reaction was allowed to reach room<br>
temperature overnight and was subsequently filtered and<br>
concentrated. The concentrate was partitioned between<br>
water and ether and separated. The ether layer was washed<br>
successively with 2 N sodium carbonate and brine and was<br><br>
then concentrated to an oil that solidified. The crude<br>
solid was then dissolved in 90 mL of glacial acetic acid,<br>
treated with 12.1 mL (107 mmol) of 30% hydrogen peroxide<br>
and heated to 100 C. The reaction was cooled to room<br>
temperature after 3 h at which time a white solid<br>
precipitated. The precipitate was collected via filtration,<br>
washed with glacial acetic acid and dried in vacuo to give<br>
6.4 g (69%) of the title compound as a white solid. 1H NMR<br>
(CDC13)  2.39 (s, 3H), 3.70 (s, 2H) , 4.48 (s, 2H) , 7.32<br>
(dd, J = 7.3, 40.2 Hz, 4H).<br>
Step B<br>
3-Ethoxy-2-p-tolylmethanesulfonylacrylonitrile (3) : To a<br>
solution of 4.4 g (21 mmol) of 2 in 17.5 mL (105 mmol) of<br>
triethylorthoformate was added 9.9 mL (105 mmol) of acetic<br>
anhydride. The resulting solution was heated to reflux for<br>
18 h before being concentrated to a solid.<br>
Recrystallization from AcOEt-hexanes gave 5.0 g (90%) of<br>
the title compound as a white solid.<br>
1H NMR (CDCl3)  1.29 (t, J = 7.0 Hz, 3H) , 2.36 (s, 3H) ,<br>
4.19 (q, J = 7.0 Hz, 2H), 4.35 (s, 2H), 7..23 (dd, J = 8.0,<br>
19.9 Hz) 7.37 (s, 1H).<br>
Step C<br>
7,7-Dimethyl-3-(4-methylbenzyl)sulfonyl)-5-phenyl-4,7-<br>
dihydropyrazolo[l,5-a]pyrimidine (4) : A slurry of 1.9 g<br>
(7.2 mmol) of 3 in 25 mL of ethanol was treated with 0.38<br><br>
mL (7.9 mmol) of hydrazine monohydrate and heated to reflux<br>
for 3 h. The reaction was concentrated in vacuo to give<br>
crude 4-p-tolylmethanesulfonyl-2H-pyrazol-3-ylamine as a<br>
tan solid. The crude pyrazole, 1.3 g (7.9 mmol) of 3-<br>
methyl-1-phenyl-but-2-en-1-one and 2.8 mL (36 mmol) of<br>
trif luoroacetic acid was dissolved in 25 mL of 2-<br>
methoxyethanol and heated to reflux for 3 days. The<br>
reaction was then cooled to room temperature, concentrated<br>
in vacuo and dissolved in AcOEt. This solution was washed<br>
successively with saturated sodium bicarbonate, water and<br>
brine before being dried over sodium sulfate. The solution<br>
was filtered, concentrated in vacuo and the resulting crude<br>
material was purified by flash chromatography eluting with<br>
a 75 to 33% hexanes/ AcOEt gradient to give 1.25 g (44%)<br>
of the title compound as a powder. 1H NMR (CDC13)  1.67<br>
(s, 6H) , 2.13 (s, 3H) , 4.26 (s, 2H) , 4.81 (d, J = 2.0 Hz,<br>
1H) , 6.39 (s, 1H) , 7.05 (dd, J = 8.0, 18.5 Hz, 4H) , 7.20<br>
(dd, J = 3.7, 7.4 Hz, 2H), 7.36-7.39 (m, 3H), 7.52 (s, 1H).<br>
MS Calcd.: 393; Found: 394 (M+H).<br>
Step D<br>
7,7-Dimethyl-3-((4-methylbenzyl)sulfonyl)-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine (5) : To 0.500 g (1.27<br>
mmol) of 4 dissolved in 8 mL of 1:1 THF:ethanol was added<br>
0.50 g of 10% palladium on carbon. The reaction vessel was<br>
capped with a rubber septum and charged with hydrogen via a<br><br>
balloon. After 2 days at room temperature, the catalyst<br>
was removed via filtration and the filtrate concentrated to<br>
a solid. Purification by flash chromatography eluting<br>
with a 75 to 33% hexanes/AcOEt gradient gave 0.385 g (77%)<br>
of the title compound as a white solid. 1H NMR (CDCl3) <br>
1.49 (s, 3H), 1.59 (s, 3H), 1.83-1.97 (m, 2H), 2.37 (s, 3H) ,<br>
4.09-4.24 (m, 3H) , 5.03 (s, 1H) , 7.06-7.13 (m, 6H) , 7.30-<br>
7.39 (m, 3H) , 7.45 (s, 1H) . MS Calcd. : 395; Found: 396<br>
(M+H).<br>
Step E<br>
4-Benzyl-7,7-dimethyl-3-((4-methylbenzyl)sulfonyl)-5-<br>
phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (6) : To<br>
a solution of 0.34 g (0.86 mmol) of 5 in 10 mL of THF at<br>
0 C was added 0.128 mL (1.07 mmol) of benzyl bromide<br>
followed by 0.034 g (0.86 mmol) of sodium hydride (60%<br>
dispersion in mineral oil) . The reaction was allowed to<br>
warm to room temperature after 30 min and stirred for an<br>
additional 30 min before being quenched with water. The<br>
quenched reaction was diluted with five volumes of water<br>
and extracted with AcOEt. The combined organic layers were<br>
washed with brine, dried over sodium sulfate, filtered and<br>
concentrated in vacuo. The crude product was purified by<br>
flash chromatography eluting with 70% hexanes/AcOEt to give<br>
0.39 g (93%) of the title compound as a white solid. 1H<br>
NMR (CDCl3)  1.27 (s, 3H) , 1.52 (s, 3H) , 1.93-2.05 (m,<br><br>
2H), 2.27 (s, 3H), 3.83 (d, J = 15.8 Hz, 1H) , 4.18-4.30 (m,<br>
3H), 5.51 (d, J = 15.8 Hz, 1H), 6.98-7.00 (m, 2H), 7.09 (dd,<br>
J = 8.2, 12.1 Hz, 4H), 7.17 (d, J = 6.8 Hz, 2H), 7.26-7.30<br>
(m, 3H), 7.32-7.40 (m, 3H), 7.47 (s, 1H).<br>
Step F<br>
4-Benzyl-7,7-dimethyl-3-((1-(4-<br>
methylphenyl)ethyl)sulfonyl)-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine (7) : A solution of<br>
0.23 g (0.47 mmol) of 6 in 4 mL of THF was cooled to 0 C<br>
and treated with 0.24 mL (0.59 mmol) of n-butyllithium (2.5<br>
M solution in hexanes) and allowed to reach room<br>
temperature for 20 min. After cooling the reaction to 0 C,<br>
0.103 mL (1.66 mmol) of iodomethane was added as a solution<br>
in 2 mL of THF. The reaction was allowed to warm to room<br>
temperature for 30 min at which time the reaction was<br>
quenched with a few drops of saturated ammonium chloride.<br>
The reaction was dried over sodium sulfate, filtered and<br>
concentrated in vacuo. The residue was purified by flash<br>
chromatography eluting with 80% hexanes/AcOEt to give 0.14<br>
g (60%) of the title compound as a white solid. MS<br>
Calcd.: 499; Found: 500 (M+H).<br>
Step G<br>
4-Benzyl-7,7-dimethyl-3-((1-methyl-1-(4-<br>
methylphenyl)ethyl)sulfonyl)-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine (8) : Using the method<br><br>
described for the synthesis of 7, the title compound was<br>
prepared in 51% isolated yield. MS Calcd.: 513; Found:<br>
514 (M+H).<br>
Step H<br>
7,7-Dimethyl-3-((1-methyl-1-(4-<br>
methylphenyl)ethyl)sulfonyl)-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine (9) : To 0.075 g (0.146<br>
mmol) of 8 dissolved in 6 mL of 1:1 THF:ethanol was added<br>
0.10 g of 10% palladium on carbon. The reaction vessel was<br>
capped with a rubber septum and charged with hydrogen via a<br>
balloon. After 2 h at room temperature, the catalyst was<br>
removed via filtration and the filtrate concentrated to<br>
give 0.056 g (91%) of the title compound as a white solid.<br>
MS Calcd.: 423; Found: 424 (M+H).<br>
Compounds of Examples 1133-1134, shown in the Table 15,<br>
were prepared in a manner similar to that described in<br>
Example 1132.<br><br><br><br>
Example 1135<br>
3-(3-Benzylpyrrolidine-1-sulfonyl)-7,7-dimethyl-5-<br>
phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine<br><br>
Step A<br>
(3-Benzylpyrrolidine-1-sulfonyl)acetonitrile (2) : To a 20<br>
mL ether solution containing 1.34 g (8.31 mmol) of 3-<br>
benzylpyrrolidine cooled to -45 C was added 0.61 g (4.4<br>
mmol) of 2-cyanoethanesulfonyl chloride as a solution in 10<br>
mL of ether. The reaction was allowed to warm to room<br><br>
temperature and was stirred for 24 h over which time an oil<br>
formed on the flask wall. The ether solution was poured<br>
away from the oil and filtered through a short plug of<br>
silica gel. The filtrate thus obtained was concentrated in<br>
vacuo to give a solid that was purified by flash<br>
chromatography eluting with 75% hexanes/AcOEt to give 1.25<br>
g (44%) of the title compound as a wax.<br>
1H NMR (CDC13)  1.73-1.83 (m, 1H) , 2.08-2.15 (m, 1H) ,<br>
2.57-2.67 (m, 1H) , 2.71-2.79 (m, 2H) , 3.21 (dd, J = 8.2,<br>
9.7, Hz, 1H), 3.49-3.55 (m, 1H), 3.63 (dd, J = 7.0, 9.4 Hz,<br>
1H), 3.69-3.74 (m, 1H), 3.95 (s, 2H), 7.16 (d, J = 7.4 Hz,<br>
2H), 7.21-7.33 (m, 3H).<br>
Step B<br>
2-(3-Benzylpyrrolidine-1-sulfonyl)-3-ethoxyacrylonitrile<br>
(3) : To a solution of 0.14 g (0.53 mmol) of 2 in 0.43 mL<br>
(2.6 mmol) of triethylorthoformate was added 0.25 mL (2.6<br>
mmol) of acetic anhydride. The resulting solution was<br>
heated to reflux for 4 h before being concentrated to an<br>
oil. The crude oil thus obtained was purified by flash<br>
chromatography eluting with 75% hexanes/AcOEt to give 0.079<br>
g (46%) of the title compound as a yellow oil. 1H NMR<br>
(CDCl3)  1.42 (t, J = 7.2 Hz, 3H) , 1.67-1.77 (m, 1H) ,<br>
2.01-2.09 (m, 1H) , 2.53-2.62 (m, 1H) , 2.71 (d, J = 7.4 Hz,<br>
2H) , 3.05 (dd, J = 8.4, 9.8 Hz, 1H) , 3.35-3.41 (m, 1H) ,<br>
3.48 (dd, J = 7.0, 9.5 Hz, 1H), 3.53-3.59 (m, 1H), 4.31 (q,<br><br>
J = 7.2 Hz, 2H) , 7.15-7.17 (m, 2H) , 7.19-7.23 (m, 1H) ,<br>
7.26-7.31 (m, 2H) , 7.76 (s, 1H).<br>
Step C<br>
3-(3-Benzylpyrrolidine-1-sulfonyl)-7,7-dimethyl-5-phenyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine (4): A 2 mL<br>
ethanol solution containing 0.079 g (0.247 mmol) of 3 was<br>
treated with 0.013 mL (0.27 mmol) of hydrazine monohydrate<br>
and heated to reflux for 5 h. The reaction was<br>
concentrated in vacuo to give crude 4-(3-benzylpyrrolidine-<br>
1-sulfonyl)-2H-pyrazol-3-ylamine. The crude pyrazole thus<br>
obtained was dissolved in 2 mL of 2-methoxyethanol<br>
containing 0.044 g (0.27 mmol) of 3-methyl-1-phenyl-but-2-<br>
en-1-one and 0.038 mL (0.49 mmol) of trifluoroacetic acid<br>
was added. The mixture was refluxed for three days then<br>
concentrated and purified by flash chromatography eluting<br>
with 60% hexanes/AcOEt to give 3-(3-benzylpyrrolidine-1-<br>
sulfonyl)-7,7-dimethyl-5-phenyl-4,7-dihydropyrazolo[1,5-<br>
a] pyrimidine that was found to be only 90% pure by HPLC<br>
analysis. This material was then dissolved in 1 mL of 1:1<br>
THF:ethanol and 0.010 g of 10% palladium on carbon. The<br>
reaction vessel was capped with a rubber septum and charged<br>
with hydrogen via a balloon. After 90 min at room<br>
temperature, the catalyst was removed via filtration and<br>
the filtrate concentrated to an oil. Purification by<br>
flash chromatography eluting with 75% hexanes/AcOEt gave<br><br>
0.024 g (20% from 3) of the title compound as a light<br>
yellow oil. 1H NMR (CDC13)  1.55-1.66 (m, 7H) , 1.94-2.03<br>
(m, 1H), 2.08-2.16 (m, 2H) , 2.37-2.50 (m, 1H), 2.58-2.70 (m,<br>
2H) , 2.90-2.97 (m, 1H) , 3.18-3.27 (m, 1H) , 3.31-3.42 (m,<br>
2H) , 4.53-4.60 (m, 1H) , 5.71(s, 1H) , 7.11-7.14 (m, 2H) ,<br>
7.19-7.23 (m, 1H) , 7.26-7.40 (m, 7H) , 7.53 (s, 1H) . MS<br>
Calcd.: 450; Found: 451 (M+H).<br>
Example 1136<br>
4,4-Dimethyl-8-[5-(1-methyl-1-phenyl-ethyl)-<br>
[l,3,4]oxadiazol-2-yl]-2-phenyl-l,2,3,4-<br>
tetrahydropyrrolo[1,2-a]pyrimidine<br><br><br>
Step A<br>
2-Amino-1H-pyrrole-3-carboxylic acid ethyl ester (1) :<br>
Carbamimidoyl-acetic acid ethyl ester (3.357g, 25.8 mmol)<br>
was dissolved in AcOEt (20 mL) . Chloroacetaldehyde (50%<br>
solution in water, 1.8 mL, 28.7 mmol) was added rapidly at<br>
room temperature. The solution stirred for 2 minutes until<br>
a precipitant formed. The solution was then brought to<br>
65 C for 0.5 h. The reaction mixture was then cooled and<br>
flash chromatographed with AcOEt. Product containing<br>
fractions were concentrated to give the desired material as<br>
a green solid. 0.68 g obtained, 31% yield. 1H NMR (400 MHz,<br>
CDCl3)  1.32 (t, J= 7.2 Hz, 3H), 4.24 (q, J= 7.0 Hz, 2H),<br>
5.08 (brs, 2H) , 6.10 - 6.13 (m, 1H) , 6.25 (t, J = 3.12, 1<br>
Hz), 8.60 (brs, 1H); MS Calcd.: 154; Found 155 (M+H).<br>
Step B<br>
4,4-Dimethyl-2-phenyl-l,2,3,4-tetrahydro-pyrrolo[1,2-<br>
a]pyrimidine-8-carboxylic acid ethyl ester (2) : Compound 1<br>
(0.68g, 4.41 mmol) was dissolved in DMF (5 mL) . NaH (60%<br>
in mineral oil, 0.19g, 4.7 mmol) was added at room<br>
temperature affording rapid gas evolution. The reaction<br>
stirred for 0.5 h upon which 3-methyl-1-phenyl-but-2-en-1-<br>
one (0.50g, 3.15 mmol) was added. The reaction stirred for<br>
0.5 h upon which EtOH (5 mL) and NaBH4 (1.19g) were added.<br>
The solution was brought to 60 C for 0.5 h. and then<br><br>
cooled to room temperature. The solution was quenched with<br>
water, extracted with Et20 (3 times) , dried (Na2SO4) and<br>
concentrated. Flash chromatography (10% AcOEt) to give the<br>
desired product as a tan solid (0.60g, 63% yield). MS<br>
Calcd.: 298; Found 299 (M+H).<br>
Step C<br>
4,4-Dimethyl-2-phenyl-l,2,3,4-tetrahydro-pyrrolo[1,2,-<br>
a]pyrimidine-8-carboxylic acid hydrazide (3) : Compound 2<br>
(0.210g, was diluted with anhydrous hydrazine (5 mL) and<br>
heated to 100 C for 3 days. The reaction was then cooled<br>
and diluted with water. The solution was extracted with<br>
AcOEt (3 times), dried (Na2SO4) and concentrated. The<br>
residue was flash chromatographed (10% MeOH/AcOEt) to give<br>
the desired material. 0.12g, 60% yield). 1H NMR(400 MHz,<br>
CDC13)  1.54 (s, 6H) , 1.99 - 2.13 (m, 2H), 3.89 (brs, 2H),<br>
4.64 (dd, J= 3.5, 11.7 Hz, 1H), 6.02 (d, J= 3.9 Hz), 6.22<br>
(d, J = 3.9 Hz, 1H), 6.55 (brs, 1H), 6.74 (brs, 1H), 7.31 -<br>
7.46 (m, 5H). MS Calcd.: 284; Found 285 (M+H).<br>
Step D<br>
4,4-Dimethyl-2-phenyl-l,2,3,4-tetrahydro-pyrrolo[1,2,-<br>
a]pyrimidine-8-carboxylic acid N-(2-methyl-2-phenyl-<br>
propionyl)-hydrazide (4) :<br>
Compound 3 (0.085g, 0.30 mmol) was dissolved in THF (2 mL).<br>
HBTU (0.136g, 0.36 mmol), ,-dimethyl-phenylacetic acid<br>
(0.059g, 0.36 mmol), and DIEA (0.10 mL, 0.60 mmol) were<br><br>
added. The reaction stirred for 2 h. and was concentrated.<br>
Flash chromatography (50% AcOEt/hexanes) gave the desired<br>
product. 0.123g obtained (96% yield). 1H NMR (400 MHz,<br>
CDC13)  1.49 (s, 3H), 1.50 (s, 3H), 1.60 (s, 3H) , 1.61 (s,<br>
3H) , 1.95 - 2.10 (m, 2H), 4.56 (dd, J = 3.1, 11.3 Hz, 1H),<br>
6.13 (d, J= 3.5 Hz, 1H), 6.17 (d, 3.5 Hz, 1H), 6.65 (brs,<br>
1H) , 7.22 - 7.43 (m, 10H), 7.81 (brs, 1H), 7.92 (brs, 1H) .<br>
MS Calcd.: 430; Found 431 (M+H).<br>
Step E<br>
4,4-Dimethyl-8-[5-(1-methyl-1-phenyl-ethyl)-<br>
[1,3,4]oxadiazol-2-yl]-2-phenyl-1,2,3,4-<br>
tetrahydropyrrolo[1,2-a]pyrimidine (5) : Compound 4 (0.060g,<br>
0.14 mmol) was diluted in POC13 (3 mL) . The solution was<br>
heated to 75 C for 3 h. The solution was cooled and<br>
carefully quenched with water. The solution was diluted<br>
with AcOEt and the mixture carefully neutralized with sat.<br>
NaHCO3. The organic layer was separated and the aqueous<br>
layer was extracted twice more with AcOEt portions. The<br>
combined organic layers were dried (Na2SO4) , concentrated,<br>
and flash chromatographed to give the desired product as a<br>
white solid. 0.016g obtained (28% yield). 1H NMR(400 MHz,<br>
CDCl3)  1.55 (s, 6H) , 1.80 (s, 6H) , 2.02 - 2.16 (m, 2H) ,<br>
4.68 (dd, J = 3.2, 11.6 Hz, 1H), 6.23 (d, J = 3.2 Hz, 1H),<br>
6.30 (d, J= 3.2 Hz, 1H), 7.20 - 7.46 (m, 10H). MS Calcd.;<br>
412; Found 413 (M+H).<br><br>
Example 1137<br>
3-Methyl-2-phenyl-2,3-dihydro-1H-imidazo[1,2-<br>
b]pyrazole-7-carboxylic acid [1-ethyl-1-(4-trifluoromethyl-<br>
phenyl)-propyl]-amide<br><br>
Step A<br>
5-Amino-1-(l-methyl-2-oxo-2-phenyl-ethyl)-1H-pyrazole-4-<br>
carboxylic acid ethyl ester (1) : 5-Amino-1H-pyrazole-4-<br>
carboxylic acid ethyl ester (7.35g, 47.3 mmol) was<br>
dissolved in 160 mL of DMF. Na2CO3 (5.02g, 47.3 mmol) was<br><br>
added followed by 2-bromopropiophenone (7.2 mL, 47.3 mmol).<br>
The reaction stirred at room temperature for 2 days. The<br>
solution was diluted with AcOEt and the organic layer was<br>
washed with sat. NaHCO3, brine, dried (MgSO4) , and<br>
concentrated. Flash chromatography (20-45% AcOEt/hexane)<br>
gave the desired product (1.58g, 12% yield). 1H NMR(400 MHz,<br>
CDC13)  1.3 (t, J = 7.0 Hz, 3H) , 1.7 (d, J = 7.4 Hz, 3H) ,<br>
4.2 (q, J == 7.0 Hz, 2H) , 5.4 (bs, 2H) , 5.9 (q, J = 7.0 Hz,<br>
1H), 7.41 - 7.59 (m, 3H), 7.60 (s, 1H), 8.0 (d, J = 8.0 Hz,<br>
2H) .<br>
Step B<br>
5-Amino-1- (2-hydroxy-1-methyl-2-phenyl-ethyl) -1H-pyrazole-<br>
4-carboxylic acid ethyl ester (2) :Compound 1 (0.7g, 2.43<br>
mmol) was dissolved in 34 mL EtOH. NaBH4 (0.18g, 4.87<br>
mmol) was added in one shot. The reaction stirred at room<br>
temperature for 0.5 h. The solution was quenched with sat.<br>
NH4Cl and extracted with CH2C12 (3 times) . The organic<br>
layer was washed with brine, dried (MgSO4) , concentrated to<br>
give a fluffy white solid 2 (0.69g, 98% yield). MS: Calcd.:<br>
289; Found: 290 (M+H).<br>
Step C<br>
3-Methyl-2--phenyl-2, 3-dihydro-1H-imidazo [1, 2-b] pyrazole-7-<br>
carobxylic acid ethyl ester (3) : Compound 2 (0.80g, 2.8<br>
mmol) was dissolved in CH2C12. SOC12 (0.61 mL, 8.3 mmol)<br>
was added dropwise. After 90 minutes, the solution was<br><br>
concentrated to give a yellow solid. After pumping on high<br>
vacuum for 5 minutes, the solid was dissolved in CHC13.<br>
Et3N (2.7 mL, 19.5 mmol) was added dropwise and the<br>
reaction mixture stirred for 1 hour. The reaction was<br>
quenched with water and diluted with AcOEt. The solution<br>
was washed with sat. NH4Cl, sat. NaHCO3, brine, and then<br>
dried (MgSO4) . Flash chromatography (20% AcOEt/hexane)<br>
gave both the syn (0.10g, 14%) and anti (0.62g, 82%)<br>
isomers 3. Anti isomer 1H NMR(400 MHz, CDC13)  1.23 (t, J<br>
= 7.0 Hz, 3H), 1.80 (d, J = 6.6 Hz, 3H) , 4.10 - 4.20 (m,<br>
2H), 4.25 - 4.35 (m, 1H), 4.38 (brs, 1H) , 5.10 (d, J = 9.8<br>
Hz, 1H), 7.17 - 7.25 (m, 5H) , 7.59 (s, 1H) . Syn isomer 1H<br>
NMR(400 MHz, CDC13)  1.28 (d, J= 7.0 Hz, 3H), 7.38 (t, J<br>
= 7.4 Hz, 3H) , 4.25 - 4.35 (m, 2H) , 7.43 - 7.52 (m, 1H) ,<br>
5.17 (brs, 1H) , 5.23 (d, J= 9.8 Hz, 1H) , 7.37 - 7.45 (m,<br>
5H) .<br>
Step D and E<br>
3-Methyl-2-phenyl-2, 3-dihydro-1H-imidazo [1, 2-b] pyrazole-7-<br>
carboxylic acid [1-ethyl-1-(4-trifluoromethyl-phenyl)-<br>
propyl]-amide (5) :<br>
Compound 3 (0.085g, 0.3 mmol) was dissolved in EtOH (3 mL).<br>
KOH (6M in water, 0.9 mL, 1.78 mmol) was added. The<br>
reaction stirred at 60 C for 3 h. The solution was cooled,<br>
diluted with AcOEt (10 mL) and water (10 mL) and shaken<br>
vigorously. The Aqueous layer was separated and acidified<br><br>
to pH = 3. This acidic layer was then extracted with AcOEt<br>
(3 times). The combined AcOEt layers were washed with<br>
brine, dried (Na2SO4) and concentrated. The residue was<br>
then dissolved in NMP (1 mL) and 1-ethyl-1-(4-<br>
trifluoromethyl-phenyl)-propylamine (0.087g, 0.37 mmol),<br>
HATU (0.14g, 0.37 mmol), and DIEA (0.14 mL, 0.78 mmol) were<br>
added. The reaction was heated to 80 C for 2 days. The<br>
solution Was then cooled, washed with water, dried (MgSO4) ,<br>
and concentrated. Flash chromatography (20% AcOEt/hexanes)<br>
gave 0.017g (12% yield) of amide 5.<br>
1H NMR (400 MHz, CDC13)  0.79 - 0.83 (m, 6H) , 1.26 (d, J =<br>
7.0 Hz, 3 H), 1.99 - 2.05 (m, 2H) , 2.23 - 2.31 (m, 2H) ,<br>
4.44 - 4.48 (m, 1H) , 5.19 (brs, 1H) , 5.24 (d, J = 10 Hz,<br>
1H), 5.66 (brs, 1H) , 7.37 - 7.63 (m, 9H) . MS Calcd.: 456;<br>
Found: 457 (M+H).<br>
Example 1138<br>
8-Methyl-5-phenyl-5, 6, 7, 8-tetrahydro-4H-<br>
pyrazolo[l,5,a][1,3]diazepine-3-carboxylic acid (1-methyl-<br>
1-phenyl-ethyl)-amide<br><br><br>
Step A<br>
5-Amino-1-[4-tert-butyl-dimethyl-silanyloxy]-1-methyl-4-<br>
phenyl-butyl]-1H-pyrazole-4-carboxylic acid ethyl ester<br>
(1) :<br>
5-Amino-lH-pyrazole-4-carboxylic acid ethyl ester (1.60g,<br>
10.3 mmol) was dissolved in 10 mL of DMF. The solution was<br>
cooled to 0 C and NaH (60% in mineral oil, 0.82g, 20.6<br>
mmol) was added in one portion. The reaction warmed to<br>
room temperature after H2 evolution ceased. The reaction<br>
stirred for 0.5 h till a bright orange color persisted.<br>
The reaction was again brought to 0 C and methanesulfonic<br>
acid 4-(tert-butyl-dimethyl-silanyloxy)-1-methyl-4-phenyl-<br><br>
butyl ester (3.49g, 9.38 mmol) was then added as a solution<br>
in 6 mL DMF. The reaction warmed to room temperature and<br>
stirred for 2.5 days. The solution was quenched with water<br>
and diluted with AcOEt. The organic layer was separated<br>
and the aqueous layer was extracted twice more with AcOEt.<br>
The combined organic layers were dried (MgSO4) ,<br>
concentrated and flash chromatographed (15% AcOEt/hexanes)<br>
to give 0.530g (13% yield) of the desired product as an oil.<br>
1H NMR (400 MHz, CDC13)  0.16 (s, 3H) , 0.17 (s, 3H) , 1.04<br>
(d, J = 10 Hz, 9H), 1.48 - 1.52 (m, 3H) , 1.55 (d, J = 6.4<br>
Hz, 3H) , 1.60 (d, J = 6.8 Hz, 3H - other diastereomer) ,<br>
1.62 - 1.75 (m, 2H) , 1.97 - 2.07 (m, 2H) , 2.10 - 2.20 (m,<br>
2H - other diastereomer), 4.02 - 4.07 (m, 1H), 4.21 - 4.29<br>
(m, 1H - other diastereomer), 4.40 - 4.43 (m, 2H) , 4.79 -<br>
4.86 (m, 1H), 5.04 (brs, 1H), 5.25 (brs, 1H - other<br>
diastereomer), 7.36 - 7.47 (m, 5H) , 7.79 (s, 1H) ; MS<br>
Calcd.: 431; Found 432 (M+H).<br>
Step B and C<br>
8-Methyl-5-phenyl-5,6,7,8-tetrahydro-4H-<br>
pyrazolo[1,5,a][1,3]diazepine-3-carboxylic acid ethyl ester<br>
(3) : Compound 1 (2.0g, 4.6 mmol) was dissolved in 9 mL THF.<br>
TBAF (1M in THF, 13.9 mL, 13.9 mmol) was added at room<br>
temperature. The reaction stirred for 0.5 h. The reaction<br>
was diluted with ether and washed with brine and water.<br>
The ether layer was dried (MgSO4) and concentrated to give<br><br>
the crude alcohol product 2. MS Cald.: 317; Found 318<br>
(M+H).<br>
Alcohol 2 was taken up in CH2C12 (80 mL) . SOC12 (1.7<br>
mL, 23.4 mmol) was added. After 1 h, the solution was<br>
concentrated and re-dissolved in 80 mL DMF. CsCO3 (12.6g,<br>
39 mmol) was added. After 3 h, additional CsCO3 (12.6g, 39<br>
mmol) was added. The reaction ran 1.5 days. The reaction<br>
was quenched with water and diluted with AcOEt. After<br>
separation of the organic layer, the aqueous layer was<br>
washed twice with AcOEt. The combined organic layers were<br>
dried (MgSO4) , concentrated, and flash chromatographed to<br>
give 0.35g (26% yield) of a mixture of cis and trans<br>
isomers which were readily separated.<br>
Anti isomer - 1H NMR(400 MHz, CDC13)  1.24 (t, J = 7.0 Hz,<br>
3H), 1.40 (d, J= 7.0 Hz, 3H), 1.93 - 2.34 (m, 4H), 4.05 (d,<br>
1H) , 4.09 - 4.23 (m, 2H) , 4.79 - 4.85 (m, 1H) , 6.40 (bs,<br>
1H) , 7.27 - 7.44 (m, 5H) , 7.64 (s, 1H) . MS Calcd. : 299;<br>
Found 300 (M+H). Syn isomer - 1H NMR(400 MHz, CDC13) <br>
1.24 (t, J= 7.0 Hz, 3H), 1.68 (d, J = 7.0 Hz, 3H), 1.70 -<br>
1.80 (m, 1H) , 2.00 - 2.23 (m, 3H) , 4.17 - 4.30 (m, 4H) ,<br>
6.43 (brs, 1H) , 7.22 - 7.40 (m, 5H) , 7.63 (s, 1H) . MS<br>
Calcd.: 299; Found 300 (M+H).<br>
Step D<br>
8-Methyl-5-phenyl-5,6,7,8-tetrahydro-4H-<br>
pyrazolo[1,5,a] [1,3]diazepine-3-carboxylic acid (1-methyl-<br><br>
1-phenyl-ethyl)-amide (4) : Compound 3 (0.074g, 0.25 mmol)<br>
was diluted with EtOH (0.8 mL). KOH (6M in water, 0.23 mL)<br>
was added and the reaction stirred at 60 C for 3.5 h. The<br>
solution was cooled and diluted with AcOEt and water.<br>
After vigorous shaking, the aqueous layer was removed and<br>
acidified to pH = 3. The aqueous layer was then extracted<br>
with AcOEt(3 times). The organic layers were combined,<br>
dried (MgSO4) , and concentrated to give 0.070g of desired<br>
carboxylic acid. MS Calcd.: 271; Found 272 (M+H).<br>
This acid residue (0.070g, 0.26 mmol) was dissolved in<br>
NMP (2 mL). HATU (0.12g, 0.31 mmol) and cumylamine (0.042g,<br>
0.31 mmol) were added followed by DIEA (0.090 mL, 0.52<br>
mmol) . The reaction stirred at 90 C for 2 h. The<br>
solution was cooled to room temperature and diluted with<br>
water. The solution was extracted from AcOEt (3 times),<br>
dried (MgSO4) , and concentrated. Flash chromatography (30%<br>
AcOEt/hexanes) gave the desired product. 0.065g obtained<br>
(65% yield). 1H NMR (400 MHz, CDC13) 8 1.65 (d, J = 6.6 Hz,<br>
3H), 1.71 (s, 3H), 1.75 (s, 3H), 2.00 - 2.21 (m, 4H), 4.21<br>
- 4.29 (m, 2H), 5.80 (brs, 1H), 7.02 (brs, 1H) , 7.18 - 7.47<br>
(m, 10H), 7.49 (s, 1H); MS Calcd.: 388; Found 389 (M+H).<br>
Example 1142<br>
(1R,4S)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl-5-(2-<br>
fluorophenyl)-2,7,7-trimethyl-4,5,6,7-<br><br><br>
1) To a solution of 1 (0.4g, 1.32 mmol) and DMF (1 drop) in<br>
toluene (4 mL) was added SOCl2 (0.31, 2.64 mmol) at room<br>
temperature. After stirring at 60C 1 h, the solvent was<br>
concentrated in vacuo. The residue was diluted with toluene,<br>
and borneol (0.3g, 1.98 mmol) and Et3N (0.3g, 2.90 mmol)<br>
was added there to. After stirring at 60  C 1 h, the<br>
reaction mixture was washed with 1N HCl and brine, dried<br>
over MgSO4, and concentrated in vacuo. Flash chromatography<br>
to give the desired product as oil. To a stirred solution<br>
of the oil obtained (90 mg, 0.2 mmol) in AcOEt (2 mL) was<br>
added 4M HCl-AcOEt (0.5 mL, 2.0 mmol) at room temperature.<br>
The precipitate was collected by filtration to give 2 as<br>
HC1 salt. MS Calcd.: 440; Found 441 (M+H).<br>
Compounds of Examples 1139-1141 shown in the Table 16,<br>
were prepared in a manner similar to that described in<br>
Example 1142.<br>
Table 16<br><br><br>
Compounds of Examples 868 - 923 and 1143-1146 shown in<br>
the table 6, were prepared from compound of Examples 35 in<br>
a manner similar to that described in followed reference<br>
1~6.<br>
1)	Poulan R F., Tartar A L., Deprez B p., Tetrahedron Lett.<br>
2001, 42, 1495.<br>
2)	Rigo B., Cauliesz P., Fasseur D., Couturier D.,Synthetic<br>
Communications 1986, 16, 1665.<br>
3)	Carlsen H J., Jorgensen K B., J. Heterocyclic Chem.,<br><br>
1994, 3.1, 805.<br>
4)	Kiryanov A A., Sampson P., Seed J., J. Org. Chem., 2001,<br>
66, 7925.<br>
5)	Kelly T R., Lang F R., Tetrahedron Lett., 1995, 36, 5319.<br>
6)	Walia J S., Walia A S., Lankin D C., Petterson R C,<br>
Singh J., J. Heterocyclic Chem., 1985, 22, 1117.<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>
Strategy for cloning of the cDNAs encoding the human<br>
CaR<br>
Strategy for cloning of the cDNAs encoding the human<br>
CaR is shown below. To amplify the cDNA encoding the N-<br>
terminal moiety of the human CaR, the synthetic DNA primers,<br>
Cal-U : 5'-AGAGTCGACGCCACCATGGCATTTTATAGCTGCTGCTGG-3' and<br>
Cal-L : 5'-AAATGAGCTCTCGGTTGGTGGCCTTGAC-3' , were constructed.<br>
In this case, SalI site was added at the 5' end of<br>
amplified cDNA. To amplify the cDNA encoding the C-terminal<br>
moiety of the human CaR, the synthetic DNA primers, Ca2-U :<br>
5'-AAACGAGCTCTCCTACCTCCTCCTCTTC-3' and Ca2-L : 5'-<br>
TCTGCGGCCGCTCCCTAGCCCAGTCTTCTCCTTCC-3', were constructed.<br>
In this case, NotI site was added at the 3' end of<br>
amplified cDNA. PCR was carried out by Hot Start method.<br>
The reaction solution of the upper phase was added of 1 pg<br>
of the human kidney-derived cDNA (TOYOBO), 0.3 mM dNTPs and<br>
2.5 unit LA Taq DNA polymerase (Takara shuzo co.) and<br>
filled up to 30 l with water and buffer attached to the<br>
enzyme. To the reaction solution of the lower phase was<br>
added 12.5 uM each of the synthetic primers and 0.5 mM<br>
dNTPs and filled up to 20 l with water and buffer attached<br>
to the enzyme. The reaction solution of the upper phase was<br>
added on the lower phase covered with an AmpliWax PCR<br>
Gem100 (Takara Shuzo Co.). The samples were subject to PCR<br>
amplification using a Thermal Cycler (Perkin-Elmer Co.).<br><br>
The amplified cDNAs were confirmed by agarose gel<br>
electrophoresis.<br>
Experiment 2<br>
Preparation of CaR-expression CHO cells<br>
The PCR products obtained in Experiment 1 were<br>
separated by agarose gel electrophoresis. The PCR products<br>
were excised and purified from the gel and subcloned into<br>
pT7Blue-T vector (Takara Shuzo Co.). The cDNA fragment<br>
encoding the N-terminal moiety of the human CaR was<br>
released from the subcloned pT7Blue-T vector treated with<br>
SalI and SacI. The cDNA fragment encoding the C-terminal<br>
moiety of the human CaR was released from the subcloned<br>
pT7Blue-T vector treated with SacI and NotI. Using DNA<br>
Ligation kit (Takara Shuzo Co.), these fragments were<br>
inserted between the site of SalI- and NotI- in the<br>
digested pMSRneo vector. Thus, the pMSRneo-CaR for animal<br>
cell expression was constructed.<br>
Ten ug of the pMSRneo-CaR was added to the solution<br>
containing 8xl06 CH0-K1 cells, and transfection was carried<br>
out using Gene Pulser (0.4cm cuvette, 0.25kV, 960mF) (Bio-<br>
Rad Laboratories). The cells were cultured in HamF12<br>
containing 10% fetal calf serum for one day. After passage,<br>
the cells were cultured in HamF12 containing 10% fetal and<br>
500ug/ml Genetisine. The cells were seeded on 96-well plate<br><br>
in 1x103 cells/well and transformants, CaR-expressing CHO<br>
cells, were selected in the selection medium.<br>
Experiment 3<br>
Selection of the CaR-expressing CHO cell line by-<br>
calcium mobilization assay<br>
A method for calcium mobilization assay is shown below.<br>
The CaR-expressing CHO cells were seeded on a 96-well white<br>
plate in 2xl04 cells/well, followed by cultivation for 48<br>
hours. After washing the cells with Phosphate-Buffered<br>
Saline, 100 l of buffer solution (120 mM NaCl, 22 mM<br>
NaHCO3, 6 mM KCl, 0.2 mM CaCl2, 1 mM MgCl2, 5 mM glucose, 5<br>
mM HEPES (pH 7.4)) containing 5 uM FuraPE3AM (Texas<br>
Fluorescence Laboratories) was added to the wells and kept<br>
at 37 C for 1 hour. The cells were washed twice with<br>
Phosphate-Buffered Saline. After adding 180 ul of the<br>
reaction buffer solution (130 mM NaCl, 5.4 mM KCl, 0.2 mM<br>
CaCl2, 0.9 mM MgCl2, 10 mM glucose, 20 mM HEPES (pH 7.4))<br>
to the wells, 20 ul of 60 mM CaCl2 was added and<br>
intracellular calcium concentration were measured with a<br>
fluorometric imaging plate reader (FDSS 2000, Hamamatsu<br>
photonics). One clone increasing intracellular calcium<br>
concentration was selected and used for the following<br>
experiment.<br><br>
Experiment 4<br>
GTPS binding assay<br>
Preparation of membrane fraction is described bellow.<br>
The human CaR-expressing CHO cells were inoculated to a<br>
F500 flask in 1.8xl05 cells/flask followed by cultivation<br>
for 2 days. The cells were scraped with 10ml of Phosphate-<br>
Buffered Saline containing 0.02% EDTA. After centrifugation<br>
(2000 rpm, 10 min) of the cells, the cell pellet was<br>
resuspended into 12 ml of homogenate buffer solution (10 mM<br>
NaHCO3, 1 mM EDTA, lx Protease inhibitor cocktail (pH 7.4))<br>
and homogenized by Polytron (20000 rpm, 1 min) . The cell<br>
debris was removed by centrifugation (2000 rpm, 10 min),<br>
and then the CaR-expressing cell membrane fraction was<br>
collected by ultracentrifugation (Beckman 70 Ti type rotor,<br>
30000 rpm, 1 hour).<br>
The GTPyS binding activity was measured as follows.<br>
Twenty ug of the CaR-expressing cell membrane was incubated<br>
with test compounds for 10min. The assays were carried out<br>
at room temperature for an hour in a reaction solution<br>
mixture containing 20 mM HEPES (pH.7.4), 100 mM NaCl, 1 mM<br>
MgCl2, 167 g/ml DTT, 5 M guanosine 5'-diphosphate, 0.4 nM<br>
[35S]-guanosine 5'-(-thio) triphosphate ( [35S]-GTPS) and 6<br>
mM CaCl2. The mixture was filtered through a GF/C filter.<br>
After washing fourth with 300 l of Phosphate-Buffered<br>
Saline, the amount of [35S]-GTPYS bound to the filter was<br><br>
measured using a Top-count scintillation counter.<br>
Effects of test compounds on [35S]-GTPYS binding were<br>
expressed in percentage terms. This was calculated from the<br>
equation [100x(t'-b)]/(t-b) where t', t and b are values of<br>
[35S]-GTPYS binding (dpm) , t' in the presence of 6mM<br>
calcium and the test compound, t in the presence of 6mM<br>
calcium only and b in the absence of both 6mM calcium and<br>
the test compound.<br>
The antagonist dose-dependently decreased [35S]-GTPYS<br>
binding in membrane preparation. The agonist dose-<br>
dependently increased [35S]-GTPS binding in membrane<br>
preparation.<br>
The results are shown in Table 7.<br><br>
INDUSTRIAL APPLICABILITY<br>
Compound (I), (II), (III) or (IIIa) of the present<br>
invention has an excellent Ca receptor modulating activity<br><br>
and enhances the secretion of PTH, and therefore, useful as<br>
drugs for treating bone diseases, kidney-acting drugs,<br>
central nervous system and endocrine-acting drugs,<br>
digestive system-acting drugs, and the like.<br><br>
WE CLAIM:<br>
1. A compound of the formula (IIIa):<br><br>
wherein R1a is<br>
(1) an optionally substituted 5- to 7-membered aromatic or non-aromatic heterocyclic<br>
group having 1-4 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom,<br>
or (2) a group of the formula: -CO-Z2c (wherein Z2c is<br>
(i) an optionally substituted 5- to 7-membered aromatic or non-aromatic heterocyclic group<br>
having 1-4 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom,<br>
(ii) -NR20c(CR21cR22cR23c) (wherein<br>
(a) R20c is H or an optionally substituted hydrocarbon group selected from C1-8<br>
saturated aliphatic hydrocarbon group, C2-8 unsaturated aliphatic hydrocarbon group,<br>
C3-7 saturated alicyclic hydrocarbon group, C3-7 unsaturated alicyclic hydrocarbon<br>
group, C9-10 partly saturated and fused bicyclic hydrocarbon group, C3-7 saturated or<br>
unsaturated alicyclic-C1-8 saturated or unsaturated aliphatic hydrocarbon group, C9-10<br><br>
partly saturated and fused bicyclic hydrocarbon-C1-4 alkyl group, C9-10 partly saturated<br>
and fused bicyclic hydrocarbon-C2-4 alkenyl group, C6-10 aryl group and C7-14 aralkyl<br>
group; and R21c is 1) an optionally substituted 5- to 7-membered aromatic or non-<br>
aromatic heterocyclic group having 1-4 hetero atoms selected from nitrogen atom,<br>
oxygen atom and sulfur atom, which may be fused with an optionally substituted<br>
benzene ring, or 2) an optionally substituted C6-10 aryl group which may be fused with<br>
an optionally substituted 5- to 7-membered aromatic heterocyclic ring having 1-4<br>
hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom; and R22c and<br>
R are the same or different and are an optionally substituted hydrocarbon group<br>
selected from C1-8 saturated aliphatic hydrocarbon group, C2-8 unsaturated aliphatic<br>
hydrocarbon group, C3-7 saturated alicyclic hydrocarbon group, C3-7 unsaturated<br>
alicyclic hydrocarbon group, C9-10 partly saturated and fused bicyclic hydrocarbon<br>
group, C3-7 saturated or unsaturated alicyclic-C1-8 saturated or unsaturated aliphatic<br>
hydrocarbon group, C9-10 partly saturated and fused bicyclic hydrocarbon-C1-4 alkyl<br>
group, C9-10 partly saturated and fused bicyclic hydrocarbon-C2-4 alkenyl group, C6-10<br>
aryl group and C7-14 aralkyl group or an optionally substituted 5- to 7-membered<br>
aromatic or non-aromatic heterocyclic group having 1-4 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom, or R22c and R23cmay be combined to form<br>
a C3-7 carbon ring, or (b) R20c is H or an optionally substituted hydrocarbon group<br><br>
selected from C1-8 saturated aliphatic hydrocarbon group, C2-8 unsaturated aliphatic<br>
hydrocarbon group, C3-7 saturated alicyclic hydrocarbon group, C3-7 unsaturated<br>
alicyclic hydrocarbon group, C9-10 partly saturated and fused bicyclic hydrocarbon<br>
group, C3-7 saturated or unsaturated alicyclic-C1-8 saturated or unsaturated aliphatic<br>
hydrocarbon group, C9-10 partly saturated and fused bicyclic hydrocarbon-C1-4 alkyl<br>
group, C9-10 partly saturated and fused bicyclic hydrocarbon-C2-4 alkenyl group, C6-10<br>
aryl group and C7-14 aralkyl group; and R21c, R22c and R23c are the same or different and<br>
are an optionally substituted C1-8 aliphatic hydrocarbon group, provided that the sum<br>
total of the number of carbon atoms is 7 or more),<br>
(iii) -NR20cR25c (wherein R20cis as defined above and R25cis an optionally substituted C6-10<br>
aryl-C2-4 alkyl, C6-10 aryloxy-C2-4 alkyl, C6-10 atylamino-C2-4 alkyl, C7-14 aralkylamino-<br>
C2-4 alkyl, 5- to 7-membered heterocyclic ring (having 1-4 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom)-C2-4 alkyl or 5- to 7-membered<br>
heterocyclic group having 1-4 hetero atoms selected from nitrogen atom, oxygen atom<br>
and sulfur atom),<br>
(iv) a substituted 5- to 7-membered cyclic amino group, or<br>
(v) -OR24c (wherein R24c is<br>
(a)	an optionally substituted C7-14 aralkyl group,<br>
(b)	an optionally substituted C3-7 alicyclic hydrocarbon group,<br><br>
(c)	an optionally substituted C7-24 aliphatic hydrocarbon group, or<br>
(d)	an optionally substituted 5- to 7-membered aromatic or non-aromatic heterocyclic<br>
group having 1-4 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom;<br>
wherein said substituents for R1a, Z2c, R20c, R21c, R22c, R23c, R24c and R25c are 1 to 3<br>
substituents selected from the group consisting of<br><br>
1)	C1-6 alkyl,<br>
2)	C2-6 alkenyl,<br>
3)	C2-6 alkynyl,<br>
4)	C3-7 cycloalkyl,<br>
5)	C6-10 aryl which may be substituted with 1 to 3 substituents selected from the group<br>
consisting of C1-6 alkyl, amino, N-(C1-6 alkyl)amino, N,N-di-(C1-6 alkyl)amino, amidino,<br>
carbamoyl, N-(C1-6 alkyl)carbamoyl, N,N-di-(C1-6 alkyl)carbamoyl, sulfamoyl, N-(C1-6<br>
alkyl)sulfamoyl, N,N-di-(C1-6 alkyl)sulfamoyl, carboxyl, C2-7 alkoxycarbonyl, hydroxyl,<br>
C1-6 alkoxy, mercapto, C1-6 alkylthio, sulfo, cyano, azido, halogen, nitro, nitroso,<br>
phosphono, C1-6 alkoxyphosphoryl, di-(C1-6 alkoxy)phosphoryl and C1-6 alkyl substituted<br>
with phosphono, C1-6 alkoxyphosphoryl and di-(C1-6 alkoxy)phosphoryl (hereinafter the<br>
group of 5) is referred to as group "C"),<br>
6)	aromatic heterocyclic group selected from (a) aromatic 5- or 6-membered heterocyclic<br>
group having 1-4 hetero atoms selected from nitrogen atom, oxygen atom and sulfur<br><br>
atom, (b) fused bicyclic heterocyclic group formed by condensation of an aromatic 5- or<br>
6-membered heterocyclic group having 1 to 3 hetero atoms selected from nitrogen atom,<br>
oxygen atom and sulfur atom with benzene ring or an aromatic 5- or 6-membered<br>
heterocyclic group having 1 to 3 hetero atoms selected from nitrogen atom, oxygen atom<br>
and sulfur atom and (c) fused tricyclic heterocyclic group formed by condensation of [1]<br>
an aromatic 5- or 6-membered heterocyclic group having 1-3 hetero atoms selected from<br>
nitrogen atom, oxygen atom and sulfur atom, [2] benzene ring, and [3] an aromatic 5- or<br>
6-membered heterocyclic group having 1-3 hetero atoms selected from nitrogen atom,<br>
oxygen atom and sulfur atom or benzene ring,<br>
7)	heterocyclic-oxy group formed by combining each of the above aromatic heterocyclic<br>
groups (a), (b) and (c) with oxy group,<br>
8)	non-aromatic 4- or 7-membered heterocyclic group having 1 to 3 hetero atoms<br>
selected from nitrogen atom, oxygen atom and sulfur atom,<br>
9)	C7-14 aralkyl which may be substituted with 1 to 3 substituents selected from the group<br>
"C",<br><br>
10)	amino group,<br>
11)	N-mono-substituted amino selected from N-(C1-6 alkyl)amino, N-(C2-6<br>
alkenyl)amino, N-(C3-7 cycloalkyl)amino group and N-(C6-10 aryl)amino which may be<br>
substituted with 1 to 3 substituents selected from the group "C",<br><br>
12)	amino substituted with two substituents selected from C1-6 alkyl, C2-6 alkenyl, C3-7<br>
cycloalkenyl and C6-10 aryl which may be substituted with 1 to 3 substituents selected<br>
from the group "C",<br>
13)	amidino,<br>
14)	acyl selected from C2-8 alkanoyl, C3-8 alkenoyl, C3-7 cycloalkyl-carbonyl, C3-7<br>
cycloalkenyl-carbonyl, C6-10 aryl-carbonyl which may be substituted with 1 to 3<br>
substituents selected from the group "C", and heterocyclic-carbonyl formed by binding<br>
of an aromatic or non-aromatic 5- or 6-membered heterocyclic group having 1-3 hetero<br>
atoms selected from nitrogen atom, oxygen atom and sulfur atom with carbonyl,<br>
15)	carbamoyl,<br>
16)	mono-substituted carbamoyl group selected from N-(C1-6 alkyl)carbamoyl, N-(C2-6<br>
alkenyl)carbamoyl, N-(C3-7 cycloalkyl)carbamoyl and N-(C6-10 aryl)carbamoyl which<br>
may be substituted with 1 to 3 substituents selected from the group "C",<br>
17)	carbamoyl substituted with two substituents selected from C1-6 alkyl, C2-6 alkenyl, C3-<br>
7 cycloalkyl and C6-10 aryl which may be substituted with 1 to 3 substituents selected<br>
from the group "C",<br>
18)	sulfamoyl,<br>
19)	N-mono-substituted sulfamoyl selected from N-(C1-6 alkyl)sulfamoyl, N-(C2-6<br>
alkenyl)sulfamoyl, N-(C3-7 cycloalkyl)sulfamoyl and N-(C6-10 aryl)sulfamoyl which may<br>
be substituted with 1 to 3 substituents selected from the group "C",<br><br>
20)	sulfamoyl substituted with two substituents selected from C1-6 alkyl, C2-6 alkenyl, C3-<br>
7 cycloalkyl and C6-10 aryl which may be substituted with 1 to 3 substituents selected<br>
from the group "C",<br>
21)	carboxyl,<br>
22)	C1-6 alkoxy-carbonyl,<br>
23)	hydroxyl,<br>
24)	C1-6 alkoxy,<br>
25)	C2-10 alkenyloxy,<br>
26)	C3-7 cycloalkyloxy,<br>
27)	C6-10 aryloxy which may be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
28)	C7-14 aralkyloxy which may be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
29)	mercapto,<br>
30)C1-6alkylthio,<br><br>
31)	C7-14 aralkylthio which may be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
32)	C6-10 arylthio which may be substituted with 1 to 3 substituents selected from the<br>
group "C",<br><br>
33)	C1-6 alkylsulfinyl,<br>
34)	C7-14 aralkylsulfinyl which may be substituted with 1 to 3 substituents selected from<br>
the group "C",<br>
35)	C6-10 arylsulfinyl which may be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
36)	C1-6 alkylsulfonyl,<br><br>
38)	C7-14 aralkylsulfonyl which may be substituted with 1 to 3 substituents selected from<br>
the group "C",<br>
39)	C6-10 arylsulfonyl which may be substituted with 1 to 3 substituents selected from the<br>
group "C",<br>
40)	sulfo,<br>
41)	cyano,<br>
42)	azido,<br>
43)	halogen,<br>
44)	nitro,<br>
45)	nitroso,<br>
46)	phosphono,<br>
47)	C1-6 alkoxy-phosphoryl<br>
48)	di-C1-6 alkoxy-phosphoryl,<br><br>
49)	C1-6 alkyl substituted with phosphono, C1-6 alkoxyphosphoryl or di-(C1-6<br>
alkoxy)phosphoryl<br>
50)	C1-6 alkyl substituted with 1 to 4 halogen atoms<br>
51)	C1-6 alkoxy substituted with 1 to 4 halogen atoms and<br>
52)	C1-6 alkylenedioxy<br>
(hereinafter the group of above 1) to 52) is referred to as group "B");<br>
R3 is H, a C1-6 alkyl group or a C7-14 aralkyl group;<br>
R6 is H, a C1-6 alkyl group, a C1-6 alkylthio group or a C1-6 alkoxy group which may be<br>
substituted with hydroxyl group;<br>
Ar is (1) a C6-10 aryl group, (2) a 5- to 7-membered aromatic or non-aromatic heterocyclic<br>
group having 1-4 hetero atoms selected from nitrogen atom, oxygen atom and sulfur atom,<br>
or (3) a C3-7 saturated or unsaturated alicyclic hydrocarbon group, each of which may be<br>
substituted with 1 to 3 substituents selected from the group "B";<br>
one of R9 and R10 is a hydrogen atom or C1-6 alkyl group which may be substituted with 1<br>
to 3 substituents selected from the group "B" and the other is (1) a hydrocarbon group<br>
selected from C1-8 saturated aliphatic hydrocarbon group, C2-8 unsaturated aliphatic<br>
hydrocarbon group, C3-7 saturated alicyclic hydrocarbon group, C3-7 unsaturated alicyclic<br>
hydrocarbon group, C9-10 partly saturated and fused bicyclic hydrocarbon group, C3-7<br>
saturated or unsaturated alicyclic-C1-8 saturated or unsaturated aliphatic hydrocarbon group,<br><br>
C9-10 partly saturated and fused bicyclic hydrocarbon-C1-4 alkyl group, C9-10 partly saturated<br>
and fused bicyclic hydrocarbon-C2-4 alkenyl group, C6-10 aryl group and C7-14 aralkyl group,<br>
each of which may be substituted with 1 to 3 substituents selected from the group "B" or<br>
(2) a 5- to 7-membered aromatic or non-aromatic heterocyclic group having 1-4 hetero<br>
atoms selected from nitrogen atom, oxygen atom and sulfur atom, which may be<br>
substituted with 1 to 3 substituents selected from the group "B", or<br>
R9 and R10 may be combined to form a C5.7 carbon ring,<br>
provided that at least one of R9and R10 is C1-6 alkyl group which may be substituted with 1<br>
to 3 substituents selected from the group "B" and the other is other than a phenyl group<br>
which may be substituted with 1 to 3 substituents selected from the group "B"; or a salt<br>
thereof.<br>
2. The compound as claimed in claim 1 comprises<br>
N-(l-ethyl-1-(4-methylphenyl)propyl)-7,7-dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[l,5-a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(1-ethyl-1-(4-methylphenyl)propyl)-5-(2-fluorophenyl)-7,7-dimethyl-4,5,6,7-<br>
tefrahydropyrazolo[l,5-a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(l-ethyl-1-(4-methylphenyl)propyl)-2,7,7-trimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[l,5-a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(l-ethyl-1-(4-ethylphenyl)propyl)-2,7,7-trimethyl-5-phenyl-4,5,6,7-<br><br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(1-ethyl-1-(4-methylphenyl)propyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(1-ethyl-1-(4-ethylphenyl)propyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-<br>
tetrahydropyra2olo[1,5-a]pyrimidine-3-carboxamide or a salt thereof,<br>
5-(2-chlorophenyl)-N-(1-ethyl-1-(4-methylphenyl)propyl)-2,7,7-trimethyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(1-(4-(dimethylamino)phenyl)-1-ethylpropyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-<br>
4,5,6,74etrahydropyrazolo[l,5-a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(1,1-diethylbutyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-<br>
a]pyrimidine-3-carboxamide or a salt thereof,<br>
N-(1-ethyl-1-phenylpropyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof,<br>
3-(5-(1-ethyl-1-(4-methylphenyl)propyl)-1,3,4-oxadiazol-2-yl)-2,7,7-trimethyl-5-phenyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof,<br>
3-(5-(1-ethyl-1-(4-methylphenyl)propyl)-l,3,4-thiadiazol-2-yl)-2,7,7-trimethyl-5-phenyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrirnidine or a salt thereof,<br>
3-((4-(benzyloxy)-2,2-diethyl-1-pyrrolidmyl)carbonyl)-7,7-dirnethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof,<br><br>
3-((2,2-diethyl-4-methoxy-1-pyrrolidinyl)carbonyl)-7,7-dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof, or<br>
3-((2,2-diethyl-4-fluoro-1-pyirolidinyl)carbonyl)-7,7-dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof.<br>
3.	N-(1-ethyl-1-(4-methylphenyl)propyl)-7,7-dimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof.<br>
4.	N-(1-ethyl-1-(4-methylphenyl)propyl)-5-(2-fluorophenyl)-7,7-dimethyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof.<br>
5.	N-(1-ethyl-1-(4-methylphenyl)propyl)-2,7,7-trimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof.<br>
6.	N-(1-ethyl-1-(4-ethylphenyl)propyl)-2,7,7-trimethyl-5-phenyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof.<br>
7.	N-(1-ethyl-1-(4-methylphenyl)propyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof.<br>
8.	N-(1-ethyl-1-(4-ethylphenyl)propyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof.<br>
9.	5-(2-chlorophenyl)-N-(1-ethyl-1-(4-methylphenyl)propyl)-2,7,7-trimethyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrirnidine-3-carboxamide or a salt thereof.<br>
10.	N-(1-(4-(dimethylamino)phenyl)-1-ethylpropyl)-5-(2-fluorophenyl)-2,7,7-<br>
trimethyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof.<br><br>
11.	N-(1, 1-diethylbutyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a salt thereof.<br>
12.	N-(1-ethyl-1-phenylpropyl)-5-(2-fluorophenyl)-2,7,7-trimethyl-4,5,6,7-<br>
tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxarnide or a salt thereof.<br>
13.	3-(5-(1-ethyl-1-(4-methylphenyl)propyl)-l,3,4-oxadiazol-2-yl)-2,7,7-<br>
trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof.<br>
14.	3-(5-(1-ethyl-1-(4-methylphenyl)propyl)-l,3,4-thiadiazol-2-yl)-2,7,7-<br>
trimethyl-5-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof.<br>
15.	3-((4-(benzyloxy)-2,2-diethyl-1-pyrrolidinyl)carbonyl)-7,7-dimethyl-5-<br>
phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof.<br>
16.	3-((2,2-diethyl-4-methoxy-1-pyrrolidinyl)carbonyl)-7,7-dimethyl-5-phenyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof.<br>
17.	3-((2,2-diethyl-4-fluoro-1-pyrrolidinyl)carbonyl)-7,7-dimethyl-5-phenyl-<br>
4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine or a salt thereof.<br>
18.	The compound according to claim 2, which is an optically active compound.<br>
19.	A pharmaceutical composition which comprises the compound according to<br>
claim 1.<br>
20.	A composition for modulating calcium receptor which comprises a<br>
compound of claim 1.<br><br>
21.	The composition according to claim 20, which is a calcium receptor<br>
antagonist.<br>
22.	The composition according to claim 20, which is an agent for preventing or<br>
treating diseases caused by abnormality of calcium concentration in a living body or a<br>
calcium receptor.<br>
23.	The composition according to claim 20, which is an agent for preventing or<br>
treating bone diseases.<br>
24.	The composition according to claim 20, which is an agent for preventing or<br>
treating osteoporosis or fracture.<br><br>
There is provided a calcium receptor modulator<br>
comprising a compound of the formula (I):<br><br><br><br>
wherein ring A is an optionally substituted 5- to 7-<br>
membered ring; ring B is an optionally substituted 5- to 7-<br>
membered heterocyclic ring; X1 is CR1, CR1R2, N or NR13; X2<br>
is N or NR3; Y is C, CR4 or N, Z is CR5, CR5R6, N or NR7; Ar<br>
is an optionally substituted cyclic group; R is H, an<br>
optionally substituted hydrocarbon group, etc.; and <br>
is a single bond or a double bond; R1, R2, R3, R4, R5, R6, R7<br>
and R13 are independently H, an optionally substituted<br>
hydrocarbon group; or a salt thereof or a prodrug thereof.<br>
Compounds of the formula (II) and (III):<br><br>
wherein ring A is an optionally substituted 5- to 7-<br>
membered ring; Q is C, CR5 or N; R8, R9, R10, R11 and R12 are<br>
independently, H, an optionally substituted hydrocarbon<br>
group, etc., or a salt thereof are also provided.<br>
Also specify X1, R3, R1, Y and X3 in formula (II) and (III)<br>
as before.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBhYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBjbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBjb3JyZXNwb25kZW5jZS0xLjEucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 correspondence-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBjb3JyZXNwb25kZW5jZS0xLjIucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 correspondence-1.2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBjb3JyZXNwb25kZW5jZS0xLjMucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 correspondence-1.3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBjb3JyZXNwb25kZW5jZS0xLjQucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 correspondence-1.4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBjb3JyZXNwb25kZW5jZS5wZGY=" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBkZXNjcmlwdGlvbihjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 description(complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBmb3JtLTEtMS4xLnBkZg==" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 form-1-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBmb3JtLTEucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBmb3JtLTE4LnBkZg==" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBmb3JtLTIucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBmb3JtLTMucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBmb3JtLTUucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBnLnAuYS5wZGY=" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 g.p.a.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBpbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBpbnRlcm5hdGlvbmFsIHNlYXJjaCBhdXRob3JpdHkgcmVwb3J0LTEuMS5wZGY=" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 international search authority report-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBpbnRlcm5hdGlvbmFsIHNlYXJjaCBhdXRob3JpdHkgcmVwb3J0LnBkZg==" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 international search authority report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBwY3Qgb3RoZXJzLnBkZg==" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 pct others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBwY3QgcmVxdWVzdC5wZGY=" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 pct request.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBwcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDAyODAta29sbnAtMjAwNSBzZXF1ZW5jZSBsaXN0aW5nIGZvcm0ucGRm" target="_blank" style="word-wrap:break-word;">00280-kolnp-2005 sequence listing form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLUtPTE5QLTIwMDUtRk9STS0yNy5wZGY=" target="_blank" style="word-wrap:break-word;">280-KOLNP-2005-FORM-27.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1jb3JyZXNwb25kZW5jZS5wZGY=" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-correspondence.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1kZXNjcmlwdGlvbiAoY29tcGxldGUpLnBkZg==" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1leGFtaW5hdGlvbiByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1mb3JtIDEzLnBkZg==" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-form 13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1mb3JtIDE4LnBkZg==" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1mb3JtIDIucGRm" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-form 2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1ncGEucGRm" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1yZXBseSB0byBleGFtaW5hdGlvbiByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-reply to examination report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1zZXF1ZW5jZSBsaXN0aW5nLnBkZg==" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-sequence listing.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MjgwLWtvbG5wLTIwMDUtZ3JhbnRlZC1zcGVjaWZpY2F0aW9uLnRpZg==" target="_blank" style="word-wrap:break-word;">280-kolnp-2005-granted-specification.tif</a></p>
		<br>
		<div class="pull-left">
			<a href="227613-dual-fuel-injection-valve-and-method-of-operating-a-dual-fuel-injection-valve.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="227615-a-method-for-designing-an-opthalmic-lens.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>227614</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>280/KOLNP/2005</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>03/2009</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>16-Jan-2009</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>14-Jan-2009</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>25-Feb-2005</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>TAKEDA PHARMACEUTICAL COMPANY LIMITED</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>1-1, DOSHOMACHI 4-CHOME, CHUO-KU, OSAKA-SHI, OSAKA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>HIROYUKI KIMURA</td>
											<td>2-20-808, OHAMANAKAMACHI 1-CHO, SAKAI-SHI, OSAKA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>MASATO YOSHIDA</td>
											<td>228-2, HIRONO, SANDA-SHI, HYOGO</td>
										</tr>
										<tr>
											<td>3</td>
											<td>ALBERT CHARLES GYOROKOS</td>
											<td>11795 DECATUR DRIVE, WESTMINSTER, CO 80234</td>
										</tr>
										<tr>
											<td>4</td>
											<td>SCOTT ALAN PRATT</td>
											<td>13099 ALCOTT PLACE, BROOMFIELD, CO 80020</td>
										</tr>
										<tr>
											<td>5</td>
											<td>CHRISTOPHER PETER CORRETTE</td>
											<td>13839 W. 66TH ARVADA, CO 80004</td>
										</tr>
										<tr>
											<td>6</td>
											<td>TSUNEO YASUMA</td>
											<td>20-5, TAKADA-CHO, IBARAKI-SHI, OSAKA</td>
										</tr>
										<tr>
											<td>7</td>
											<td>AKIRA MORI</td>
											<td>358, KASHIRA-CHO, NIJO-SAGARU, SHINAINOMACHI, SAKYO-KU, KYOTO-SHI, KYOTO</td>
										</tr>
										<tr>
											<td>8</td>
											<td>MASAHIRO KAWASE</td>
											<td>14-5, WAKABA 2-CHOME, INAGAWA-CHO, KAWABE-GUN, HYOGO</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2003/026317</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2003-08-21</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/466,129</td>
									<td>2003-04-28</td>
								    <td>U.S.A.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>60/406,012</td>
									<td>2002-08-26</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/227614-calcium-receptor-modulating-compound-and-use-thereof by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:37:52 GMT -->
</html>
